Aesthetic Medicine
Peter M. Prendergast • Melvin A. Shiffman Editors
Aesthetic Medicine Art and Techniques
Editors Dr. Peter M. Prendergast, M.B., B.Ch., MRCSI. Venus Medical Heritage House Dundrum Office Park Dublin 14 Ireland
[email protected]
Dr. Melvin A. Shiffman, M.D., J.D. Surgery Section Newport Specialty Hospital 17501 Chatham Drive Tustin, CA 92780-2302 USA
[email protected]
ISBN 978-3-642-20112-7 e-ISBN 978-3-642-20113-4 DOI 10.1007/978-3-642-20113-4 Springer Heidelberg Dordrecht London New York Library of Congress Control Number: 2011928412 © Springer-Verlag Berlin Heidelberg 2011 This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer. Violations are liable to prosecution under the German Copyright Law. The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Product liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature. Cover design: eStudioCalamar, Figueres/Berlin Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com)
This book is dedicated to my beautiful children, Ciara and Niall, and to my wife and dearest love, Pyn. Peter M. Prendergast, M.B., B.Ch., MRCSI.
Foreword
In 1973 in Paris the words medicine and aesthetic appeared alongside each other. The combination of these two words gave rise to a new concept of correcting various aspects of the human body. Cosmetic surgery for years has created transformations, and aesthetic medicine can achieve similar results using a lighter technique. From 1973 until the early 1980s, aesthetic medicine spread from France to the Mediterranean, and then on to America, maintaining and using all the medicine and physiotherapy that make aesthetic improvements to the body. The reason for this wide and rapid spread was the desire for changes in people’s ways of life in a more modern society. In fact, the most important aspect had become ‘time.’ People had less time and more things to think about in this increasingly competitive way of living. Therefore, the time needed for two people to meet was insufficient to really get to know each other, which meant that people began to find ways of improving themselves: how they dress, their way of speaking, their body language, and last but not least their appearance. The old saying “Clothes don’t make the man” could be seen as incorrect and actually the exact opposite is true: first impressions count. To dwell on how much this transformation is or is not true would just stray from the point. The reality is that people request the expertise of surgeons and doctors to better their aesthetic appearance to conform with what is seen as the ideal in society today. Corrective treatments should not be seen as negative. In fact, improving the aesthetic appearance allows individuals to like themselves more and feel more balanced psychologically. This not only improves the psyche, but also the metabolism. Today a new science called psycho-neuro-endocrino-immunology studies the positive and negative effects our psyche, equilibrium, anxiousness, stress, and depression can have on our endocrine system, interfering with the metabolism and immune system, which defends us against infection and cancer. Helping someone to see him/ herself in a better light not only improves ‘beauty,’ but also health, having a positive effect on the nervous, immune, and endocrine systems. Therefore today, aesthetic medicine should be seen as an important branch of medicine improving the quality of people’s lives. It is important to have correct scientific information for those doctors who wish to enter into the field of aesthetic medicine All scientific information originates from study and should communicate the reasoning behind and technical operation of aesthetic medicine. Peter Prendergast and Melvin A. Shiffman are doctors with great skills and experience in aesthetic medicine and cosmetic surgery who have put together a text that includes all the theoretical and practical information needed to operate in this area. A staff of international specialists, expert in particular areas, have
vii
viii
Foreword
been selected to compile chapters in a way that gives students the best knowledge and know-how regarding aesthetic treatment. The book starts by looking at aesthetic medicine and its ethics, and continues on to other clinical aspects relating to this branch of medicine, going into useful techniques for improving the patients’ body. Also new to this area are techniques like mesotherapy, always respecting science and medical and surgical guidelines. The title of this book, “Aesthetic Medicine: Art and Techniques,” means that we can ultimately understand that this area appears simple, but in fact is not only a science but also an art. Furthermore, the maintenance and improvement of aethestic harmony in our patients not only require scientific knowledge and technical skills, but also, and arguably more importantly, artistic inspiration and taste. This book represents up-to-date advances in the aesthetic medicine sector, and can be used as a base and reference for all who wish to advance in the field of aesthetic medicine. Rome, Italy
Maurizio Ceccareli, M.D., Sc.D., Cl.Path.S.
Preface
Aesthetic medicine is a rapidly growing specialty that is largely procedure-oriented. Non-surgical and minimally invasive techniques for enhancing the face and body are now possible without the need even for sedation. These include facial rejuvenation with lasers, lights, and tissue tightening technologies, augmentation with fillers and autologous fat, chemodenervation, and thread lift techniques. Breast augmentation with fat or fillers is performed under local anesthesia, as is body contouring using the tumescent technique. Although procedures in aesthetic medicine certainly do not replace those in cosmetic surgery, patients frequently request rejuvenation that is minimally invasive and requires little or no downtime. This demand has steadily increased over the last decade and has been the driving force in the evolution of aesthetic medicine into a discipline practiced by surgeons and physicians alike. Indeed, many of the techniques described in this book, such as facial volumizing and skin resurfacing, are ideal adjuncts to a plan of surgical facial rejuvenation. The pace of growth in aesthetic medicine, coupled with the explosion in the number of new devices and treatment modalities for rejuvenation, precludes any exhaustive text on the subject. However, we have endeavored to include topics of interest for the beginning and advanced practitioner in aesthetic medicine, including advanced applications of the most common procedures such as botulinum toxins and fillers. Separate chapters detail the latest techniques in suture face lifts, stem cell-enriched fat transfer, mesotherapy, carboxytherapy, thermolysis, Vaser lipoplasty, and treatments for cellulite, varicose veins, and telangiectasias. This book is intended as a manual. The emphasis is on protocols, parameters, instruments, materials, and descriptions of techniques. Our aim is not only to facilitate an understanding of the principles of aesthetic medicine, but also to allow the reader to incorporate the various techniques described into their practice. The book will also serve as a valuable resource for physicians and surgeons of any specialty undergoing formal instructional courses or workshops in aesthetic medicine. The contributors, all international authorities in their fields, share their advice, tips, and experience using clear explanations, illustrations, and step-by-step photographs. We hope that, by describing and showing the techniques in detail, the reader will both appreciate the artistic element of aesthetic medicine and gain a practical knowledge for immediate application. Dublin, Ireland Tustin, California, USA
Peter M. Prendergast, M.B., B.Ch., MRCSI. Melvin A. Shiffman, M.D., J.D.
ix
Contents
Part I Aesthetic Medicine 1 Defining Aesthetic Medicine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Peter M. Prendergast
3
2 Ethical Aspects of Aesthetic Medicine . . . . . . . . . . . . . . . . . . . . . . . . . . . Urban Wiesing
7
Part II Preoperative 3 Medical History. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Melvin A. Shiffman 4 Clinical Assessment of Facial Aging. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Melvin A. Shiffman 5 Assessment and Treatment of Excess Weight. . . . . . . . . . . . . . . . . . . . . . 29 Melanie T. Turk 6 Phytonutrient and Phytotherapy for Improving Health. . . . . . . . . . . . . 47 Jian Zhao 7 Skin Imaging in Aesthetic Medicine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59 Peter M. Prendergast 8 Cosmeceutical Treatment of the Aging Face . . . . . . . . . . . . . . . . . . . . . . 69 Jennifer Linder Part III Cutaneous Procedures 9 Local Regional Anesthesia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87 Peter M. Prendergast 10 Botulinum Toxins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103 Peter M. Prendergast 11 Biostimulation and Biorestructuring of the Skin. . . . . . . . . . . . . . . . . . . 131 Maurizio Ceccarelli 12 Microdermabrasion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145 Preeti H. Savardekar 13 Aesthetic Cryotherapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151 Michael H. Swann xi
xii
14 Facial Peels. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157 Niti Khunger 15 Fractional Laser Resurfacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179 Vic A. Narurkar 16 Capacitive Radiofrequency Skin Rejuvenation. . . . . . . . . . . . . . . . . . . . 187 Manoj T. Abraham and Joseph J. Rousso 17 The Use of Intense Pulsed Light (IPL) in Aesthetic Medicine . . . . . . . . 197 Bruce M. Freedman and Toral P. Balakrishnan 18 Thermolysis in Aesthetic Medicine: 3D Rejuvenation . . . . . . . . . . . . . . 205 Nassim Tabatabai and Neil S. Sadick 19 Neodym-Yag-Laser Treatment for Hemangiomas and Vascular Malformations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 213 Thomas Hintringer 20 Foam Sclerotherapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221 Marcondes Figueiredo 21 Facial Laser Hair Removal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 235 Benjamin A. Bassichis 22 Laser Treatment of Telangiectasias. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 241 Alia S. Brown and David J. Goldberg 23 Mesotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 249 Narmada Bharia 24 Mesotherapy Solutions for Inducing Lipolysis and Treating Cellulite. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 255 Benje Gutierrez and Frank L. Greenway 25 Cellulite: Etiology, Classification, Pathology, and Treatment. . . . . . . . . 265 Melvin A. Shiffman 26 Dermaroller: The Transepidermal Delivery System. . . . . . . . . . . . . . . . 273 Madhuri Agarwal 27 Scar Management. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 277 George John Bitar, Priscilla Patel, and Lauren Craig 28 Arnica montana. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 289 Melvin A. Shiffman Part IV Shaping Face and Body 29 Augmentation with Injectable Fillers. . . . . . . . . . . . . . . . . . . . . . . . . . . . 297 Peter M. Prendergast 30 Potential Risks and Complications of Injectable Alloplastic Facial Fillers. . . . . . . . . . . . . . . . . . . . . . . . . . . . 337 Melvin A. Shiffman
Contents
Contents
xiii
31 Facial Augmentation with Autologous Fat. . . . . . . . . . . . . . . . . . . . . . . . 347 Melvin A. Shiffman 32 Face and Neck Remodeling with Ultrasound-Assisted Lipoplasty (Vaser). . . . . . . . . . . . . . . . . . . . . . . . . . 357 Alberto Di Giuseppe and George Commons 33 Injection/Filler Rhinoplasty. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 371 George John Bitar, Olalesi Osunsade, and Anuradha Devabhaktuni 34 Suture Lifting Techniques . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 391 Peter M. Prendergast 35 Breast Augmentation with Hyaluronic Acid Filler . . . . . . . . . . . . . . . . . 427 Peter M. Prendergast 36 Cell-Assisted Lipotransfer for Breast Augmentation . . . . . . . . . . . . . . . 445 Kotaro Yoshimura, Yuko Asano, Noriyuki Aoi 37 Penile Enhancement Using Fillers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 459 Hassan Abbas Khawaja and Enrique Hernandez-Perez 38 Body Contouring with Ultrasound-Assisted Lipoplasty (VASER). . . . . 465 Peter M. Prendergast 39 The Use of Low-Level Laser Therapy for Noninvasive Body Contouring. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 509 Robert F. Jackson and Ryan Maloney 40 Ultrasound-Assisted Lipoplasty: Basic Physics, Tissue Interactions, and Related Results/Complications . . . . . . . . . . . . 519 William W. Cimino 41 Medical Management Options for Hair Loss . . . . . . . . . . . . . . . . . . . . . 529 Samuel M. Lam, Brian R. Hempstead, and Edwin F. WilliamsIII 42 Hair Removal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 537 Afshin Sadighha and Gita Meshkat Razavi 43 Carboxytherapy in Aesthetic Medicine . . . . . . . . . . . . . . . . . . . . . . . . . . 547 Nina Koutná 44 Emerging Technologies: Chemical Peels. . . . . . . . . . . . . . . . . . . . . . . . . . 577 Basil M. Hantash and Vishal Banthia 45 Emerging Technologies: Laser Skin Resurfacing . . . . . . . . . . . . . . . . . . 587 Basil M. Hantash and Vishal Banthia 46 Emerging Technologies: Nonablative Lasers and Lights . . . . . . . . . . . . 605 Basil M. Hantash and Vishal Banthia 47 Emerging Technologies in Aesthetic Medicine: Nonablative Skin Tightening. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 617 Basil M. Hantash Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 627
Part I Aesthetic Medicine
1
Defining Aesthetic Medicine Peter M. Prendergast
1.1 Introduction Aesthetic medicine is an art and a science. It is an emerging branch of medicine that relies on procedures and techniques to improve and enhance the appearance, texture, and contours of the skin, face, and body. Although some degree of overlap exists between aesthetic medicine and aesthetic surgery, for the most part, aesthetic medicine employs techniques and technologies that are either noninvasive or minimally invasive and performed without general anesthesia. Invasive surgical procedures that require significant tissue undermining, dissection, or skin excision, such as rhytidectomy, brachioplasty, and abdominoplasty remain the exclusive domain of aesthetic surgery, and are mostly performed in the hospital setting under general anesthesia. Typically, “invasive” procedures in aesthetic medicine require only dermal or subcutaneous injections, punctures, or small incisions. These include botulinum toxins, temporary fillers, fat transfer, suture lifts, and various forms of lipoplasty. These topics are covered in detail in this book. The rapid growth in aesthetic medicine internationally is partly due to an increased patient demand for rejuvenating procedures that do not involve surgery. Patients request procedures not because they are unwell but because they want to look and feel better. This patient profile is unique to aesthetic medicine and surgery, in contrast to most other medical specialties where the focus is on the diagnosis and treatment of
P.M. Prendergast Venus Medical, Heritage House, Dundrum Office Park, Dublin 14, Ireland e-mail:
[email protected]
pathologies and illnesses. With the advent of botulinum toxins, hyaluronic acid fillers, and other nonsurgical procedures, patients can look and feel better quickly and discretely, with virtually no downtime. There is a natural enthusiasm for therapies that are quick, relatively painless, offer natural-looking but measurable results and cause little interruption to normal activities. Although aesthetic medicine has been embraced for this reason, it does not serve to replace aesthetic surgery. The relationship between the two disciplines is synergistic. Occasionally, less invasive techniques can be used in place of surgery for similar indications in patients who request them or where it is considered more appropriate (Table 1.1).
1.2 Origins of Aesthetic Medicine Aesthetic medicine as it is practiced today has evolved from the pioneering efforts, inventions, and discoveries of individuals from a variety of medical and surgical specialties. Jean Carruthers, an ophthalmologist, discovered the remarkable aesthetic application of botulinum toxin [1]. Chemodenervation with botulinum toxins is the most commonly performed procedure in aesthetic medicine [2]. Jeffrey Klein, a dermatologist, developed tumescent anesthesia, making lipoplasty a safe and effective possibility in the office-based setting without sedation or general anesthesia [3]. Fischer, Ilouz, and Fournier, with backgrounds in gynecology, plastic and general surgery, pioneered liposuction techniques in the 1980s [4]. Although fillers have been used for decades, the development and approval of safe, cross-linked hyaluronic acid fillers has revolutionized the practice of soft tissue augmentation for the
P.M. Prendergast and M.A. Shiffman (eds.), Aesthetic Medicine, DOI 10.1007/978-3-642-20113-4_1, © Springer-Verlag Berlin Heidelberg 2011
3
4
P.M. Prendergast
Table 1.1 A comparison of options in aesthetic surgery and aesthetic medicine Indication Face lift Neck lift
Aesthetic surgery Rhytidectomy, MACS lift Neck lift, platysmaplasty
Brow lift Lip enhancement Gummy smile Cheek or chin enhancement Nose reshaping Skin laxity Breast augmentation
Foreheadplasty, endoscopic brow lift Surgical, mucosal advancement Surgical lip lengthening Surgical implants Rhinoplasty Resection, e.g., abdominoplasty Silicone/saline implants
Aesthetic medicine Suture lift Suture lift, tissue tightening, chemodenervation of platysma bands Botulinum toxin, suture brow lift Hyaluronic acid fillers Botulinum toxin Augmentation with injectable fillers Injectable fillers Tissue tightening, e.g., radiofrequency Injectable hyaluronic acid or fat
MACS minimal access cranial suspension
treatment of wrinkles, as well as contouring the face and body. Laser medicine and dermatology developed following the original description of selective photothermolysis by Anderson and Parrish in 1983 [5]. Carbon dioxide laser skin resurfacing became popular in the early 1990s but has largely been replaced by safer, nonablative, or fractional resurfacing devices. Dermatologists, such as Goldberg, have made significant contributions to the dissemination of knowledge on the aesthetic applications of lasers and lights. Shiffman, a general, cosmetic, and oncologic surgeon, has further defined aesthetic medicine by writing and editing numerous books on topics such as liposuction, facial rejuvenation, and body contouring. Aesthetic medicine is therefore characterized by an eclectic collection of techniques, developed or derived from several disciplines, including dermatology, plastic and reconstructive surgery, laser medicine, and various other surgical subspecialties.
1.3 Procedures Procedures in aesthetic medicine address most aging signs including abnormal skin pigmentation, skin laxity, ptosis, rhytids, fat loss, and contour irregularities such as the tear trough deformity. In addition, contouring of the face and body using fillers or lipoplasty is achieved to improve facial and lip volume, define the cheekbones, or remove unwanted fat. A summary of the most common procedures in aesthetic medicine is provided in Table 1.2.
1.4 Training Many of the procedures in aesthetic medicine have been performed for decades, including mesotherapy, lipoplasty, and chemodenervation with botulinum toxins. More recently, aesthetic medicine has emerged as a discipline that integrates established techniques with newer ones such as hyaluronic acid fillers, skin tightening, fractional resurfacing, third generation ultrasound-assisted lipoplasty, and advanced skin imaging. Implementing techniques in aesthetic medicine safely requires appropriate theoretical and practical training in anatomy, aging, patient assessment and selection, anesthesia, technique, potential side effects, and complications and their management. In addition, a thorough knowledge of the materials, products, and devices used in aesthetic medicine should be attained. These include botulinum toxins, temporary, long-lasting, and permanent fillers, volume stimulators, lasers, lights, radiofrequency systems, peeling agents, suture devices, and cosmeceuticals. Several accredited training programs in aesthetic medicine are available worldwide that offer instruction and hands-on training for physicians and surgeons with varying levels of experience [6].
1.5 Future Directions The most defining landmark in the evolution of modern aesthetic medicine was the aesthetic application of botulinum toxin type A. Its use for the treatment of hyperdynamic lines remains the most widely performed cosmetic procedure [2]. Aesthetic applications have
1 Defining Aesthetic Medicine
5
Table 1.2 Procedures in aesthetic medicine Indication Hyperdynamic rhytids Lower face rhytids
Treatment modality Chemodenervation STA with fillers
Facial contouring Photoaging Acne scarring Textural irregularities Dyschromias Telangiectasias, varicose veins Ptosis jowls, brow, cheeks, neck Skin laxity Breast augmentation Lipoplasty Striae
STA with fillers, fat Skin resurfacing Micro-needling Microdermabrasion Selective photothermolysis Sclerotherapy Suture lifting techniques Radiofrequency, infrared STA with fillers Ultrasound-assisted lipoplasty Carboxytherapy
Example products/devices Botox, Dysport, Xeomin Restylane, Teosyal global action, Juvederm SubQ, Teosyal ultimate, Radiesse Fractional CO2 lasers, chemical peels Genuine dermaroller SilkPeel Intense pulsed light Fibro-vein, sclerofoam Silhouette sutures, Anchorage sutures KonturMD, titan Macrolane VRF 20/30 VASER Carboxypen, RioBlush
STA soft tissue augmentation
been expanded to include use in the lower face and neck, as well as hands, axillae, and feet for hyperhidrosis. The future of botulinum toxins will include the addition of new brands, and further refinement in techniques to enhance results. Similarly, novel filler agents will be brought to market with the hope of competing with the main hyaluronic acid brands. The concept of volume restoration with fillers and stimulating agents for facial rejuvenation will continue to play a central role in aesthetic medicine and compliment procedures in aesthetic surgery. Cell-assisted lipotransfer (CAL) and stem cell-enriched fat transfer are novel approaches to autologous fat transfer that promise to improve graft cell survival after grafting to the face or breasts [7, 8]. The role of sutures for facial rejuvenation continues to interest the world of aesthetic medicine. The goal is to improve further upon current suture designs and techniques to enhance results and increase the longevity of visible benefits. It is certain that lasers, ultrasound, and radiofrequency technologies will play a prominent role in the future of aesthetic medicine. Emerging techno logies include fractional lasers, focused ultrasound devices, and multipolar radiofrequency technology for fat reduction and skin tightening [9]. For the same reasons that aesthetic medicine has become widely practiced, antiaging medicine has become one of the fastest growing medical fields today. Put simply, more and more people want to feel good and look good. It behooves the aesthetic physician and surgeon to pay attention to the world of antiaging, preventive, and regenerative medicine as it relates to his own
practice and the patients they treat. Optimizing skin health with nutritional supplements, hormone replacement, or phytotherapy exemplify the synergy between aesthetics and antiaging.
References 1. Carruthers JD, Carruthers JA (1992) Treatment of glabellar frown lines with C: botulinum A exotoxin. J Dermatol Surg Oncol 18(1):17–21 2. The American Society for Aesthetic Plastic Surgery: Cosmetic surgery national databank statistics (2009); Available at: ASAPS website www.surgery.org 3. Prendergast PM (2010) Liposculpture of the abdomen in an office-based practice. In: Shiffman MA, Di Giuseppe A (eds) Body contouring: art, science and clinical practice. Springer, Berlin, pp 219–237 4. Flynn TC (2006) The history of liposuction. In: Shiffman MA, Di Giuseppe A (eds) Liposuction, principles and practice. Springer, Berlin, pp 3–6 5. Anderson RR, Parrish JA (1983) Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 220(4596):524–527 6. The European College of Aesthetic Medicine. Available at: ECAM website www.ecamedicine.com 7. Yoshimura K, Sato K, Aoi N, Kurita M, Inoue K, Suga H, Eto H, Kato H, Hirohi T, Harii K (2008) Cell-assisted lipotransfer for facial lipoatrophy: efficacy of clinical use of adiposederived stem cells. Dermatol Surg 34(9):1178–1185 8. Yoshimura K, Sato K, Aoi N, Kurita M, Hirohi T, Harii K (2008) Cell-assisted lipotransfer for cosmetic breast augmentation: supportive use of adipose-derived stem/stromal cells. Aesthetic Plast Surg 32(1):48–55 9. Fatemi A (2009) High-intensity focused ultrasound effectively reduces adipose tissue. Semin Cutan Med Surg 28(4):257–262
2
Ethical Aspects of Aesthetic Medicine Urban Wiesing
2.1 Introduction When physicians concern themselves with the aesthetic aspects of their patients, public opinion varies on the topic. On the one hand, certain measures are required in order to improve the aesthetic appearance of a person. They are a normal part of the medical profession. For example, to reconstruct the deformed face of a caraccident victim or to give a patient with a serious skin disease the most “normal” appearance possible undoubtedly belongs to the art of medicine. On the other hand, there are several medical procedures that are concerned with the aesthetics of their patients being criticized. For example, one could mention television programs in which physicians help participants to look more like celebrities (“I want a famous face,” MTV). Furthermore, there are cases in which physicians performed aesthetic operations obviously too frequently and with harm to the patient or did not do so in accordance with safety standards [1]. Here the question arose whether physicians’ participation is ethically acceptable. The doubts were supported by the fact that medicine is expanding with the growing number of aesthetic measures to a field that frequently does not have anything to do with the treatment of illness anymore and goes beyond the traditional core of medicine.
U. Wiesing Institut für Ethik und Geschichte der Medizin, Eberhard-Karls-Universität Tübingen, Gartenstrasse 47, 72074 Tübingen, Germany e-mail:
[email protected]
At this point, it should be addressed whether and – if so – under what conditions physicians should perform aesthetic interventions on their patients. This question cannot be answered without reference to the medical profession and its characteristics. Furthermore, one must systematize the various medical efforts for the aesthetics of the patient. Only then, it can be clarified to what extent certain measures are in accordance with the ethos of the medical profession and what responsibility physicians have. Aesthetic operations on children and adolescents as a special case should be examined as well. At this point, the question concerning the participation of the medical profession in certain measures should be discussed. It should not be asked whether a person should have an aesthetic operation or not, but whether physicians should perform it.
2.2 Preliminary Remarks 1. The only measures to be addressed here are those that exclusively serve aesthetic purposes. If measures are carried out for medically functional reasons, then there are usually enough reasons to consider them medically necessary and ethically acceptable (the patient’s consent as a requirement). Furthermore, if medically functional measures happen to be aesthetically beneficial as well, like frequently in dentistry, then this additional characteristic does not provide a reason to doubt its ethical acceptability. 2. Actions for the sake of one’s own aesthetic improvement belong to the basic behavior of human beings. To consciously form the body beyond pure
P.M. Prendergast and M.A. Shiffman (eds.), Aesthetic Medicine, DOI 10.1007/978-3-642-20113-4_2, © Springer-Verlag Berlin Heidelberg 2011
7
8
U. Wiesing
naturalness under aesthetic aspects distinguishes human beings from the animal world. They do this in many ways, be it clothes, cosmetics, care, or sport. It would therefore not be the activity itself, but the measures – the medical, especially surgical intervention – which give rise to a special investigation.
2.3 Moral Construction of the Medical Profession Why should one ask the question whether physicians are allowed to take part in this genuinely human action with all their knowledge and capability? There are people who wish for better looks and physicians who can make this wish come true. What should be problematic about it – it could be asked. In other professions, expansion does not usually raise critical questions. So, why in the medical profession? The medical profession is a unique profession, and whoever doubts it, can take a look in the “Declaration of Geneva of the World Medical Association”. There, the medical profession is committed to one particular goal, namely to the health of the patients: “The health of my patient will be my first consideration” [2]. This goal shapes physicians’ behavior, and for this reason, the medical profession is a profession and not a business. What does this mean? What makes the medical profession so unique? Professions have established themselves in all developed industrial nations and possess the following traits [3]: They primarily aim for a worthwhile goal and not – like a business – primarily for the realization of profit. (That, of course, does not exclude that the members of certain professions earn their livelihood through their job.) However, professions are primarily committed to a socially deemed and important task. The task of medicine is clear: It is supposed to maintain and re-establish health, ease suffering and help sick people. The professions are geared toward the interests of their clients or – in medicine – their patients. For this, a high ethos is expected from the members, an ethos that puts the patient in the center of the considerations and actions. Or, as the World Medical Association International Code of Medical Ethics describes it: “A physician shall be dedicated to providing competent medical service in full professional and moral independence, with compassion and respect for human dignity” [2]. In professions, the services frequently have to be locally based and be personally delivered. They cannot be delegated,
with the exception of assistant physicians. Advertising is only allowed within limits – at least in numerous countries – as to not induce demand. Why is this orientation so important for physicians, why is a high ethos from the members of the medical profession demanded, why do they have to work in a patient-oriented fashion? If one puts oneself in the situation of a patient, then an answer can be found: people experience various difficulties in the course of their lives such as health problems, and it proved to be beneficial as an answer to these contingencies for sick people that the members of certain professions (in this case the medical profession) dedicate themselves to the patients’ problems, are competent and act patient-oriented. Sick people must expect that the members of the medical profession know exactly what they are doing, have a command of their duties and simultaneously use these abilities to the benefit of the patient. Patients must trust that physicians possess a certain ethos, a work-related, humane disposition. Physicians cannot guarantee the success of a medical measure, but they can guarantee that they possess abilities and take a certain moral stance. Since the patients cannot verify the stance of each and every member of the profession in advance, they have to rely on the fact that just because someone is a member of the profession, certain capabilities and moral stances can be expected. It is in the sense of professionalism, of a binding professional ethos, because it makes the so-called system of anticipatory trust possible [4]. A working party on “Doctors and Society Medical professionalism in a changing world” of the Royal College of Physicians defined in 2005 medical professionalism “as a set of values, behaviours, and relationships that underpin the trust the public has in doctors” [5]. The patient can expect certain behavior simply because of the membership in the medical profession. The system of medicine entitles one to the expectation. This confidence is certainly not to be understood as a nostalgically glorifying adjunct to a service relationship, but is essential in the doctor– patient relationship. With that, the profession agrees to a contract with society. “Professionalism is the basis of medicine’s contract with society. It demands placing the interests of patients above those of the physician, setting and maintaining standard of competence and integrity” [6]. This should also be considered if one wants to answer the question to what extent physicians should
2 Ethical Aspects of Aesthetic Medicine
be devoted to the aesthetics of their patients. Then, one should study the measures taken to change the aesthetics of a person to determine whether they threaten the constitutive element of medicine, namely the “system of anticipatory trust.”
2.4 Classification of Aesthetic Interventions First, the undisputed cases are discussed that were already mentioned above: there is no doubt that several aesthetic interventions are compatible with the medical ethos. As a profession, physicians are committed to health. When they treat the ill, thereby correcting the aesthetic drawbacks of a disease, there is no contradiction with the medical ethos. However, with that the whole area of aesthetic interventions is not covered for the following two reasons: 1. The concept of disease is fuzzy around the edges; it also has changed historically. For many symptoms, it can be difficult to say whether they should be regarded as a disease or not. The best-known examples are the symptoms of aging: Are they diseases or the physiological course of events? 2. Certain aesthetic interventions to correct conditions are beyond what – despite all the uncertainty – is widely seen as a disease. How should physicians face up to that? In order to assess these aesthetic interventions ethically, a subdivision is proposed here that is oriented to the attention of events. Medical interventions for the purpose of altering the aesthetic appearance can 1. diminish undesired, excluding or negatively perceived attention from other people, 2. increase positively perceived attention from other people. We must realistically concede that this distinction is not clear-cut for all cases. There could be cases in which both aspects are touched upon. However, this distinction proves to be helpful for the issue discussed here.
2.5 Medical Ethos and Aesthetic Activities The first group: This includes, for example, medical treatment of disfigurements or of characteristics that act stigmatizing and often but not always have a disease reference, which often but not always differs widely
9
from the average. The treatments are reconstructive in many cases, inasmuch as they want to restore a “normal” state as much as possible. With these treatments, people should get the chance to lead a life free of excessive, unwanted negatively perceived attention, a life free of stigmas. Basically, one wants to help them get to that “normal” level of attention as much as possible and avoid stigmatization and exclusion. These measures can be justified by considerations of justice: It’s about giving people chances for a good life, or, as the “Central Ethics Commission at the German Medical Association” recently formulated it, as a maxim for allocating resources in health care, making it possible for humans to “participate in social life” [7]. There is no doubt that measures to prevent stigmatization – within the scope of good medical treatment – are compatible with the medical ethos and do not compromise the medical profession in any way, provided that they are carried out lege artis. This is also true when it is a matter of aesthetic, not functional corrections. The other group of aesthetic measures, including operations, however, intends to increase desired, positively perceived attention from others through physical changes. In addition, the changed appearance is supposed to contribute to the attractiveness in comparison with others. Frequently, these operations are supposed to correct the symptoms of old age or effects of excess weight. There is usually no sign of disease and no “medical” indication. The patient’s desire and money decide on the measure. What happens in the relationship between physician and patient in this case? There is no medical indication and therefore the physician is not responsible for an indication. The physician is only responsible for proposing a method by which the patient’s goal should be achieved and for proper performance. Therefore, the physician’s responsibility has changed dramatically. Since it has nothing to do with the health of a patient, the physician is not obligated to perform such measures. But are physicians not allowed to perform for this reason? And if they do it, if physicians offer purely cosmetic measures, even operations, will the medical profession be compromised? Simply because of the lacking reference to illness, trust in the medical profession is not necessarily compromised when it comes to purely aesthetic measures. For example, physicians are already working in areas beyond illness, whether it be abortion, contraception, improvement of performance through training in
10
sports, etc. However, what needs to be guaranteed to ensure that the “system of anticipatory trust” is not compromised? 1. Measures that the patient wants but cannot really help the patient in any way should not be performed. For example, if the patient’s desire for a change in appearance is caused by a serious mental disorder, a medically obtained change in appearance will probably not relieve the suffering of the patient. Here, it is the physician’s duty to recognize this and suggest other helpful measures such as further discussions or psychotherapy. The International Code of Medical Ethics of the WMA states: “A physician shall act in the patient’s best interest when providing medical care” [2]. 2. The consultation must also be geared toward the goal of assisting the patient and searching for an appropriate approach for him or her. The consultation shall not serve the purpose of “selling” a particular measure. “Placing the interests of patients above those of the physician” [6] is one of the fundamental principles of professionalism. 3. The patients also have to be thoroughly informed that there is no medical indication to be found. They have to be informed in detail about the measure and must give their free informed consent. 4. The high standards of avoiding harm must be maintained. Medical measures generally bear risks, but the avoidable ones should be avoided, especially those that come with voluntary operations. Otherwise, it would go against the basic principle of “setting and maintaining a standard of competence of professionalism” [6]. 5. Advertising should be limited to factual information as not to induce demand. These conditions must be met in order to exclude that a measure, which is most likely not helpful, is implemented, that the patient is forced to do it, is not sufficiently informed and that preventable damage occurs. All this would jeopardize the “system of anticipatory trust” in the medical profession. But, if this is largely excluded, then the answer to the central question of how aesthetic actions jeopardize the medical profession is: This is not the case, provided that the orientation towards the patient and the high quality of consultation and implementation are guaranteed. Cosmetic medicine and particularly cosmetic surgery expand what medicine has to offer, but they do not demonstrate any unknown, new dimension of
U. Wiesing
medical practice. It would certainly give cause for concern if physicians displayed in their traditional area (the treatment of diseases) even some of the attitude from aesthetic medicine, namely that only the will and financial power of the customer can make something happen. However, provided that this is not the case for the main medical duty – the prevention, treatment or alleviation of disease – the medical profession would with certain cases of cosmetic interventions, in particular of purely cosmetic surgery, only expand their services. If the medical profession makes this expansion recognizable, and a high standard of quality in aesthetic medicine and patient orientation is guaranteed, there is no reason for a threat to the “system of anticipatory trust” and the medical profession to be seen.
2.6 Aesthetic Measures for Children and Adolescents? The suggested distinction between “reducing undesired attention” and “increasing desired attention” is also supportive for assessing the situation of children and adolescents. Of course, a clear-cut line cannot always be found even in these cases. Nevertheless, one can divide the interventions according to the previously noted distinction concerning attention to events into two groups: How should aesthetic medical interventions, even operations on children and adolescents be assessed, that are supposed to reduce undesired, exclusionary, negatively perceived attention from other people and those intended to increase positively perceived attention? In the first group, for example, could be operations on injuries that caused disfigurement or characteristics that can have a stigmatizing effect. A good example would be bat ears. Their correction carried out on children and adolescents can be justified insofar as one would like to provide the child or adolescent with the chance of an unencumbered childhood or adolescence without frequent, undesired, negatively perceived attention, without a stigma. Exclusion and teasing should be prevented. At this particular period in life, social contacts and confidence are extremely important because they facilitate opportunities for a further good life. Orientations on a concept of illness in the process are not helpful and are not even mentioned, for example, at the surgery on bat ears.
2 Ethical Aspects of Aesthetic Medicine
The assessment looks completely different for operations or measures that only serve the purpose of drawing desired, positively perceived attention from others onto oneself through physical change. With such operations or measures, children or adolescents enter a contest for additional attention. The contest is present anyway and is largely unavoidable, especially in youth. However, this raises the question as to whether this contest should be exacerbated by the possibilities of medicine. There are convincing reasons to speak against it, especially when it comes to aesthetic operations. First, the medical risks should be mentioned: In addition to the usual medical risks, the results of operations during childhood or adolescence are more difficult to be predicted because of their growth. The possibility of an unwanted result is increased in case of some surgical procedures. Furthermore, cosmetic operations and other medical measures confirm and strengthen the competition for desired, positively perceived attention through physical appearance just by being yet another available tool. The pursuit of altering the aesthetic appearance (that does not stop at surgery) is problematic in two senses: It suggests that we must be beautiful on the one hand and must be willing to have cosmetic surgery for beauty on the other. This could induce increased suffering, while simultaneously offering services for the reduction of suffering. It would be more desirable to not dictate new standards and suggest new measures for rule compliance, but to provide an unencumbered childhood and adolescence without additional aesthetic pressures. These arguments speak for a restriction of aesthetic measures and operations on children and adolescents that only serve the purpose of increasing the desired attention. Nevertheless, there are convincing arguments for the avoidance of stigmatization of children and adolescents through medical interventions.
11
2.7 Conclusions Medical interventions that are only supposed to increase the desired, positively perceived attention from others are not necessary according to medical ethos. However, they do not go against them, provided that high quality requirements are guaranteed. The measures have to be deemed beneficial to the patient in advance, a patient must be informed and the avoidance of harm must be guaranteed. Aesthetic measures, especially operations, which only serve the purpose of increasing desired, positively perceived attention, should not be performed on children and adolescents. Nevertheless, there are convincing arguments for an avoidance of stigmatization of children and adolescents, even through medically aesthetic measures.
References 1. Mercer N (2009) Clinical risk in aesthetic surgery. Clin Risk 15:215–217 2. http://www.wma.net/en/30publications/10policies/c8/index. html 3. Taupitz J (1991) Die Standesordnungen der freien Berufe, Geschichtliche Entwicklung, Funktionen, Stellung im Rechtssystem. De Gruyter, Berlin 4. Schluchter W (1980) Rationalismus der Weltbeherrschung, Studien zu Max Weber. Suhrkamp, Frankfurt am Main, p 191 5. http://www.rcplondon.ac.uk/pubs/books/docinsoc/docinsoc. pdf 6. ABIM Foundation. American Board of Internal Medicine, ACP-ASIM Foundation. American College of PhysiciansAmerican Society of Internal Medicine, European Federation of Internal Medicine (2002) Medical professionalism in the new millennium: a physician charter. Ann Intern Med 136(3):243–246 7. Stellungnahme der Zentralen Kommission zur Wahrung ethischer Grundsätze in der Medizin und ihren Grenzgebieten (Zentrale Ethikkommission) bei der Bundesärztekammer. Priorisierung medizinischer Leistungen im System der Gesetzlichen Krankenversicherung (GKV). Deutsches Ärzteblatt (2007) 104:A1–5, A2
Part II Preoperative
3
Medical History Melvin A. Shiffman
3.1 Introduction With any patient who is first seen by the physician, a proper history should be obtained. Not only the patient complaints but a proper complete medical history should be taken. In aesthetic medicine, as with many medical specialties, there is a tendency to shortcut the history with the idea that it is not important to learn everything about the patient. In medical malpractice litigation, the medical record is the best defense.
3.2 Content of the History 3.2.1 Format of a Proper Medical History Some of the worst and consistent problems this author has encountered in examining records for medical legal problems are the lack of enough information to make a diagnosis and decide on treatment and the extraordinary lack of readable handwriting. If the record cannot be read by another person, it is useless. The physician with poor hand writing must understand that the record must then be printed or typed out, whatever the cost. The record should contain the present complaints, list of allergies, past medical history, prior surgical
M.A. Shiffman Surgery Section, Newport Specialty Hospital, 17501 Chatham Drive, Tustin, CA 92780-2302, USA e-mail:
[email protected]
procedures, family history, and review of systems. This is taught in medical school and should be followed consistently. Many of these aspects of the history can be filled out by the patient if there is a standard form.
3.2.2 Present Complaints The first aspect of a proper history is to find out what the patient is complaining about. Have the patient explain what he/she is concerned about, why he/she is bothered by the perceived deficit, and what he/she wishes to have done. Cover all the possible aesthetic problems with the patient. Have the patient point out the exact areas of the face or body to be sure what is being complained about.
3.2.3 Allergies A standard form (Table 3.1) with a request to list allergies may not be enough. Some injectable fillers with a known propensity for allergies should be listed, such as collagen, porcine products, and hyaluronic acid. Charriere et al. [1] reported a positive skin test in 3.8% of patients and adverse reactions in 2.3% of patients with negative skin testing. Allergic reaction to hyaluronic acid complications has occurred [2]. Lidocaine is in some injectable fillers and should be specifically listed since allergy can be present. There should be a question as to whether the patient has had any reaction, especially allergic, to any subdermal filler.
P.M. Prendergast and M.A. Shiffman (eds.), Aesthetic Medicine, DOI 10.1007/978-3-642-20113-4_3, © Springer-Verlag Berlin Heidelberg 2011
15
16 Table 3.1 Allergies 1. Please list any allergies especially to foods and medications _________________________________________________ _________________________________________________ _________________________________________________ 2. Have you ever had a reaction to (please circle): a. Iodine b. Seafood c. Collagen injections d. Porcine (pig) products e. Hyaluronic acid injections f. Any dermal fillers g. Any local anesthetic including lidocaine
For safety purposes, the list of allergies should be placed on the front of the patient’s chart.
3.2.4 Present Medications A list of all present medications should be obtained (Table 3.2). A standard form requesting the information can be used. Present medications may give an indication of disorders being treated that were not recalled by the patient. Ask if the patient has had steroids within the prior 6 months.
M.A. Shiffman Table 3.2 Present medications Please list all medications you are presently taking: _________________________________________________ _________________________________________________ _________________________________________________ _________________________________________________ Are you taking any medications with aspirin? _______________ Are you taking any nonsteroidal anti-inflammatory drugs? _____________ Are you taking any medications for or are you on a diet for diabetes? ____________ Do you take any herbal medications? ________________
3.2.6 Past Surgical History The past surgical history can be in the form of a questionnaire (Table 3.4). The past surgical history may not seem important for an aesthetic medicine physician, but any surgical procedure that had been performed in the area you intend to treat may portend problems if not known about. Be especially aware of prior cancer having been treated surgically. The area of treatment may have residual or recurrent cancer or there may be metastatic disease. Sometimes it may be prudent to send for the surgical records from prior surgery.
3.2.5 Past Medical History The past medical history can be a questionnaire filled out by the patient (Table 3.3). Some specific questions should be asked about autoimmune diseases, including dermatomyositis, lupus erythematosis, or rheumatoid arthritis, since collagen should not be injected into such patients. All prior medical aesthetic procedures should be in the questionnaire including the exact place of each area that was treated and with what method. If fillers have been used, then the exact kind of filler should be determined. If the patient does not know, a release for medical records should be signed and the records retrieved from the treating physician. Most of the time, it is best to send for the records since there may be more to the prior treatment than the patient remembers.
3.2.7 Family History The family history can be in a standard questionnaire form (Table 3.5). Ask specific questions of the important body systems that may be related to hereditary problems to be sure nothing is missed.
3.2.8 Review of Systems Review of systems is usually in a standard questionnaire form including each system (Table 3.6). Be especially aware of heart and/or lung problems, if deep sedation or general anesthesia is contemplated.
3 Medical History Table 3.3 Past medical history Please list all chronic or serious diseases that you have had treated: _________________________________________________ _________________________________________________ _________________________________________________ Have you ever had (please circle): 1. Hypertension (high blood pressure), heart or lung disease 2. Diabetes 3. Kidney or urinary tract disease 4. Autoimmune disease such as lupus erythematosis, dermatomyositis, rheumatoid arthritis 5. Thrombosis or pulmonary embolism 6. Cancer 7. Liver disease 8. HIV or AIDS Have you ever been hospitalized for any disorder? If yes, please explain _________________________________________________ _________________________________________________ Have you had a recent infection (within the past 30 days)?
17 Table 3.5 Family history Please circle any of the disorders below that have occurred in any of your family members including children, parents, aunts and uncles, and grandparents: 1. Cancer 2. Heart disease 3. Autoimmune disease such as lupus erythematosis, dermatomyositis, rheumatoid arthritis 4. Glaucoma Table 3.6 Review of systems Have you had within the past 6 months any disorders involving (please circle): 1. Eyes, ears, nose, or throat 2. Heart or lungs 3. Kidney or urinary tract 4. Sex organs 5. Joints or bones including the back 6. Muscles 7. Stomach or bowel 8. Skin
3.3 Conclusions
Table 3.4 Past surgical history Please list all the cosmetic or aesthetic procedures that you have ever had including the dates if possible: [Please include injections of dermal or skin fillers and botulinum toxin] _________________________________________________ _________________________________________________ _________________________________________________ _________________________________________________ Please list all surgeries that you have had (include the dates if possible): _________________________________________________ _________________________________________________ _________________________________________________ _________________________________________________
A proper history is the essence of the practice of medicine. Even with limited medical aesthetic procedures to be proposed, there is a need to evaluate the patient properly and thoroughly. It is relatively simple for patients to fill out the necessary forms before being seen by the physician.
References 1. Charriere G, Bejot M, Schnitzler L, Ville G, Hartmann DJ (1987) Reactions to a bovine collagen implant. Clinical and immunologic study in 705 patients. J Am Acad Dermatol 21(6):1203–1208 2. http://www.ukcosmeticsurgery.info;hylaform. Accessed 23 Dec 2009
4
Clinical Assessment of Facial Aging Melvin A. Shiffman
4.1 Introduction The purpose of classifying facial aging is to have a clinical method to determine the severity of the aging process in the face. This allows an estimate as to the types of procedures that the patient would need to have the best results. Procedures that are presently used for facial rejuvenation include laser, chemical peels, suture lifts, fillers, neck left, brow lift, blepharoplasty, rhinoplasty, otoplasty, suture facelift, modified facelift, and full facelift. All of these procedures have modifications and variations. The physician is already using his best judgment to determine which procedure would be best for any particular patient. This classification may help to refine these decisions.
4.2 Clinical Classification The clinical classification utilizes different areas of the face that are affected by the aging process (Table 4.1). The appearance of a tear trough depression is one of the first manifestations of facial aging. This is followed by extension of the tear trough and
loss of cheek fat, prominence of the jowls, and then deepening of the various facial folds. The most prominent fold is the nasolabial fold followed in time by the marionette lines. The use of neck manifestations such as loose skin, platysmal bands, and transverse folds is variable since a heavy neck would hide these changes (Fig. 4.1) and a thin neck may show the changes earlier. These bands and skin looseness may require neck lift and resection of the platysmal bands. Rhytids (wrinkles) generally are a result of heredity, skin aging from sun damage, overuse of facial expression muscles, sleep pressure, and skin laxity (Fig. 4.2). Rhytids can be treated with chemical peel or laser resurfacing. Laxity of eyelid skin and appearance of eyelid fat pads occur with aging but the skin laxity may be associated with heredity and sun damage. Treatment would consist of blepharoplasty. Ears can be prominent and distressing to the patient and this is corrected with otoplasty. The nose may have features that are noticeable and bothersome to the patient that would require some form of rhinoplasty.
4.3 Use of the Clinical Classification M.A. Shiffman Surgery Section, Newport Specialty Hospital, 17501 Chatham Drive, Tustin, CA 92780-2302, USA e-mail:
[email protected]
The clinical classification for rapid evaluation of a patient concerns mainly the midface. The first change of aging from Stage 0 (no changes noted) to Stage 1 is the appearance of a deepening in the tear trough and a very
P.M. Prendergast and M.A. Shiffman (eds.), Aesthetic Medicine, DOI 10.1007/978-3-642-20113-4_4, © Springer-Verlag Berlin Heidelberg 2011
19
20
Table 4.1 Clinical classification of facial aging [1]
a
M.A. Shiffman Stage 0 1 2 3 4
Tear trough depth None Slight: to cheek fat Mild: into cheek fat Moderate Severe
Cheek fat loss No loss No loss Slight loss medially Moderate Severe: flattening of cheek prominence
b
c
Fig. 4.1 Morbid obesity leaves the neck fat, hanging, and a challenge to treat
Nasolabial fold depth None Slight Mild Moderate Severe
Jowl prominence None None Slight Moderate Severe
4 Clinical Assessment of Facial Aging
a
21
b
Fig. 4.2 (a) A face with no aging. (b) The same face when submitted to rhytids, skin damage with hyperpigmentations, deep nasolabial folds, neck platysma bands, and flattening of the cheeks
slight appearance of the nasolabial fold depth (Figs. 4.3 and 4.4). This is followed by extension of the tear trough with slight loss of cheek fat medially, mild nasolabial fold deepening, and the appearance of the jowl prominence in Stage 2 (Fig. 4.5). Stage 3 (Fig. 4.6) has a slightly more prominent tear trough depth than in Stage 2, moderate loss of total cheek fat, moderate depth of the nasolabial fold, and mild to moderate prominence of the jowls. Stage 4 has severe changes in all of the areas being examined (Fig. 4.7). Not every patient presents with these changes at the same time or in the same order. The most prominent category of change is in the extent of the tear trough and loss of cheek fat. Classification should take this into account when deciding the type of procedure for any particular patient.
4.4 Treatment Stage 0 ordinarily needs no treatment, whereas Stage 1 would improve with a filler such as autologous fat to the tear trough. Stage 2 would be improved with fillers to the tear trough and cheeks while suture lifts can be attempted to improve the jowl prominence (possibly with minimal liposuction) and nasolabial fold. Stage 3 would be treated with fillers in the defect areas, liposuction of the prominent jowls, as well as possibly a modified facelift if there were sufficient skin laxity. Stage 4 would benefit by fillers and possibly a full facelift. As the skin gets more sun damage and more rhytids appear, consideration should be given to the use of chemical peels and laser. Suture lift of the neck for mild
22
a
M.A. Shiffman
b
c
Fig. 4.3 Stage 0. No loss of fat in the cheeks or evidence of nasolabial trough
4 Clinical Assessment of Facial Aging
a
23
b
c
Fig. 4.4 Stage 1. No loss of cheek fat but slight tear trough depression
24
a
M.A. Shiffman
b
c
Fig. 4.5 Stage 2. Slight loss of cheek fat with mild tear trough depression
4 Clinical Assessment of Facial Aging
a
25
b
c
Fig. 4.6 Stage 3. Moderate loss of cheek fat with tear trough depression into the cheek
26
a
M.A. Shiffman
b
c
Fig. 4.7 Stage 4. Severe loss of cheek fat and tear trough extending into cheek
4 Clinical Assessment of Facial Aging
27
loose skin does not work very well. Neck lift surgery should be considered for moderate laxity of the neck skin and transection of platysmal bands would help.
shape of the ears and nose. Classifying these problems helps to determine the possible treatment that may be required.
4.5 Conclusions
Reference
Evaluation of the face and neck includes all aspects of the skin including looseness, wrinkles, scarring, and depressions; fat accumulations or loss; bone loss; and
1. Shiffman MA (2007) Facial aging: a clinical classification. Indian J Plast Surg 40(2):178–180
5
Assessment and Treatment of Excess Weight Melanie T. Turk
5.1 Introduction Overweight (a body mass index [BMI] between 25.0 and 29.9 kg/m2) and obesity (a BMI of 30 kg/m2 or more) [1] are wide-spread, global health problems [2]. In fact, obesity has surpassed undernutrition and infectious disease as the most substantial contribution to poor health and mortality worldwide [3]. The latest prevalence statistics for the United States from 2007 to 2008 show that 68.3% of adults age 20 and older are either overweight or obese, with 33.9% of this group considered obese [4]. Recent predictions indicate that as many as 47.5% of US adults will be obese by 2018, and $344 billion or 21% of US direct health care dollars will be spent on obesity-related illnesses [5]. Clearly, extensive weight loss treatment strategies are needed to abate this epidemic. Primary methods for the treatment of overweight and obesity have included a number of approaches. Behavioral modification of lifestyle in combination with reduced energy intake and increased energy expenditure continues to be the cornerstone of obesity treatment. Additional modalities of treatment, including pharmacotherapy and bariatric surgical approaches, have shown some success in assisting with weight loss, but potential side effects or complications are an unfortunate reality of these interventions. Ongoing adherence to lifestyle change is often difficult for many patients though, making successful long-term management of weight
M.T. Turk Duquesne University School of Nursing, 524 Fisher Hall, 600 Forbes Avenue, Pittsburgh, PA 15282, USA e-mail:
[email protected]
problematic, but some strategies have been shown to improve weight loss maintenance. This chapter presents techniques for the treatment of overweight and obesity based on empirical findings and evidence-based clinical guidelines and will include (1) assessment and evaluation of the overweight or obese patient; (2) treatment strategies including lifestyle modification (dietary intake, physical activity, behavioral modification), pharmacotherapy, and surgical therapy; and (3) weight loss maintenance strategies.
5.2 Assessment 5.2.1 Body Mass Index Evaluation of the patient should begin with assessment of BMI, which can be calculated as the weight in kilograms divided by the height in meters squared or weight in pounds multiplied by 704.5 then divided by the height in inches squared [6]. See Table 5.1 for the categorization of overweight and obesity according to BMI. Increased risk for chronic health problems is seen as BMI rises; even within the normal range, an increased risk is noted from a BMI of 21 kg/m2 [7]. An evidence-based review centered upon the primary care clinician’s role in diagnosing and treating overweight and obese patients concluded that BMI should be another vital sign used to screen for and determine treatment options for these patients [8]. Information ascertained by a scientific review of the World Health Organization (WHO) indicates that different relationships between BMI, percentage of body fat percentage, and health risks exist for Asian patients compared to patients of European descent [9]. A prospective
P.M. Prendergast and M.A. Shiffman (eds.), Aesthetic Medicine, DOI 10.1007/978-3-642-20113-4_5, © Springer-Verlag Berlin Heidelberg, 2011
29
30
M.T. Turk
Table 5.1 Categorization of body mass index (BMI) BMI (kg/m ) <18.5 18.5–24.9 25–29.9 30–34.9 35–39.9 ³40 2
Category Underweight Normal weight Overweight Obese: Class 1 Obese: Class 2 Obese: Class 3
Adapted from National Heart, Lung, and Blood Institute [6]
study in Taiwan of more than 36,000 adults age 40 and older found that for every unit increase in BMI, from 25 kg/m2 and higher, a 9% increase in all-cause mortality risk was noted [10]. Thus, the Western Pacific Regional Office of the WHO in conjunction with the International Association for the Study of Obesity and the International Obesity Task Force recommend that the BMI cut point for obesity be lowered to 25.0 kg/m2 and to 23.0–24.9 kg/m2 for overweight among Asian populations [11]. Differences between specific Asian groups suggest the need for BMI cut points that are specific to the Asian country and ethnicity [12].
5.2.2 Waist Circumference Because central or abdominal obesity is associated with visceral fat around the abdominal organs, measurement and monitoring of waist circumference is an important part of the complete clinical assessment. Abdominal obesity has in fact been found to have a strong relationship with risk for coronary heart disease and metabolic disorders like impaired glucose functioning or diabetes mellitus [13, 14]. Specifically, intra-abdominal adiposity is a more sensitive predictor of obesity-related morbidity and mortality than BMI [15, 16], and a large waist is associated with an increased risk of heart failure, myocardial infarction, and all-cause mortality in patients with cardiovascular disease [17]. Even among normalweight patients, an elevated waist circumference is associated with increased risk of disease [18, 19]. The National Heart, Lung, and Blood Institute’s evidence report on the evaluation and treatment of overweight and obesity [1] advises measurement of waist circumference as a suitable technique for assessing the patient’s visceral adiposity (Table 5.2). Cutpoints by gender have been determined as a basis for pinpointing relative risk to develop obesity-associated health problems. High risk for the development of
Table 5.2 Process for waist circumference measurement • With the patient wearing an examining gown, stand to the right of the patient and palpate the right iliac crest • Draw a horizontal line just above the edge of the iliac crest and cross the horizontal line with a vertical line at the midaxillary position • With the measuring tape horizontal to the floor and snuggly against the skin without pressure, circle the abdomen at the level of the marked location • Measure the circumference at the end of the patient’s normal exhalation Adapted from National Heart, Lung, and Blood Institute [6]
morbidities related to obesity (dyslipidemia, cardiovascular disease, and type 2 diabetes) is associated with a waist circumference of 102 cm (40 in.) for men and 88 cm (35 in.) for women [20]. As with BMI, increased risk is seen at a lower waist circumference for Asian populations compared to those of European descent. Because of this, recommended waist circumference cut-points have been designated at 90 cm (35.5 in.) for Asian men and 80 cm (31.5 in.) for Asian women [11]. Further investigations of the relationship between waist circumference and disease risk have noted differences among Asian groups, and subsequent recommendations include an 80–85 cm waist circumference for men and a 70–75 cm waist for Asian women [21, 22]. See Table 5.2 for the description of how to accurately measure waist circumference.
5.2.3 Assessment of Knowledge and Motivation Ascertaining the patient’s underlying knowledge of nutrition, physical activity, and the consequences of obesity along with the patient’s motivation to enact lifestyle change is an important initial step in treating patients with excess weight. Assessment of current eating patterns and the interest in changing eating habits can be accomplished using a brief questionnaire [23] that can assist in identifying particular problem areas for calorie intake, e.g. high-calorie snacks or sugar-sweetened beverages. This assessment may also be accomplished by asking the patient to complete a 3-day food diary, which would include documenting all food intake on two working days and one leisure day; the patient should be directed as to how to complete the diary and the specifics to include (e.g., precise amount of food consumed and actual food labels
5 Assessment and Treatment of Excess Weight
if the item is uncommon) [24]. Evaluation of current physical activity patterns is essential to determine the patient’s energy expenditure, and brief assessment tools are available that ask the patient to report the duration and frequency of vigorous activity and moderate activity (like walking) in a typical week [25]. Furthermore, patients may not have an understanding of the health consequences of obesity or realize the effects of excess body weight (EBW) on physical and mental health. Younger patients may need to be educated about the effects of elevated glucose or cholesterol levels, while older patients already experiencing the comorbidities associated with obesity may not realize that some are reversible with weight loss. Patient goals and motivation for change play a critical role in weight loss success. Providers need to evaluate factors like the patient’s attitude related to weight loss, history of weight loss attempts, readiness to begin lifestyle changes [1], and self-efficacy for [26] and barriers to weight loss [27]. Patient goals and expectations for weight loss are often 2–3 times higher than the 8–15% weight loss typically seen; patients are then dissatisfied when they do not reach these goals [6]. Clinicians should help patients be realistic about weight loss goals and reinforce the value of losing 5–10% of one’s body weight, a loss that is associated with an improvement in the metabolic profile and decrease in heart disease risk factors [28]. The initial goal for weight loss should be 10% of current weight at a rate of 1–2 lb (0.5–0.9 kg) per week with the maintenance of that lower body weight long-term [6]. Decisions about goals for weight loss should be arrived at jointly between the clinician and the patient. Evidence suggests that an adverse health episode is a motivating event for a patient to initiate weight loss and actually relates to higher weight loss and less weight regain [29], which indicates that these episodes could be used by clinicians to initiate the discussion about weight loss with the patient. For patients who are ambivalent about weight loss, the clinician should discuss the health risks of EBW along with the benefits of losing weight and how the clinician will assist the patient with the process. Motivational interviewing, a patient-centered style of counseling aimed at bringing about behavior change by increasing intrinsic motivation and assisting patients to examine and reconcile ambivalence [30], can be an effective method to encourage behavior change and weight loss [31], even in the format of a brief 15-min appointment [32].
31
5.3 Treatment Approaches Lifestyle modification for weight loss includes three chief components – dietary treatment, increased physical activity, and behavioral therapy [6]. Behaviors resulting in a reduction in caloric intake and an increase in energy expenditure are promoted and reinforced by strategies learned through standard behavioral weight loss treatment [33]. Pharmacotherapy and surgical intervention are second-line treatment approaches considered adjunctive to lifestyle modification. The addition of pharmacotherapy is reserved for individuals with a BMI ³ 30 kg/m2 or those with a BMI ³ 27 kg/m2 and comorbid weight-related diseases or risk factors. Surgical intervention is considered for individuals with extreme obesity (BMI ³ 40 kg/m2) or a BMI ³ 35 kg/m2 if comorbid conditions exist [1]. The following paragraphs discuss the elements of lifestyle modification as well as pharmacotherapy and surgical treatment for weight loss.
5.3.1 Dietary Treatment A negative energy balance is the feature component of successful weight loss and the extent of this deficit is the greatest determining factor for how quickly and how much weight is lost [34]. A reduction in daily caloric intake is the main characteristic of dietary therapy, and patients should reduce total calories consumed by 500–1,000 kcal/day to achieve a 1–2 lb/ week weight loss. This low-calorie diet typically results in patients consuming 1,000–1,600 calories per day and has been associated with an 8% weight loss after 6 months [6]. In addition to reducing calories, patients should be counseled to decrease fat intake to 20–30% of total daily calories in order to address risk factors like elevated blood cholesterol and hypertension. Nutritional education is also incorporated in dietary therapy. For example, patients are instructed about the energy content of foods (4 calories in a gram of carbohydrate or protein, 9 calories in a gram of fat, and 7 calories in a gram of alcohol), how to read and evaluate food labels, food preparation techniques to reduce fat and calorie content, limiting consumption of high-calorie foods, and reducing portion sizes. See Table 5.3 for the Low-Calorie Step I diet suggested by the National Heart, Lung, and Blood Institute [6].
32
M.T. Turk
Table 5.3 Low-calorie step 1 diet Nutrient Calories Total fat Saturated fatty acids Monounsaturated fatty acids Polyunsaturated fatty acids Cholesterol Protein Carbohydrate Sodium chloride
Calcium Fiber
Recommended consumption Reduction of 500–1,000 kcal/ day from typical intake Maximum of 30% of total calories 8–10% of total calories Up to 15% of total calories Up to 10% of total calories Less than 300 mg/day About 15% of total calories 55% of total calories Maximum of 100 mmol/day (about 2.4 g of sodium or 6 g of sodium chloride) 1,000–1,500 mg/day 20–30 g/day
Adapted from National Heart, Lung, and Blood Institute [6]
Much attention has recently been given to the use of low-carbohydrate diets for weight loss. When consuming a very-low-carbohydrate diet (e.g., <20 g/day), ketones are generated to maintain fuel utilization in the brain, which some short-term evidence suggests may help with dietary adherence through decreased hunger [35]. Although larger weight losses have been seen with a low-carbohydrate diet in the short term [36], long-term data are still lacking regarding the benefits of this diet for weight loss maintenance. A large, multisite trial found that diets with a reduction in calories resulted in similar 2-year weight losses no matter which macronutrient was emphasized [37]. Similar results were noted by Vetter et al. [38] after 36 months, although their results showed a larger weight regain after 12 months in the low-carbohydrate group compared to the low-fat group. A trial that compared the popular diets of Atkins, Zone, Weight Watchers, and Ornish found that adherence to the dietary plan was more important for 1-year weight loss than the type of diet [39]. Of concern regarding the low-carbohydrate diet is the high-fat and high-protein intake that often accompanies this diet and the subsequent effect on heart disease risk factors. Benefits and disadvantages to the low-carbohydrate diet regarding the effect on the lipid profile compared to a low-fat diet have been reported. Greater decreases in triglycerides and increases in HDL-cholesterol have been associated with following a low-carbohydrate diet, but increases in LDL-cholesterol and total cholesterol have also been noted [40, 41]. A recent study examining the
effect of these diets on endothelial function suggests that diets that are very low in carbohydrate intake and high in fat intake may result in decreased flow-mediated dilatation and have negative long-term effects on vascular function [42]. Additional aspects of dietary treatment that must be considered by practitioners as they provide guidance to patients about weight loss include counseling on food portion sizes along with frequency and timing of meals [43]. The ubiquity of large portion sizes in our environment has led to a perception that these portions of food and beverages, which are commonly at least two times the size of a standard serving size [44], are appropriate amounts to consume in one eating session. This distortion of portion sizes is supported by serving utensils, plates, glasses, and silverware that have grown in size as well [45]. Portion control is an important contributor to an energy deficit that should be emphasized with dietary treatment. Strategies for informing patients about how to control portion sizes include education on the appearance and calorie content of commonly eaten foods (e.g., ½ cup of cereal vs. 1 bowl of cereal), the use of prepackaged foods (e.g., caloriecontrolled frozen or snack foods), and portion control dinnerware that partitions the plate into specified sections for proteins, carbohydrates, cheese, sauces, and vegetables [43, 46, 47]. Although the evidence on the weight-loss benefits of a specific frequency for eating and timing of meals, like consuming a breakfast, is cross-sectional in nature, the American Dietetic Association advocates that total energy intake be dispersed throughout the day consisting of 4–5 meals and snacks (including breakfast); consuming a greater proportion of calories earlier in the day may be more desirable than evening consumption [43].
5.3.2 Physical Activity The incorporation of physical activity as a component of weight loss treatment and maintenance is fundamental to successful outcomes. For health maintenance and prevention of chronic diseases, current recommendations from the American College of Sports Medicine (ACSM) and the American Heart Association (AHA) state that persons between age 18 and 65 should take part in moderate-intensity aerobic physical activity, like walking at 3.5–4.0 mph, for a minimum of 30 min on 5 days of each week or vigorous intensity aerobic
5 Assessment and Treatment of Excess Weight
activity, like jogging or bike riding at 10 mph, for at least 20 min on 3 days of each week. Moderateintensity activity results in a noticeably elevated heart rate, e.g., brisk walking; vigorous activity results in rapid breathing and a significant elevation in heart rate. The 2007 guidelines from the ACSM and AHA also include recommendations for muscle strength training at least twice each week performing 8–10 exercises using the major muscles with 8–12 repetitions [48]. The quantity of physical activity needed to prevent weight gain, lose weight, and prevent weight regain after weight loss is higher than the amount of physical activity needed for health maintenance. In order to prevent weight gain through adulthood, one should partake in 60 min of moderate-to-vigorous physical activity a day on most days of the week. A decrease of 3,500 kcal from usual intake is necessary to lose one pound of body weight in a week [1], and physical activity provides a tool for tipping energy balance in the negative direction. Because physical activity alone as a weight loss intervention has only been associated with a 3% weight loss [49], caloric restriction is also necessary for individuals who need to lose a larger amount of weight. Physical activity combined with reduced caloric intake results in significantly greater weight loss than dietary restriction alone [50]. For an average weight loss of approximately 2–3 kg (4.4– 6.6 lb), physical activity of moderate intensity in the amount of at least 150 min/week is recommended. Moderate-intensity activity between 225 and 420 min each week results in a 5–7.5 kg (11–16.5 lb) weight loss, and a dose–effect relationship for physical activity and weight loss appears to exist [49]. Among individuals who were formerly obese, 60–90 min of moderateintensity activity each day is necessary to maintain weight loss and prevent regain [48]. These sizeable amounts of activity can be quite daunting for many individuals. Fortunately, evidence indicates that physical activity can be accumulated in multiple 10-min intervals throughout the day and remain beneficial for weight loss [51, 52]. To facilitate engagement in physical activity, practitioners should encourage their patients to develop a specific plan for physical activity at the start of each week, make the time in their schedule to carry it out, and write down in a diary the duration and intensity of their exercise activities [6]. Although there has been a slight decrease from 2000 to 2008 in the proportion of US adults reporting no leisure-time physical activity (27.8–25.1%) [53],
33 Table 5.4 Varying-intensity activities for patient teaching Intensity Very light Light Moderate High
Activity Painting a room, yard work, ironing Walking slowly, child care, golf Brisk walking, gardening, tennis Jogging (10 min/mile), basketball
Adapted from National Heart, Lung, and Blood Institute [6]
most individuals are sedentary and not particularly motivated to increase their activity level [6]. Various approaches are available for persons beginning to exercise and should be introduced and increased gradually for the obese patient. Pedometers have recently become popular for motivating people to do more walking. A systematic review of 26 studies examining the use of pedometers to increase physical activity found that pedometer use was significantly associated with increased physical activity and decreased BMI and blood pressure. Having a goal for number of steps taken, like 10,000 steps/day was predictive of increased activity [54]. Daily lifestyle activity is an additional means of augmenting weight loss efforts. Encouraging patients to include activities in each day that result in increased energy expenditure (e.g., using the stairs instead of elevator and parking further from entrances) and discouraging the amount of sedentary activities (i.e., television viewing or Internet use) can help to shift overall daily calories toward an energy deficit. See Table 5.4 for examples of very light to high-intensity activities for patient teaching.
5.3.3 Behavioral Therapy Cognitive behavioral therapy (CBT), as applied to weight loss treatment, seeks to influence eating, activity, and thinking behaviors that affect the overweight or obese patient’s weight [33]. Behavioral therapy for weight loss stems from the principle of classical conditioning, which indicates that certain stimuli repeatedly present before or with a particular behavior (e.g., eating) will become linked to that behavior. For example, snacking on junk food is often linked to watching television; the more frequently these two activities are coupled, the stronger the relationship between them becomes [55]. Through participation in CBT for weight loss, patients learn to identify antecedent events or cues for eating or inactivity and then develop new reactions
34
that are more congruent with their weight loss goals. The consequences of behaviors are also examined, and reinforcement of new, more appropriate eating and activity behaviors is emphasized. Internal thoughts and ideas about oneself also impact behavior, and patients are taught to restructure negative thoughts about weight management to more positive thinking, when these thoughts do not match identified weight loss behaviors or goals [56]. The three defining characteristics of behavioral treatment are that it is goal-focused, process-oriented, and encourages small instead of large changes in behavior [33]. Specific, measurable goals (e.g., a number of calories to consume each day or a number of steps to register on the pedometer) are defined that enable a clear assessment of goal attainment. Process orientation is focused on assisting patients to decide what they wish to accomplish and how they will go about identifying and carrying out the behaviors to accomplish their goal. It advocates a skill-building perspective that weight loss involves a set of skills and strategies one can learn. Lastly, behavioral treatment promotes small behavior changes over large ones, which is derived from the learning principle of successive approximation or behavior shaping, where a patient has a chance to be successful at small changes and can build on these successes to obtain more difficult goals [33]. Behavioral therapy is typically structured as a group format with a planned curriculum where individuals meet weekly for the initial 4–6 months and then the frequency of meetings is gradually decreased to biweekly for an additional few months and then monthly until treatment is complete. Treatment sessions for hospital or university-based programs are typically provided to groups of about 10–20 patients and are approximately an hour in duration. Sessions are led by professionals from multiple disciplines that may include psychologists, registered dieticians, exercise physiologists, or physicians, and the group structure allows for social support as well as a friendly competitive atmosphere. A weigh-in with each session provides motivation for patients to stay on track with their goals. Various behavioral strategies to facilitate behavior change for weight loss are covered in the group meetings, and rather than simply lecturing on the topic being covered, group leaders encourage patients to discuss their progress, problem solve, and ask questions. A set of behavioral strategies is common to standard behavioral therapy [33]:
M.T. Turk
1. In goal setting, patients are allotted goals to help them achieve their desired weight loss. These goals must be outcome-specific, short-term, and achievable for the patient. In most situations according to goal setting theory, establishing specific goals leads to enhanced performance compared with no goals or unclear goals [57]. Daily goals are assigned for total calories and fat grams (based on a percent of calories from fat, e.g., 25%); weekly goals are given for energy expenditure through exercise [56]. Goals should focus on the patient’s change in behavior, (e.g., selecting a piece of fruit for a snack instead of a candy bar), rather than on physiologic results, (e.g., lower serum cholesterol level), since behaviors are under a patient’s direct influence and many factors can impact physiologic outcomes. Goals that are incremental in nature allow the patient to experience small achievements; yet, the patient will not take seriously goals that are too simplistic and will not make an attempt at those that are too difficult. Regular feedback from the practitioner regarding goal attainment will instill in the patient a sense of mastery and accomplishment [58]. 2. Self-monitoring, recording one’s eating and activity behaviors, is one of the true hallmarks of behavioral therapy and includes a detailed, daily description of the type, amount, caloric content, and fat gram content of all foods consumed as well as the type and duration of physical activity. Selfmonitoring may also incorporate information on places and feelings related to eating. The intent of self-monitoring is to enhance individuals’ awareness of their existing eating and activity behaviors and the related circumstances that would benefit from behavior change [33]. Patients become aware of patterns of behavior and may express surprise at seeing their excessive food intake in writing [59]. While self-monitoring has traditionally been performed in a paper diary and patients were required to look up in a reference booklet the calorie and fat gram content of foods, technological advances have provided additional methods for recording food intake and activity. Internet sites, like www.sparkpeople.com, www.FitDay.com, and www.caloriecount. about.com, are accessible as a mechanism for online self-monitoring. Additionally, software for personal digital assistants now exists and contains a comprehensive database of foods and physical activities, removing the necessity of searching for the
5 Assessment and Treatment of Excess Weight
nutrient composition of foods in a booklet [60]. The body of literature continues to grow in support of the observation that self-monitoring dietary intake and physical activity is a critical element for success in weight loss [61–63]. 3. Problem solving is a behavioral strategy whereby the patient identifies the problematic circumstance associated with poor food and/or activity behaviors, formulates solutions, chooses a solution, tests that solution, and evaluates the solution’s effect on the problem [64]. It is preferable that the practitioner allow the patient to formulate possible solutions to the problem situation him/herself, and have the patient practice a few of the identified solutions. For example, the patient could role play how he/she might respond to a host who is adamant about serving the patient a second helping of the dinner foods. 4. Stimulus control is based on the notion that environmental triggers influence behaviors, and stimulus control strategies assist the patient to handle triggers related to eating and activity behaviors that do not support the weight loss goals. Avoiding high-risk situations and changing environmental cues to positive cues for appropriate eating and exercise behaviors results in actions that are congruent with goals. For example, patients are instructed to avoid all-you-can-eat restaurants or unhealthy grocery store aisles, to reduce exposure to poor food choices by avoiding the workplace vending machine and packing ready-to-eat fruits as an afternoon snack, to store food out of one’s sight, and to remove serving plates from the table to avoid overeating during meals [33]. 5. In cognitive restructuring, patients are taught how negative thoughts, self-critical perceptions, all-ornone thinking, and comparisons with others foil the patient’s weight loss efforts. For example, a patient who envisions having a piece of cake as “sabotaging the diet,” may continue with this catastrophic perspective and despair that overeating for the rest of the day is inevitable. With the cognitive restructuring strategy, patients learn to alter their inappropriate ideas to include positive, rational thoughts about their behaviors and themselves [33]. 6. Relapse prevention involves patients learning that lapses in weight control behaviors are a normal occurrence. These lapses need to be expected in certain occasions (like vacations, parties, special
35
events) and planned for by using strategies to cope with the circumstances, thereby preventing relapses [65]. Practitioners can discuss these potential problem situations in advance and help patients to problem solve and plan appropriate methods of coping with the temptations they face. 7. Other behavioral strategies include recruiting social support from friends and family to assist with and reinforce lifestyle changes, incorporating contingency management and rewards associated with meeting an incremental goal, and including stress management to reduce the use of inappropriate eating as a coping mechanism [66]. In order to promote adherence to the eating and activity changes, evidence suggests that ongoing contact and the frequency with which patients interact with the health care provider is an important contributor to successful weight control [6]. This contact may take the form of interaction with the office staff or nurse, in the interim between physician visits, and need not be restricted to in-person contact. Empirical findings support the use of telephone contact [67] as well as e-mail and Internet behavioral counseling [68] as a beneficial means of continuing to support patients in their weight loss efforts. The most promising results for treatment success are attained through a combination of behavioral treatment, dietary treatment, and increased activity, and multi-center trials using these techniques have demonstrated not only a 5–10% loss of body weight but also a decrease or even the prevention of obesity-related comorbid conditions like diabetes and hypertension [69–71]. Importantly, obesity must be recognized as a chronic disease that requires long-term, continued treatment in order to achieve long-term weight management success [72].
5.3.4 Pharmacotherapy Despite the inherent appeal of pharmacologic treatment of obesity, the multi-faceted nature of this disease with its genetic [73], metabolic [74], and behavioral influences [75] has eliminated the reality of a single, “silver bullet” pharmacotherapy. Lifestyle modification that includes dietary, activity, and behavioral therapy remains the first tier of treatment with pharmacotherapy being considered as a second tier used in combination with lifestyle change for those
36
who are unsuccessful at standard interventions. Pharmacotherapy is reserved for individuals with no serious contraindications to using the medication(s) who have a of BMI > 30 kg/m2 or > 27 kg/m2 if significant co-morbidities are present [1]. Individual response to medication use varies greatly between patients with 2–5% experiencing a better than average weight loss and a large proportion exhibiting little to no weight loss [76]. Medications that have been utilized have resulted in an increase in the average amount of weight lost in 1–2 years by approximately 4–6% [77, 78] but also undesirable or even harmful side effects, some of which have necessitated removing the medication from the market, e.g., cardiac valvulopathy associated with fenfluramine [76]. US Food and Drug Administrationapproved (FDA) medications indicated for the treatment of obesity are discussed here. Phentermine is an adrenergic reuptake inhibitor that enhances adrenergic signals in peripheral tissue and the brain; it is thought to augment weight loss by decreasing food intake and increasing resting energy expenditure through sympathetic nervous system activation [76]. Phentermine was previously used in combination with fenfluramine until detrimental effects on cardiac valves were identified, but phentermine was not associated with valvulopathy as fenfluramine was [79, 80]. Because of its adrenergic effects, however, in addition to constipation and xerostomia, side effects may include tachycardia and hypertension, and phentermine should be cautiously used in patients with known cardiovascular disease or uncontrolled hypertension. Usual dosing is 18.75–37.5 mg/day for phentermine-HCl and 15–30 mg/day for phentermine resin; usage for 3 months is approved by the FDA [76]. Among six placebo-controlled randomized clinical trials, the average weight loss for phentermine was 3.6 kg greater than placebo [81]. Orlistat, a pancreatic and intestinal lipase inhibitor, stops the breakdown of consumed triglycerides and the absorption of monoacylglycerols and fatty acids resulting in up to 30% non-absorption of dietary fat [82, 83]. Among 22 studies reporting 1-year results, participants using orlistat lost 2.9 kg more weight than participants taking placebo [43]. Usual dosing is 120 mg three times daily with meals and requires dietary counseling to encourage decreased consumption of high-fat foods. Over-the counter dosing is now available at 60 mg three times daily and has been associated with a 50% greater weight loss after 4 months compared to placebo, for
M.T. Turk
individuals with a BMI between 25 and 28 kg/m2 following a reduced-calorie and reduced-fat diet [84]. Treatment with orlistat is associated with gastrointestinal side effects including steatorrhea, flatulence, diarrhea, fecal incontinence, and anal discharge [76]. Of particular concern is the potential for fat-soluble vitamin deficiencies (vitamins A, D, E, and K) that may occur due to the malabsorption associated with orlistat. Patients treated with this weight loss medication should take a daily supplement of these vitamins at least 2 h prior to or after every orlistat dose [82]. In particular due to the higher prevalence of vitamin D deficiency among obese individuals, vitamin D levels should be measured prior to initiating orlistat therapy and intermittently throughout treatment to ensure a serum 1,25-OH-vitamin D level of at least 30 IU/mL [76]. Sibutramine is a monoamine reuptake inhibitor and suppresses appetite by inhibiting the reuptake of serotonin and norepinephrine [85]. Although pharmacologically similar to fenfluramine, the use of sibutramine has not been associated with cardiac valvulopathy and seems to result in a mean weight loss of 3–4% (~4.5 kg) over placebo during the first year of treatment [76, 86]. Sibutramine is approved by the FDA for up to 1 year of use, but extending treatment beyond 1 year may result in less weight regain [87], and some clinicians continue to prescribe it for individuals who are responding to the medication and not regaining weight. Typical dosing is 10–15 mg/day with 10 mg/day as the preferred initial dose, and patients who lose ³4 lb each month for 3 months are considered to have an appropriate clinical response to continue with treatment [76]. Doses above 15 mg/day have not been associated with greater efficacy and are not recommended [88]. Major side effects, hypertension and tachycardia, are attributed to the adrenergic effects of sibutramine with 10–15% of patients experiencing hypertension that is controlled by anti-hypertensive medication or discontinuation of sibutramine. Fewer patients experience tachycardia, but an increase of 4.9 beats per minute has been noted among patients receiving sibutramine compared to placebo [89]. Due to the higher risk of serotonin syndrome, (e.g., hypotension, diarrhea, flushing), the use of sibutramine is typically contraindicated for patients taking serotonin-selective reuptake inhibitors (SSRI) [76]. In support of the notion that pharmacotherapy should be combined with a treatment plan that includes dietary, physical activity, and behavioral therapy,
5 Assessment and Treatment of Excess Weight
Wadden et al. [63] found the greatest 1-year weight loss was experienced by the treatment group that received sibutramine plus lifestyle modification with group meetings. The other three treatment arms were sibutramine alone, lifestyle modification alone, and sibutramine with brief primary care provider visits. Of note, the group that received sibutramine plus brief primary care provider visits (8 brief, 10–15 min sessions over the course of a year) experienced the second highest weight loss among the four groups. These findings support that practitioners play an valuable role in counseling for weight loss; the provider visits combined with sibutramine therapy were superior to medication alone or lifestyle modification alone [63]. Currently only two medications are FDA-approved for weight loss treatment beyond 3 months and both have been associated with modest results as well as weight regain when medications are discontinued [90]. Obesity is a disease with complex metabolic and behavioral components that may be amenable to medication therapy, but these pharmacotherapeutic agents with an acceptable side effect profile have not yet been identified and approved for use. Because of this complexity, it is improbable that any one drug with a single mechanism of action will be the weight-loss answer for the obese patient. With increased understanding of the physiologic mechanisms that affect body weight regulation, new targets for treating obesity have been identified and over 80 medications are currently in development [76]. Long-term weight control may in the future be managed by multiple medications with various mechanisms of action, but current pharmacotherapy is limited and must be combined with lifestyle modification that includes nutritional planning, increased physical activity, and behavioral treatment.
5.3.5 Surgical Treatment Bariatric surgery is another treatment option for severely obese individuals who have been unsuccessful at other methods of weight loss. Because of the inherent anatomical changes, surgery has the advantage of promoting long-term weight loss. Guidelines for determining which patients are candidates for surgical intervention were developed in 1991 by the NIH Consensus Conference for Bariatric Surgery and are still utilized today [91]. These criteria indicate that patients have Class 3 obesity (BMI ³ 40 kg/m2) or Class 2 obesity
37
(BMI 35–39.9 kg/m2) with significant obesity-related health conditions like type 2 diabetes mellitus, sleep apnea, hypertension, or cardiomyopathy. Other surgical criteria include an age range of 18–60 years, failure at other more conservative treatment, and acceptable operative risk (e.g., adequate cardiac function, myocardial perfusion, pulmonary function, normal gastrointestinal anatomy) [92]. Updated recommendations added by the American Society for Bariatric Surgery Consensus Conference in 2004 include that bariatric surgery in an experienced center be considered for adolescents with Class 3 obesity, and surgery may be warranted for Class 1 obesity (BMI 30–34.9 kg/m2) if the patient’s obesityrelated co-morbidity could be substantially improved or cured by significant, lasting weight loss. Furthermore, a multidisciplinary approach to the care of bariatric patients is essential for long-term successful outcomes, including an internist, dietician, nurse, and other necessary specialists (e.g., cardiologist, psychologist) in addition to the surgeon and anesthesiologist [91]. Although both open and laparoscopic procedures are effective modalities [92], bariatric surgeries should be performed laparoscopically when possible [93]. Procedures that are minimally invasive and circumvent an open abdomen with a sizeable abdominal incision are particularly suited to these patients because of the negative interaction of obesity and the inflammatory physiological responses [94]. Additional benefits of the laparoscopic technique are decreased length of hospitalization and postoperative pain, fewer wound complications, and more rapid normalization of bowel function [95, 96], even though this technique also has an increased intra-abdominal complication rate when compared with the open technique [91]. Other surgeryrelated factors associated with better outcomes include the volume of bariatric patients treated at the medical center along with surgeon experience and skill [43]. Specific bariatric “Centers of Excellence” have been designated by the American College of Surgeons and the American Society for Metabolic and Bariatric Surgery based on surgical outcomes and medical-center patient volume. Centers that reported over 100 cases annually had lower mortality rates, fewer complications, shorter length of stay, and lower costs compared to facilities with fewer than 50 cases annually [97]. Weight loss outcomes for bariatric surgeries are measured in terms of percent of excess body weight (EBW) that is lost, where excess body weight is calculated by subtracting ideal weight from the patient’s actual
38
weight; ideal weight is based on the 1983 Metropolitan Life Insurance height and weight tables’ determination of the weight associated with the longest life expectancy [98]. Three main categories of bariatric surgery exist – malabsorptive, restrictive, and combined restrictive and malabsorptive procedures [99]. Malabsorptive surgeries cause a reduced absorption of calories and nutrients by decreasing the functional amount of small intestine involved in digestion. Resultant weight loss from malabsorptive techniques often comes with nutritional deficits including protein, vitamin, and mineral insufficiencies that must be medically managed longterm. Restrictive surgeries decrease the size and capacity of the stomach to store food, thereby inducing satiety earlier in the meal, which results in reduced energy intake. Because procedures that are solely restrictive do not affect small bowel anatomy, they infrequently result in metabolic complications but are associated with an increased risk of dumping syndrome and some nutritional deficiencies (particularly calcium, iron, and vitamin B12) [100]. Some procedures incorporate both restrictive and malabsorptive techniques to induce weight loss. Four currently recommended surgical options – biliopancreatic diversion with/without duodenal switch, vertical banded gastroplasty, laparoscopic adjustable gastric banding, and gastric bypass – are used worldwide. The biliopancreatic diversion with/without duodenal switch is the least commonly performed bariatric procedure among the four [101] and is considered a malabsorptive approach. It involves performing a gastrectomy of approximately 80% of the distal stomach, preserving a 100–150 mL gastric compartment, and creating a Roux-en-Y construction with an alimentary limb, a biliopancreatic limb, and a common limb. While the alimentary and biliopancreatic limbs are approximately the same length, the degree of malabsorption is controlled by the length of the common limb. With the duodenal switch, the pylorus is preserved using a vertical-sleeve gastrectomy, and a duodeno-ileostomy is created. Weight loss after this surgery is typically approximately 70% of EBW [91]. Long-term complications are those associated with malabsorptive procedures. The vertical banded gastroplasty and laparoscopic adjustable gastric banding are restrictive techniques where a small upper gastric compartment is constructed to limit the capacity of the stomach to hold food.
M.T. Turk
Restrictive techniques are generally less difficult to perform than malabsorptive techniques with fewer long-term complications but may result in less weight loss [99]. Typically an open procedure, the vertical banded gastroplasty is performed by stapling off the fundus parallel to the lesser curvature and applying a band to narrow the distal opening of this small compartment (~50 mL) into the body of the stomach. Usual percent of EBW lost is 50% [91]. For the laparoscopic adjustable gastric banding procedure, the upper 5% of the stomach is partitioned off using an inflatable, silicone band. A gastric pouch of approximately 20 mL is created by inflating the band using a subcutaneous port. This band can be adjusted by the physician at office visits to accommodate the needs of the patient, and periodic adjustments may be necessary up to six times a year for appropriate outcomes. This procedure is associated with a loss of about 50% of EBW [91]. Common side effects of these restrictive procedures include vomiting as a result of over consumption, eating too quickly, not chewing food well, or drinking fluids right after eating [94]. Gastric bypass is the most commonly performed bariatric surgery worldwide [91] and has both restrictive and malabsorptive features. In the restrictive component, a 15–25 mL gastric pouch is divided from the distal stomach with four rows of staples or completely separated. Continuity of the pouch with the jejunum is re-established using a Roux-Y limb, incorporating a malabsorptive element as the distal stomach, duodenum and part of the proximal jejunum are bypassed. The Roux-en-Y technique is the preferred approach, and variations of this approach include using a long Roux limb or a very long limb to affect more substantial weight loss in individuals with a BMI ³ 50 kg/m2. After the standard Roux-en-Y bypass, weight loss outcomes of approximately 65–70% of EBW are achieved [91]. Empirical evidence suggests that this surgery results in decreased plasma levels of the hormone ghrelin [102, 103], mainly secreted in the fundus of the stomach and known to stimulate appetite [104], which may be an additional mechanism contributing to the sustained weight loss observed after gastric bypass surgery. Surgical treatment of obesity results in substantial weight loss that is largely maintained by patients and leads to amelioration or even resolution of co-morbidities [100] as well as decreased mortality [105]. The Swedish Obesity Study is a large, prospective trial that
5 Assessment and Treatment of Excess Weight
compared bariatric surgery patients with matched, obese control patients. At 2 and 10 years, this study showed that recovery from diabetes mellitus, hypertriglyceridemia, hypertension, a low HDL cholesterol level, and hyperuricemia was more frequent in the surgical patients than in the control patients. Although weight loss peaked at 1–2 years, long-term weight loss outcomes from bariatric surgeries at 15 years were 27 ± 12%, 18 ± 11%, and 13 ± 14%, for gastric bypass, vertical banded gastroplasty, and gastric banding, respectively; the mean 15-year weight change among the control group was ±2% [106]. Lifelong adjustments in eating behaviors and medical supervision are essential following these surgical procedures, however, and patients need to be counseled about the lifestyle changes necessary to reduce complications and maintain weight loss.
5.4 Weight Loss Maintenance Long-term maintenance of lost weight has remained the Achilles heel of weight loss treatment as approximately one third of weight lost among patients treated with lifestyle modification is regained by the first year after treatment [107]. Average 4-year weight losses approximate 1.8 kg or an unremarkable 4 lb [108]. Some have suggested that the behaviors necessary for weight loss differ from those required in weight loss maintenance in that the goal of maintenance is to undo small weight gains before they become large ones where as the goal for weight loss is to lose substantial amounts of weight after an extended period of gain. While active weight loss treatment is time restricted, weight loss maintenance is long-term and continued. Weight loss is tangibly rewarding and individuals often receive positive feedback and reinforcement from significant others and health care practitioners about their new appearance or improved health status, whereas in maintenance ongoing reinforcement tends to lapse [109]. The greatest challenge in obesity treatment for health care professionals is not only assisting patients in their weight loss efforts but also helping them to sustain the weight loss they have achieved. Much of what is known about the behaviors related to successful weight loss maintenance comes from a large registry of individuals who have successfully lost 13.6 kg (30 lb) and maintained that loss for a minimum of 1 year with the average weight loss being 30.4 kg
39
(67 lb) that has been maintained for 5.7 years [110, 111]. Many descriptive studies of this National Weight Control Registry (NWCR) have reported on behavioral strategies used by these successful weight loss maintainers – increasing physical activity, consuming a diet low in fat, regularly self-monitoring weight and food intake [112], limiting the variety of foods eaten [113], eating breakfast [114], and restricting time spent watching television [115]. Factors associated with weight regain in this group have included a greater initial weight loss, shorter period of time in weight maintenance and psychological factors like depressive symptoms, increases in disinhibition (vulnerability to loss of control over eating), and decreases in eating restraint (conscious control of eating) [111, 115, 116]. These findings from the NWCR have been corroborated by other cross-sectional [117] and prospective studies [118] and provide information about areas of weight maintenance that providers can address when counseling patients. Two elements of weight loss treatment have been noted as particularly beneficial for weight loss maintenance – pharmacotherapy and physical activity. Both sibutramine and orlistat, combined with dietary modification and caloric deficit, have been repeatedly shown to be efficacious in promoting longterm maintenance [87]. A 3-year randomized controlled trial (RCT) of weight loss maintenance using orlistat or placebo found that patients who received orlistat maintained a 2.4 kg greater weight loss than those who received a placebo [119]. In a 1-year RCT examining sibutramine versus placebo for weight maintenance, Apfelbaum and colleagues found that 75% of the sibutramine patients maintained at least 100% of their lost weight compared to 42% of placebo patients who achieved this level of maintenance [120]. There is some evidence that sibutramine might be effectively used intermittently for weight loss maintenance. One maintenance RCT found a similar amount of weight change over 44 weeks for the participants that received 15 mg of the drug continuously (−3.8 kg) compared to those receiving sibutramine intermittently (−3.3 kg). The intermittent sibutramine group received a placebo for two 6-week periods, after week 12 and week 30 of the trial [121]. These medications may play an important role in weight loss maintenance, but they are currently FDA-approved for 1–2 years of continued use only [78], and dietary and behavioral modification must be emphasized and sustained.
40
Physical activity has been frequently highlighted as an essential component of successful weight loss maintenance in both descriptive [122, 123] and intervention studies [124–126] with patients engaging in higher amounts of activity regaining less weight [124, 126]. A contributing factor to the need for physical activity has been labeled the energy gap [127]. This gap, approximated at 8 kcal/day for each pound of weight lost, is created after weight loss because one’s total energy expenditure decreases as a result of a drop in resting metabolic rate and less energy needed to move and support less total body weight. For example, a patient who had lost 50 lb would need to continually maintain a 400 kcal/day deficit in total caloric intake below his/ her pre-weight loss intake. Some experts believe that, in the current obesogenic environment promoting lessthan-healthful foods in large portions, increasing energy expenditure through physical activity is an easier way to fill this energy gap [127]. The ideal amount of physical activity for maintenance of weight loss remains somewhat unclear however, because most evidence does not come from randomized controlled trials [49]. Jakicic et al. [128] recently reported that among individuals who had lost at least 10% of their original weight and maintained that loss for 24 months, physical activity levels were 275 min per week; others have noted similar findings with this level of activity at 2 years after a very-low-calorie diet [129]. Recommendations for maintaining lost weight in adults include partaking in at least 60–90 min of moderate-intensity activity daily [48], and the recent position stand from ACSM reinforces that avoiding a weight change of more than 3% likely requires approximately 60 min of daily, moderate-intensity physical activity, like brisk walking for 4 miles [49]. Although these levels of physical activity may be challenging for many patients to maintain, they seem to be associated with the best weight maintenance outcomes. With weight loss typically peaking at 6 months after initiation of a behavioral lifestyle treatment plan [130], a weight maintenance plan should be introduced at this time. Maintenance plans that include a schedule of sustained, frequent contact with the health care practitioner who provides ongoing support, instruction, and health monitoring are recommended to promote longterm weight loss maintenance [1]. These visits might be handled via an office nurse, allowing patients to stop in to be weighed, have their food diaries reviewed, receive feedback on a problem area, or receive words
M.T. Turk
of encouragement for motivation and support [131]. Empirical evidence suggests that providing patient contact by telephone is even efficacious for promoting weight loss maintenance [132], provided the contact is made by an individual who is known to the patient [133]. Additionally, a practitioner could suggest that a patient join a self-help (e.g., Taking Off Pounds Sensibly) or commercial group (e.g., Weight Watchers) as a means of providing ongoing support for adhering to the behaviors necessary to maintain weight loss.
5.5 Conclusions Obesity and overweight are chronic conditions with numerous adverse health effects that require direct, ongoing attention by the health care provider. The goals of weight loss treatment are improved overall health and decreased morbidity. Current first-line treatment consists of lifestyle modification that includes dietary, physical activity, and behavioral therapy, with pharmacotherapy and bariatric surgery as subsequent weight loss modalities when indicated. The treatment of this chronic disorder requires a multidisciplinary approach including health professionals with expertise in nutrition, exercise, and possibly clinical psychology as members of the comprehensive, weight management health care team [3]. Similar to treating other chronic conditions like hypertension and diabetes, providers should instruct patients about self-management strategies for prolonged weight loss maintenance because the positive effects on risk-factor reduction do not remain unless weight loss is sustained [134]. Health care providers have a major part in helping this ever-increasing subgroup of patients successfully lose and maintain weight so that patients can continue to benefit from the physical and psychological effects of a lower body weight.
References 1. National Institutes of Health (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res 6(suppl 2):51S–209S 2. Roth J, Qiang X, Marban SL, Redelt H, Lowell BC (2004) The obesity pandemic: Where have we been and where are we going? Obes Res 12(suppl 2):88S–101S 3. Lau DC, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E, Obesity Canada Clinical Practice Guidelines Expert Panel (2007) 2006 Canadian clinical practice
5 Assessment and Treatment of Excess Weight guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ 176(8):S1–S13 4. Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999– 2008. J Am Med Assoc 303(3):235–241 5. United Health Foundation, The American Public Health Association (2009) Partnership for Prevention: The future costs of obesity: national and state estimates of the impact of obesity on direct health care expenses. Retrieved from http:// www.nccor.org/downloads/CostofObesityReport-FINAL.pdf 6. National Heart Lung and Blood Institute, North American Association for the Study of Obesity (2000) Practical guide to the identification, evaluation, and treatment of overweight and obesity in adults. Available via http://www. nhlbi.nih.gov/guidelines/obesity/prctgd_c.pdf. Accessed 19 May 2010 7. World Health Organization (2006) Obesity and overweight: What are overweight and obesity? Retrieved from http:// www.who.int/mediacentre/factsheets/fs311/en/index.html 8. Orzano JA, Scott JG (2004) Diagnosis and treatment of obesity in adults: an applied evidence-based review. J Am Board Fam Pract 17(5):359–369 9. WHO Expert Consultation (2004) Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363(9403):157–163 10. Wen CP, David CTY, Tsai SP, Chan HT, Hsu HL, Hsu CC, Eriksen MP (2009) Are Asians at greater mortality risks for being overweight than Caucasians? Redefining obesity for Asians. Public Health Nutr 12(4):497–506 11. World Health Organization, International Association for the Study of Obesity & International Obesity Task Force (2000) The Asia-Pacific perspective: redefining obesity and its treatment. Retrieved from http://www.wpro.who.int/ internet/resources.ashx/NUT/Redefining+obesity.pdf 12. Low S, Chin MC, Ma S, Heng D, Deurenberg-Yap M (2009) Rationale for redefining obesity in Asians. Ann Acad Med Singapore 38(1):66–69 13. Mosca L, Edelman D, Mochari H, Chrisian AH, Paultre F, Pollin I (2006) Waist circumference predicts cardiometabolic and global Framingham risk among women screened during National Woman’s Heart Day. J Women’s Health Larchmt 15(1):24–34 14. Canoy D, Boekholdt SM, Wareham N, Luben R, Welch A, Bingham S, Buchan I, Day N, Khaw KT (2007) Body fat distribution and risk of coronary heart disease in men and women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk cohort: a population-based prospective study. Circulation 116(25):2933–2943 15. Kuk JL, Katzmarzyk PT, Nichaman MZ, Church TS, Blair SN, Ross R (2006) Visceral fat is an independent predictor of all-cause mortality in men. Obesity 14(2):336–341 16. Zhu S, Heymsfield SB, Toyoshima H, Wang Z, Pietrobelli A, Heshka S (2005) Race-ethnicity-specific waist circumference cutoffs for identifying cardiovascular disease risk factors. Am J Clin Nutr 81(2):409–415 17. Dagenais GR, Yi Q, Mann JF, Bosch J, Pogue J, Yusuf S (2005) Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 149(1):54–60 18. Chen Y, Rennie D, Cormier YF, Dosman J (2007) Waist circumference is associated with pulmonary function in
41 normal-weight, overweight, and obese subjects. Am J Clin Nutr 85(1):35–39 19. Balkau B, Deanfield JE, Despres JP, Bassand JP, Fox KA, Smith SC Jr, Barter P, Tan CE, Van Gaal L, Wittchen HU, Massien C, Haffner SM (2007) International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168 000 primary care patients in 63 countries. Circulation 116(17):1942–1951 20. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, Coordinating Committee of the National Cholesterol Education Program (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 44:720–732 21. Pan W-H, Flegal KM, Chang H-Y, Yeh W-T, Yeh C-J, Lee W-C (2004) Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for definitions of overweight and obesity for Asians. Am J Clin Nutr 79(1):31–39 22. Wildman RP, Gu D, Reynolds K, Duan X, He J (2004) Appropriate body mass index and waist circumference cutoffs for categorization of overweight and central adiposity among Chinese adults. Am J Clin Nutr 80(5):1129–1136 23. Kushner RF, Kushner N (2003) Dr. Kushner’s personality type diet. St. Martin’s, New York 24. Krall EA, Dwyer JT (1987) Validity of a food frequency questionnaire and a food diary in a short-term recall situation. J Am Diet Assoc 87(10):1374–1377 25. Marshall AL, Smith BJ, Bauman AE, Kaur S (2005) Reliability and validity of a brief physical activity assessment for use by family doctors. Br J Sports Med 39(5): 294–297 26. Warziski MT, Sereika SM, Styn MA, Music E, Burke LE (2008) Changes in self-efficacy and dietary adherence: the impact on weight loss in the PREFER study. J Behav Med 31:81–92 27. Burke LE, Styn MA, Elci OU, Music E, Warziski M (2007) How do barriers to healthy eating impact weight loss? Circulation 115(suppl 8):55 28. Klein S, Burke LE, Bray GA, Blair S, Allison DB, Pi-Sunyer X, Hong Y, Eckel RH, American Heart Association Council on Nutrition, Physical Activity, and Metabolism (2004) Clinical implications of obesity with specific focus on cardiovascular disease. A statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 110(18):2952–2967 29. Gorin AA, Phelan S, Hill JO, Wing RR (2004) Medical triggers are associated with better short- and long-term weight loss outcomes. Prev Med 39(3):612–616 30. Miller WR, Rollnick S (1991) Motivational interviewing preparing people to change addictive behavior. The Guildford, New York 31. West DS, DiLillo V, Bursac Z, Gore SA, Greene PG (2007) Motivational interviewing improves weight loss in women with type 2 diabetes. Diabetes Care 30(5):1081–1087 32. Rubak S, Sandbaek A, Lauritzen T, Christensen B (2005) Motivational interviewing: a systematic review and metaanalysis. Br J Gen Pract 55(513):305–312
42 33. Wadden TA, Crerand CE, Brock J (2005) Behavioral treatment of obesity. Psychiatr Clin North Am 28(1):151–170 34. Jakicic JM, Otto AD (2005) Physical activity recommendations in the treatment of obesity. Psychiatr Clin North Am 28(1):141–150 35. Johnstone AM, Horgan GW, Murison SD, Bremner DM, Lobley GE (2008) Effects of a high-protein ketogenic diet on hunger, appetite, and weight loss in obese men feeding ad libitum. Am J Clin Nutr 87(1):44–55 36. Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, Williams T, Williams M, Gracely EJ, Stern L (2003) A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 348(21):2074–2081 37. Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, McManus K, Champagne CM, Bishop LM, Laranjo N, Leboff MS, Rood JC, de Jonge L, Greenway FL, Loria CM, Obarzanek E, Williamson DA (2009) Comparison of weightloss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 360:859–873 38. Vetter ML, Iqbal N, Dalton-Bakes C, Volger S, Wadden TA (2010) Long-term effects of low-carbohydrate versus lowfat diets in obese persons. Ann Intern Med 152(5): 334–335 39. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ (2005) Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. J Am Med Assoc 293(1):43–53 40. Nordmann AJ, Nordmann A, Briel M, Keller U, Yancy WS Jr, Brehm BJ, Bucher HC (2006) Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med 166(3):285–293 41. Brinkworth GD, Noakes M, Buckley JD, Keogh JB, Clifton PM (2009) Long-term effects of a very-low-carbohydrate weight loss diet compared with an isocaloric low-fat diet after 12 mo. Am J Clin Nutr 90(1):23–32 42. Wycherley TP, Brinkworth GD, Keogh JB, Noakes M, Buckley JD, Clifton PM (2010) Long-term effects of weight loss with a very low carbohydrate and low fat diet on vascular function in overweight and obese patients. J Intern Med 267(5):452–461 43. Seagle HM, Strain GW, Makris A, Reeves RS, American Dietetic Association (2009) Position of the American Dietetic Association: weight management. J Am Diet Assoc 109(2):330–346 44. Young LR, Nestle M (2003) Expanding portion sizes in the US marketplace: implications for nutrition counseling. J Am Diet Assoc 103(2):231–234 45. Wansink B, van Ittersum K (2007) Portion size me: downsizing our consumption norms. J Am Diet Assoc 107(7):1103–1106 46. Pedersen SD, Kang J, Kline GA (2007) Portion control plate for weight loss in obese patients with type 2 diabetes mellitus: a controlled clinical trial. Arch Intern Med 167:1277–1283 47. The Diet Plate. Portion control made easy. Retrieved from http://www.thedietplate.com/ 48. Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, Macera CA, Heath GW, Thompson PD, Bauman A (2007) Physical activity and public health: updated recommendation for adults from the American
M.T. Turk College of Sports Medicine and the American Heart Association. Circulation 116(9):1081–1093 49. Donnelly JE, Blair SN, Jakicic JM, Manore MM, Rankin JW, Smith BK, American College of Sports Medicine Position Stand (2009) Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc 41(2):459–471 50. Curioni CC, Lourenco PM (2005) Long-term weight loss after diet and exercise: a systematic review. Int J Obes Lond 29:1168–1174 51. Jakicic JM, Winters C, Lang W, Wing RR (1999) Effects of intermittent exercise and use of home exercise equipment on adherence, weight loss, and fitness in overweight women: a randomized trial. J Am Med Assoc 282(16):1554–1560 52. Jakicic JM, Wing RR, Butler BA, Robertson RJ (1995) Prescribing exercise in multiple short bouts versus one continuous bout: effects on adherence, cardiorespiratory fitness, and weight loss in overweight women. Int J Obes Lond 19:893–901 53. Centers for Disease Control and Prevention (2010) Physical activity statistics, 1988–2008 no-leisure time physical activity trend chart. Retrieved 12 May 2010 from http://www. cdc.gov/nccdphp/dnpa/physical/stats/leisure_time.htm 54. Bravata DM, Smith-Spangler C, Sundaram V, Gienger AL, Lin N, Lewis R, Stave CD, Olkin I, Sirard JR (2007) Using pedometers to increase physical activity and improve health: a systematic review. J Am Med Assoc 298(19):2296–2304 55. Stuart RB (1967) Behavioral control of overeating. Behav Ther 5:357–365 56. Wing RR (2002) Behavioral weight control. In: Wadden T, Stunkard AJ (eds) Handbook of obesity treatment. Guilford, New York, pp 301–316 57. Rothman AJ, Baldwin AS, Hertel AW (2004) Self-regulation and behavior change: disentangling behavioral initiation and behavioral maintenance. In: Vohs KD, Baumeister RF (eds) The handbook of self-regulation: research, theory, and applications. Guilford, New York, pp 130–148 58. Strecher VJ, Seijits GH, Kok GJ, Latham GP, Glasgow R, DeVellis B, Meertens RM, Bulger DW (1995) Goal setting as a strategy for health behavior change. Health Educ Q 22(2):190–200 59. Burke LE, Swigart V, Turk MW, Derro N, Ewing LJ (2009) Experiences of self-monitoring: successes and struggles during treatment for weight loss. Qual Health Res 19(6):815–828 60. Burke LE, Warziski M, Starrett T, Choo J, Music E, Sereika S, Stark S, Sevick MA (2005) Self-monitoring dietary intake: current and future practices. J Ren Nutr 15(3): 281–290 61. Acharya SD, Elci OU, Sereika SM, Music E, Styn MA, Turk MW, Burke LE (2009) Adherence to a behavioral weight loss treatment program enhances weight loss and improvements in biomarkers. Patient Prefer Adherence 3:151–160 62. Tate DF, Wing RR, Winett RA (2001) Using Internet technology to deliver a behavioral weight loss program. J Am Med Assoc 285(9):1172–1177 63. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, Hesson LA, Osei SY, Kaplan R, Stunkard AJ (2005) Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 353(20): 2111–2120
5 Assessment and Treatment of Excess Weight 64. D’Zurilla TJ, Goldfried MR (1971) Problem solving and behavior modification. J Abnorm Psychol 78(1):107–126 65. Marlatt GA, Gordon JR (1980) Determinants of relapse: implications for the maintenance of behavior change. In: Davidson PO, Davidson SM (eds) Behavioral medicine: changing health lifestyles. Brunner/Mazel, New York, pp 410–452 66. Wing RR (2004) Behavioral approaches to the treatment of obesity. In: Bray GA, Bourchard C, James WPT (eds) Handbook of obesity: clinical applications, 2nd edn. Marcel Dekker, New York, pp 147–167 67. Jeffery RW, Sherwood NE, Brelje K, Pronk NP, Boyle R, Boucher JL, Hase K (2003) Mail and phone interventions for weight loss in a managed-care setting: weigh-to-be oneyear outcomes. Int J Obes Lond 27(12):1584–1592 68. Tate DF, Jackvony EH, Wing RR (2003) Effects of Internet behavioral counseling on weight loss in adults at risk for type 2 diabetes: a randomized trial. J Am Med Assoc 289(14):1833–1836 69. Svetkey LP, Erlinger TP, Vollmer WM, Feldstein A, Cooper LS, Appel LJ, Ard JD, Elmer PJ, Harsha D, Stevens VJ (2005) Effect of lifestyle modifications on blood pressure by race, sex, hypertension status, and age. J Hum Hypertens 19(1):21–31 70. The Look AHEAD Research Group (2007) Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 30(6):1374–1383 71. Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, Hämäläinen H, Härkönen P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J, Finnish Diabetes Prevention Study Group (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368(9548):1673–1679 72. Hill JO (1998) Dealing with obesity as a chronic disease. Obes Res 6(suppl 1):S34–S38 73. Loos RJF, Bouchard C (2003) Obesity – Is it a genetic disorder? J Intern Med 254(5):401–425 74. Chitwood LF, Brown SP, Lundy MJ, Dupper MA (1996) Metabolic propensity toward obesity in black vs white females: responses during rest, exercise and recovery. Int J Obes Lond 20(5):455–462 75. Kayman S, Bruvold W, Stem JS (1990) Maintenance and relapse after weight loss in women: behavioral aspects. Am J Clin Nutr 52(5):800–807 76. Kaplan LM (2010) Pharmacologic therapies for obesity. Gastroenterol Clin North Am 39(1):69–79 77. Bray GA (2008) Lifestyle and pharmacological approaches to weight loss: efficacy and safety. J Clin Endocrinol Metab 93(11 suppl 1):s81–s88 78. Padwal R, Li SK, Lau DC (2003) Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes 27(12):1437–1446 79. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337(9):581–588 80. Centers for Disease Control and Prevention (CDC) (1997) Cardiac valvulopathy associated with exposure to fenflu-
43 ramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations. MMWR Morb Mortal Wkly Rep 46:1061–1066 81. Stafford RS, Radley DC (2003) National trends in antiobesity medication use. Arch Intern Med 163(9):1046–1050 82. Leung WYS, Neil TG, Chan JCN, Tomlinson B (2003) Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clin Ther 25(1):58–80 83. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M (1998) Randomised placebocontrolled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 352(9123):167–172 84. Anderson JW, Schwartz SM, Hauptman J, Boldrin M, Rossi M, Bansal V, Hale CA (2006) Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial. Ann Pharmacother 40(10):1717–1723 85. McNeely W, Goa KL (1998) Sibutramine. A review of its contribution to the management of obesity. Drugs 56(6): 1093–1124 86. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC (2005) Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 142(7):532–546 87. Turk MW, Yang K, Hravnak MH, Sereika SM, Ewing LJ, Burke LE (2009) Randomized clinical trials of weight loss maintenance: a review. J Cardiovasc Nurs 24(1):58–80 88. Bray GA, Ryan DH (2007) Drug treatment of the overweight patient. Gastroenterology 132(6):2239–2252 89. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD (2000) Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 160(14):2185–2191 90. Klein S (2004) Long-term pharmacotherapy for obesity. Obes Res 12(suppl):S163–S166 91. Buchwald H, Consensus Conference Panel (2005) Consensus conference statement bariatric surgery for morbid obesity: health implications for patients, health professionals, and third-party payers. Surg Obes Relat Dis 1(3):371–381 92. NIH Consensus Conference Statement Online (1991) Gastrointestinal surgery for severe obesity. Obesity 9(1):1–20. http://www.ncbi.nlm.nih.gov/books/NBK15123/. Accessed 24 May 2010 93. Kral JG, Naslund E (2007) Surgical treatment of obesity. Nat Clin Pract Endocrinol Metab 3(8):574–583 94. Kral JG (2006) ABC of obesity management: part III– surgery. Br Med J 333(7574):900–903 95. El Shobary H, Christou N, Beckman SB, Gvocdic B, Schricker T (2006) Effect of laparoscopic versus open gastric bypass surgery on postoperative pain and bowel function. Obes Surg 16:437–442 96. Samplis JS, Liberman M, Auger S, Christou N (2004) The impact of weight reduction surgery on health-care costs in morbidly obese patients. Obes Surg 14:939–947 97. Nguyen NT, Paya M, Mavandadi S, Zainabadi K, Wilson SE (2004) The relationship between hospital volume and outcome in bariatric surgery at academic medical centers. Ann Surg 240:586–593 98. Deitel M, Greenstein RJ (2003) Recommendations for reporting weight loss. Obes Surg 13:159–160
44 99. Bult MJF, van Dalen T, Muller AF (2008) Surgical treatment of obesity. Eur J Endocrinol 158(2):135–145 100. Schneider BE, Mun EC (2005) Surgical management of morbid obesity. Diabetes Care 28:475–480 101. Buchwald H, Williams SE (2004) Bariatric surgery worldwide 2003. Obes Surg 14:1157–1164 102. Tritos NA, Mun E, Bertkau A, Grayson R, Maratos-Flier E, Goldfine A (2003) Serum ghrelin levels in response to glucose load in obese subjects post-gastric bypass surgery. Obesity 11(8):919–924 103. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ (2002) Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346(21):1623–1630 104. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50(8):1714–1719 105. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Agren G, Carlsson LM, Swedish Obese Subjects Study (2007) Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357(8):741–752 106. Sjostrom L, Lindroos A, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sullivan M, Wedel H, Swedish Obese Subjects Study Scientific Group (2004) Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351(26):2683–2753 107. Wadden TA, Butryn ML, Byrne KJ (2004) Efficacy of lifestyle modification for long-term weight control. Obes Res 12(suppl):S151–S162 108. Perri MG, Foreyt JP (2004) Preventing weight regain after weight loss. In: Bray GA, Bouchard C (eds) Handbook of obesity: clinical applications, 2nd edn. Marcel Dekker, New York, pp 185–199 109. Wadden TA (1995) What characterizes successful weight maintainers? In: Allison DB, Pi-Sunyer F (eds) Obesity treatment: establishing goals, improving outcomes, and reviewing the research Agenda. Plenum Publishing Corp, New York, pp 103–111 110. Klem ML, Wing RR, McGuire MT, Seagle HM, Hill JO (1997) A descriptive study of individuals successful at long-term maintenance of substantial weight loss. Am J Clin Nutr 66(2):239–246 111. Butryn ML, Phelan S, Hill JO, Wing RR (2007) Consistent self-monitoring of weight: a key component of successful weight loss maintenance. Obesity 15(12):3091–3096 112. Wing RR, Hill JO (2001) Successful weight loss maintenance. Annu Rev Nutr 21:323–341 113. Raynor HA, Jeffery RW, Phelan S, Hill JO, Wing RR (2005) Amount of food group variety consumed in the diet and long-term weight loss maintenance. Obes Res 13(5): 883–890 114. Wyatt HR, Grunwald GK, Mosca CL, Klem ML, Wing RR, Hill JO (2002) Long-term weight loss and breakfast in subjects in the National Weight Control Registry. Obes Res 10(2):78–82
M.T. Turk 115. Raynor DA, Phelan S, Hill JO, Wing RR (2006) Television viewing and long-term weight maintenance: results from the National Weight Control Registry. Obesity 14(10): 1816–1824 116. McGuire MT, Wing RR, Klem ML, Lang W, Hill JO (1999) What predicts weight regain in a group of successful weight losers? J Consult Clin Psychol 67(2):177–185 117. Weiss EC, Galuska DA, Khan LK, Gillespie C, Serdula MK (2007) Weight regain in U.S. adults who experienced substantial weight loss, 1999–2002. Am J Prev Med 33(1):34–40 118. Wing RR, Papandonatos G, Fava JL, Gorin AA, Phelan S, McCaffery J, Tate DF (2008) Maintaining large weight losses: the role of behavioral and psychological factors. J Consult Clin Psychol 76(6):1015–1021 119. Richelsen B, Tonstad S, Rossner S, Toubro S, Niskanen L, Madsbad S, Mustajoki P, Rissanen A (2007) Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care 30(1):27–32 120. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E (1999) Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 106(2):179–184 121. Wirth A, Krause J (2001) Long-term weight loss with sibutramine: a randomized controlled trial. J Am Med Assoc 286(11):1331–1339 122. Kruger J, Blanck HM, Gillespie C (2008) Dietary practices, dining out behavior, and physical activity correlates of weight loss maintenance. Prev Chronic Dis 5(1):1–14 123. McGuire MT, Wing RR, Klem ML, Seagle HM, Hill JO (1998) Long-term maintenance of weight loss: Do people who lose weight through various weight loss methods use different behaviors to maintain their weight? Int J Obes Lond 22(6):572–577 124. Tate DF, Jeffery RW, Sherwood NE, Wing RR (2007) Long-term weight losses associated with prescription of higher physical activity goals. Are higher levels of physical activity protective against weight regain? Am J Clin Nutr 85(4):954–959 125. Villanova N, Pasqui F, Burzacchini S et al (2006) A physical activity program to reinforce weight maintenance following a behavior program in overweight/obese subjects. Int J Obes Lond 30(4):697–703 126. Jeffery RW, Wing RR, Sherwood NE, Tate DF (2003) Physical activity and weight loss: Does prescribing higher physical activity goals improve outcome? Am J Clin Nutr 78(4):684–689 127. Hill JO, Thompson H, Wyatt H (2005) Weight maintenance: What’s missing? J Am Diet Assoc 105(5):63–66 128. Jakicic JM, Marcus BH, Lang W, Janney C (2008) Effect of exercise on 24-month weight loss maintenance in overweight women. Arch Intern Med 168(14):1550–1559 129. Ewbank PP, Darga LL, Lucas CP (1995) Physical activity as a predictor of weight maintenance in previously obese subjects. Obes Res 3(3):257–263 130. Jeffery RW, Drewnowski A, Epstein LH, Stunkard AJ, Wilson GT, Wing RR, Hill DR (2000) Long-term maintenance of weight loss: current status. Health Psychol 19(1 suppl):5–16
5 Assessment and Treatment of Excess Weight 131. Anderson DA, Wadden TA (1999) Treating the obese patient. Suggestions for primary care practice. Arch Fam Med 8(2):156–167 132. Perri MG, McAdoo WG, Spevak PA, Newlin DB (1984) Effect of a multicomponent maintenance program on longterm weight loss. J Consult Clin Psychol 52(3):480–481 133. Wing RR, Jeffery RW, Hellerstedt WL, Burton LR (1996) Effect of frequent phone contacts and optional food provi-
45 sion on maintenance of weight loss. Ann Behav Med 18(3):172–176 134. Wadden TA, Anderson DA, Foster GD (1999) Two-year changes in lipids and lipoproteins associated with the maintenance of a 5% to 10% reduction in initial weight: some findings and some questions. Obes Res 7(2): 170–178
6
Phytonutrient and Phytotherapy for Improving Health Jian Zhao
6.1 Introduction Advancing scientific research and increasing knowledge on medicine and food nutrition has dramatically changed the concepts about food, medicine, and healthcare and brought in a revolution on them in past decades. What people eat or drink has become the major cause of various diseases and health problems, besides infections or epidermal diseases. Nowadays people pay extensive attentions to what they eat, including foods and medicines, which largely determine one’s health in the life. In addition to staple foods, fruits, and vegetables, strong recommendations by nutrition or clinical professionals to consume nutraceuticals and phytonutrients have become progressively popular [1]. Alternative therapeutics based on nutraceutical therapy and phytotherapy have emerged as new healing systems and quickly and widely spread [1, 2]. It is generally believed that plant nutrients and bioactive natural products (here all together called phytonutrients) in plant-derived diets, herbs and botanicals hold great promise in benefiting human health due to their potentials to promote overall health, prevent some diseases, reduce side effects associated with chemotherapy or radiotherapy, reduce the health care cost, or to even improve drug effectiveness by various mechanisms [1, 3]. A large population in all over the
J. Zhao Plant Biology Division, The Samuel Roberts Noble Foundation, 2510 Sam Noble Parkway, Ardmore, OK 73401, USA e-mail:
[email protected],
[email protected]
world, including two-thirds of Americans, regularly take certain kinds of nutraceuticals or herbs for various health purposes. Correspondingly, manufacturing and marketing of nutraceuticals and phytonutrients and related therapeutic and professional practices are rapidly growing. While concerns on the use, quality control, safety, efficacy, or standardization of phytonutrients and phytotherapy remain as major issues, legislations on these foods and healthcare products are yet to be completed [1]. The information regarding these phytonutrients and their related alternative therapies from media such as Internet, TVs, printed publications, and even in research data is either limited or confusing or sometime controversial. This chapter attempts to display and remark on phytonutrients and phytonutrientbased therapeutics, phytotherapy, and to give a more comprehensive but clear view of these. It introduces phytonutrients and phytotherapy from their scientific concepts, scientific research- or evidence-based facts, clinical trials, and epidemiological studies, to their roles with beauty and cosmetic surgery. It can lead to a complete understanding of the most aspects of phytonutrients and phytotherapy.
6.2 Plant Food, Medicine, Natural Product, and Phytonutrients Plant natural products provide humans with huge sources for foods, medicines, flavors, colors, fine chemicals, and other agricultural and industrial materials. Human beings once and now still extensively rely on plant resources and environments. Plant-derived foods, such as grains, fruits, and vegetables, provide humans a major portion of dietary nutrients, such as carbohydrates,
P.M. Prendergast and M.A. Shiffman (eds.), Aesthetic Medicine, DOI 10.1007/978-3-642-20113-4_6, © Springer-Verlag Berlin Heidelberg, 2011
47
48
lipids, proteins, vitamins, minerals, and dietary fibers. Food chemistry and nutrition studies have revealed that humans actually benefit from plant foods all the time from numerous aspects because of their rich and diverse natural products. Plant foods provide rich and ideal phytonutrients combinations for human beings, such as whole sets of different types of vitamins, essential amino acids, essential fatty acids, macro- and micro-minerals, and plant-specific proteins, lipids, and carbohydrates. Although many of them can also be taken up from animal-derived foods, the presence of other nonhealthy or even potentially harmful ingredients such as high levels of cholesterol, saturated fatty acids, and disease infection and contaminations makes animal-derived foods less desirable. Even fish and other sea foods that are popularly regarded as the top omega-3-containing healthy foods is often inevitably contaminated with heavy metals such as mercury or other toxic organic chemicals. Therefore, plant foods, particularly raw organic plant foods such as grains, fresh vegetables and fruits, nuts, with high phytonutrient values, are strongly recommended for human health benefit. Epidemiological and prospective studies indicate that comprehensive lifestyle changes may modify the progression of prostate cancer [4]. Similarly, dietary habits and changes could significantly affect overall health status and lifespan [5], although the molecular mechanisms by which improvements in diet and lifestyle might affect the prostate microenvironment are poorly understood. Recent studies have suggested that dietary choices may have an effect on epigenetic of individual genome, providing a profound insight into our understanding of relationships between diet and human health [6]. Human beings rely on plants not only due to foods for relief of starvation, but also for their medicine effects and healthcare function. From ancient time, human beings have been using some medicinal plants to diagnose and treat various diseases, or to enhance health and increase longevity of their lives. Extensive use of plants for healthcare and disease treatment have led to numerous discoveries of diverse important plant natural products from medicinal plants and crops, and accumulated invaluable therapeutic experiences. The heritages of folk medicine or traditional medicine and their therapies benefit human health for thousands of years and now continue to serve humans [7]. The modern pharmaceutical industry is born from folks or traditional plant medicine. Many important drugs used in chemotherapy are originally derived
J. Zhao
from plant natural products such as aspirin originating from salicin, a natural product in Salix alba plants. Some drugs now still heavily rely on extraction from medicinal plant: anti-lymphoma and histiocytosis drugs vinblastine/vincristine from Madagascar periwinkle (Catharanthus roseus); anticancer drug Taxol (paclitaxel) from the pacific yew tree; antimalaria drugs derived from natural lead artemisinin in a Chinese tradition medicinal plant wormwood (Artemisia annua); anticancer drug (ovarian and small cell lung cancers) topotecan synthesized from its natural analogue podophyllotoxin in Mayapple (Podophyllum peltatum); anticholinergic medicine atropine from Atropa belladonna, etc. Although synthetic drugs and modern drug discovery based on them have become standard and mainstream for many years, plant-derived folk medicines, herbs or botanicals, continue to be used or developed into effective therapies [7]. For example, Chinese traditional medicines, a long-history therapy system and multi-component herb medicines, have been main pharmaceuticals in China and now are gradually recognized as an important complementary healing system and new drug discovery resources by western countries [8]. On the other hand, many synthetic drugs have been reported regarding of their toxicity and/or serious side-effects, together with their almost unaffordable expensive costs, and failures to treat many common degenerative diseases, drive people to look for alternative therapies, including phytonutrients- and phytotherapies. Such return back to plant functional foods and phytotherapy is also due to greater-than-expect performances of many phytonutrients and phytotherapy.
6.3 Clearance of Concepts and Terms Because of long history of using medicinal plants by humans, the similar concepts with phytonutrient and phytotherapy have been given different names in different regions, nations, or at development stages and by different producers or providers [1, 7]. These cause a lot of confusing and misunderstanding. For examples, herbs, herbal medicines, botanical medicines, medicinal plants, phytonutrients, phytomedicines, herbalism, herbology, herbal therapy, and phytotherapy appeared in different types of media actually refer to concepts with the similar meanings: plants or plant extracts with proved health benefits, and therapeutics
6 Phytonutrient and Phytotherapy for Improving Health
based on such materials. Clarifying these concepts are of particular importance to avoid any misunderstanding or misleading of patients, professionals, researchers, other interested parties. Herbs, herbal medicine, medicinal plants, botanicals, folk medicines, or phytomedicine refer to plants or parts of plants and their extracts with certain biological activities and can be used for promote health, prevent or treat human disease. Health benefits of these plant materials or plant-derived materials are either proved by a long history of using and their treatment evidence in folks, or by modern scientific research on their bioactive components with biological activity against health problems. However, usually an herb contains multiple bioactive components, which makes their overall therapeutic effects more complicated and research on them difficult. Their major ingredients may show similar and synergistic effects or different and even antagonist effects because of their targets on similar or different biochemical pathways or cellular processes. Herbal remedy, or herbalism, medical herbalism, and herbology are old names for phytomedicine-based belief or theory, studying subjective or healing and disease treatment system. All of them believe that medicinal plants contain necessary medicines for solving most human health problems. However, due to the lack of strict practical protocols, supporting evidence from scientific study, standardization of quality and quantity of herbs regarding of their bioactive components, and thereby reliable clinical effects, many old herbal remedies have been discarded or changed for modern medicine study, if they are still believed valuable. Phytonutrients refer to plant-derived all natural products with particular biological activities in supporting human health. The concept covers the common food nutrients derived from agricultural plants, but also covers plant natural products with biological activity. Unlike phytochemicals that generally refers to all plantderived chemicals regardless of their biological activity, also different from phytomedicine that only includes plant natural products that show potent biological activity and can potentially be developed into drugs, phytonutrient focuses on plant derived bioactive products with health benefits. Therefore, phytonutrients here include all nutrients derived from plants, not only function-known vitamins, proteins, lipids, and carbon essential minerals, but also unknown health-promoting plant natural products including primary and secondary metabolites. Such broad definition on phytonutrient is
49
based on (1) plants are born to be an important part of human beings’ life. All natural products in plant foods and medicinal plants are significantly involved in the evolution of humans. (2) “Let food be thy medicine and medicine be thy food” is still the wisdom prediction of the relationship between appropriate foods for health and their therapeutic benefits and the final goal of food nutrition and medical sciences. (3) Our understanding of plant natural bioactive products continues expending with advancing scientific research on phytochemistry, nutrition, and medical sciences. New beneficial effects of plant natural products on human health are being revealed, and therefore, the concept phytonutrient evolves. Phytonutrients play positive roles in maintaining well being, enhancing health, and modulating immune function to prevent specific diseases. Under proper management, phytonutrient hold great promise in clinical therapy due to their potential to improve health conditions of humans in a more natural way, to cure diseases without side effects and affordable cost, to complement the shortages of current chemotherapy or radiotherapy by reducing side effects associated with chemotherapy or radiotherapy and significantly reducing the healthcare cost [4]. Phytotherapy presents an alternative healing system with long histories using whole or parts of medicinal plants or herbals or their effective extracts to improve health conditions, prevent or treat diseases. Compared with herbal remedy, phytotherapy is an evolved concept and its methodology is based on modern phytochemistry, nutrition, and medicine research, although most phytotherapeutics are developed from herbal remedy that uses folk medicines to promote health and treat diseases. However, compared to herbal remedy, phytotherapy is based on modern scientific researches and most often are through various types of clinical trials. The phytonutrients have been and are continuously being improved for their safety, bioactivity, and quality and quantity control. Advancing studies on their photochemical principles and biological activities, and clinical trials on feeding protocols pave a solid base for patient practice. Phytotherapy relies on diverse bioactive phytonutrients that make plant foods cannot only relief hunger, but also modify health status, aid in medical practices such as drug delivery. The plant primary and secondary metabolites include several classes such as essential amino acids, essential fatty acids,
50
unique carbohydrates, and many potent bioactive secondary metabolites such as terpenoids, phenolics, alkaloids, and others. They provide humans with numerous biologically active products, which have been used extensively as food additives, flavors, colors, drugs, fragrances, and other fine chemicals. Exploration of new phytonutrients and their biological activities has led and continue to make more discoveries for improving phytotherapies.
6.4 Health Benefits of Phytonutrients and Phytotherapy 6.4.1 Dietary Fibers Plant dietary fiber can reduce cholesterol level and risk of cardiovascular diseases, maintain healthy weight, therefore has promising benefits to obesity and diabetic patients [9]. FDA for the first time approved the claim about solid functions of soluble fiber from plant foods. Plant foods rich in dietary fibers include wheat bran (rich in insoluble fiber with benefit of reducing risk of breast or colon cancer), psyllium and oat and barley mails (rich in soluble fiber and beta-glucan, well known for lowering low density lipoprotein (LDL) and total cholesterol and reducing risk of cardiovascular disease and some cancers).
6.4.2 Phenolic and Polyphenolic Compounds Chlorogenic acid is marketed under the trademark Svetol in Norway and the United Kingdom as a food active ingredient used in coffee, chewing gum, and mints to promote weight reduction. Resveratrol found in nuts and red wine has strong antioxidant, antithrombotic, anti-inflammatory, and anti-carcinogenesis activities. Hydroxytyrosol from olives and olive oil is a potent antioxidant. Curcumin from Indian spice turmeric shows strong antioxidant, anti-inflammatory, and anticancer activity [10]. Plant lignans are contained in plants-derived foods and have multiple biological activities, such as antimitotic, antifungal, antioxidant, and antiviral activity. The most famous lignan is podophyllotoxin, which has potent anticancer activity and its derivatives have been developed into drugs for chemotherapy against different
J. Zhao
types of cancers. Secoisolariciresinol and matairesinol were the first plant lignans identified in foods. The main dietary lignans in our daily foods might be pinoresinol and lariciresinol, which contribute about 75% to the total lignan intake whereas secoisolariciresinol and matairesinol contribute only about 25% [11]. Flax seed and sesame seed are rich in lignans, such as secoisolariciresinol diglucoside. Other sources of lignans include cereals (rye, wheat, oat and barley), pumpkin seeds, soybeans, broccoli, beans, and some berries. Flavonoids such as anthocyanins, flavonols, isoflavones, proanthocyanidins (also known as tannins) are most abundant dietary plant secondary metabolites, and widely contented in plant foods. OPC (oligomeric proanthocyanidins) are combined proanthocyanidin extract (mainly from grape seeds). OPC has been marketed for many years as a phytonutrients in phytotherapy with strong antioxidant and anti-aging agents, recently the active components oligomeric proanthocyanidins from grape seeds are shown to delay Alzheimer’s disease [12]. Proanthocyanidins can improve urinary tract health by preventing urinary tract infection and reducing risk of cardiovascular disease through their strong antioxidant activity. A positive correlation between dietary flavonoid (such as myricetin, quercetin, and isoflavones) intake and decreased mortality from coronary heart disease, partly due to the inhibition of LDL oxidation and reduced platelet aggregability by flavonoids [13–16]. Dietary intake of flavonoids ranges between 23 mg/day estimated in The Netherlands (mainly green tea, onions, apples, and red wine) and 170 mg/day estimated in the USA. The consumption of 30–50 mg/day of soy isoflavones in the traditional eastern diet may help lower the incidence of breast cancer. The soy isoflavone phytoestrogens, genistein and daidzein, and a daidzein metabolite equol produced by intestinal microflora have potent antioxidant activity. Particularly, equol is an inhibitor of LDL oxidation taking place in the arterial intima. Therefore, intake of soy-derived phytoestrogens provides protection against oxidative modification of LDL, and helps to reduce the risk of atherosclerosis, cardiovascular disease, and cancer [17]. A randomized, double-blind, placebo-controlled, cross-over study with 30 healthy postmenopausal women indicated that 8 weeks consumption of cereal bars enriched with 50 mg soy isoflavones/d increased plasma nitrite and nitrate concentrations and improved endothelium-independent vasodilatation in healthy postmenopausal women [17]. There are continuously increasing numbers of breast
6 Phytonutrient and Phytotherapy for Improving Health
cancer patients in Western societies, which are higher than these in eastern Asian countries, mainly because Asian women eat more soy and other plant-derived foods such as tofu, vegetables, and raw cereals that contain phytoestrogens, lignans, and fibers [1, 17].
6.4.3 Terpenoids Plant terpenoids are an important group of phytonutrients, including pre-vitamin A carotenoid, zeaxanthin, and vitamin E, Coenzyme Q10, and bioactive monoterpene, sesquiterpenes, diterpenoids. Coenzyme Q is a lipid-soluble antioxidant and a very popular food supplement. carotenoid lycopene. Epidemiological studies have clearly shown the great benefits of consumption of tomato to human health due to tomato carotenoids, mainly lycopene, b-carotene, and lutein [18]. Lycopene from tomatoes and other fruits is a potent antioxidant carotenoid protective against prostate and other cancers and inhibiting tumor cell growth in animals [18]. b-Carotene from carrots, fruits and other vegetables not only are pre-vitamin A, but also have potent antioxidant activity by neutralizing free radicals, which are regarded as one of the major causes of aging and various cancers. Humans benefit from eating dietary carotenoid-rich plants and various vegetables containing vitamin E, lycopene, lutein, zeaxanthin through their strong antioxidant and anti-aging activity. Monoterpenes in citrus fruits, cherries, peppermint, and herbs have anticarcinogenic actions, as well as cardioprotective effects in experimental models. Sesquiterpenes from plants usually have strong antibacterial, antiviral, antifungal, and insecticidal activities, and are used to treat infectionrelated diseases. The unique monoterpene derivatives thujaplicins from trees are widely used as antifungal medicine in clinic, cosmetic products, and wood preservation [19]. The most well-known sesquiterpenes such as artemisinin and their derivatives are dominant antimalarial drugs [20]. Many plant diterpenes are medicines such as famous anticancer drugs Taxol and derivatives. Another important class of terpenoid phytosterols, such as stigmasterol, sitosterol, campesterol, are natural components of many plant foods. Because of their similar structures with cholesterols from meats, phytosterols competitively inhibit human cholesterol absorption by the gut [21, 22]. FDA approved the claim “Foods containing at least 0.4 gram per serving of plant sterols, eaten twice a day with meals for a daily total intake of at
51
least 0.8 gram, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease.”
6.4.4 Fatty Acids and Lipids Fat occupies nearly 60% of human brains and determines brain’s integrity and performance. Clinical studies have associated the imbalanced dietary intake of essential fatty acids including alpha-linolenic acid (an omega-3 fatty acid) and linoleic acid (an omega-6 fatty acid) with impaired brain development, performance, and diseases [23]. They are essential for human body to make many important molecules affecting neurofunction, cellular function, inflammation, mood, and behavior. Dietary long-chain polyunsaturated fatty acids, such as arachidonic acid, eicosapentaenoic acid (EPA), and decosahexaenoic acid (DHA) are also helpful for proper function of the retina and visual cortex [24]. People now take extra omega-3 fatty acids from fish oils, flaxseeds, or nutraceutical products. However, correct intake in terms of EFA form, dosage, and time for optimal wellness is still speculative. Plant foods such as flaxseed, soya oil, canola oil, Oliver oil, pumpkin seeds, sunflower seeds, leafy vegetables, and walnuts contain different levels of omega-3 fatty acids. Although the ideal and higher ratio of omega-3 to omega-6 fatty acids varies largely in these foods. A plenty of scientific evidence shows that substitution of dietary saturated fat by oleic acid and/or polyunsaturated omega-3 fatty acids benefit cardiovascular health by reducing blood cholesterol, LDL-cholesterol and triglycerides [25]. Recent studies show that medium-chain fatty acids or triglycerides also have benefits to human health [26]. Unlike long- or very-long-chain fatty acids, these fatty acids passively diffuse into the portal system without requirements of modification and digestion. Therefore, malnutrition or malabsorption patients are treated with these medium-chain fatty acids (MCFAs) and triglycerides (MCTs). Metabolic syndromes, such as abdominal obesity, dyslipidemia, hypertension and impaired fasting glucose, contribute to increased cardiovascular morbidity and mortality. Medium-chain fatty acids and medium-chain triglycerides suppress fat deposition through enhanced thermogenesis and fat oxidation in animal and human subjects [27]. Several reports suggest that MCFAs/MCTs offer the therapeutic advantage of preserving insulin sensitivity in animal
52
models and patients with type 2 diabetes [27]. Coconut oil is composed of approximately 66% medium-chain triglycerides.
6.4.5 Essential Amino Acids Eight essential amino acids are so called because mammals cannot synthesize them by themselves but have to take up from plant foods or meat sources. Taking up adequate essential amino acids are very important for health since they are building blocks of proteins, which carried functions of human body [1, 28]. Tryptophan is used for synthesis of neurotransmitter serotonin and relief of depression; flaxseeds have high tryptophan levels. Tyrosine is for dopamine, norepinephrine and adrenaline synthesis for normal neurosystem activity and enhances positive mood. Isoleucine is necessary for the synthesis of hemoglobin in red blood cells. Leucine has beneficial effects for skin, bone and tissue wound healing, and promotes growth hormone synthesis. Lysine and valine are essential for muscle proteins, as well as the synthesis hormones and l-carathine which is essential for healthy nervous system function. Methionine is essential for all protein synthesis and helps in breakdown of fats and reduces muscle degeneration. All these essential amino acids can be found in plant foods such as cereals, soybean, flaxseeds, nuts, and peas [29]. Phenylalanine is beneficial for healthy nervous system and boosts memory and learning. Phenylalanine may be useful against depression and suppressing appetite. In addition, l-Arginine is a conditional essential amino acid for infants and growing children, as well as for pregnant women. Glutamine is considered a conditionally essential amino acid in metabolic stress.
6.4.6 Phytoestrogen Various phytoestrogens are diverse nonsteroidal plant secondary metabolites with similar structure with hormone estradiol and thus with ability to cause estrogenic or/and antiestrogenic effects. Many of them are contained in our daily diets, such as soybean and cabbage, nuts, and oilseeds, therefore also called “dietary estrogens.” These phytonutrients such as coumarins, prenylated flavonoids, and isoflavones can act as antioxidants, estrogen agonists, and antagonists with multiple effects [30]. An optimal “estrogen balance” has implications
J. Zhao
for cancer prevention and successful aging in both women and men. They protect against heart disease, anticancer activity against some cancers such as breast cancer, lower LDL, and total cholesterol [18]. Soybean products, cruciferous vegetables such as cabbage, cauliflower, and broccoli possess unique phytochemicals able to modify the metabolism of estrogen or to enhance the beneficial action and safety of estrogen. Several large-scale investigations suggest that the likely contributory factor to dramatic difference between Asian women who have significantly lower levels of breast cancer and women in western countries may be that Asian women take a vegetarian diet with higher intake of legumes and other plant foods containing a variety of lignans, dietary fibers, and isoflavonoid phytoestrogens, which act as nature’s sex hormone modulators and provide estrogenic effects and an anti-estrogenic competitive effect [16, 17, 31]. Epidemiological studies demonstrated that l-arginine, chlorogenic acid, fermented milk, garlic, onion, tea, soybean, ginger, hawthorn, and fish oil have beneficial effects on prevention, improvement, or treatment of patient’s elevated blood pressure [32].
6.5 Herbs and Multi-Component Herbal Formulations Phytotherapy strategies using herbal drug combinations with superior efficacy and lesser side effects in comparison with single isolated constituents of plant extracts has been repeatedly assessed clinically as well as pharmacologically [1]. A multicomponent herbal preparation, STW5, has been clinically proved effective for the treatment of patients with functional dyspepsia and irritable bowel syndrome [33]. Like other Chinese herbal medicines combined with various herbs containing different bioactive substances, STW5 is a combination of nine plant extracts with different active constituents [34]. Except for nutraceuticals such as glucosamine and chondroitin, many herbs have been tried for treatment of osteoarthritis and rheumatoid arthritis diseases [1, 35]. Other degenerative diseases and immunosystem problems that could not be effectively treated by current synthetic drugs become targets of herbs, nutraceuticals, and phytotherapies. Allergic rhinitis is the most frequently occurring immunological disorder. A traditional Chinese formulation Aller-7 comprising seven herbal extracts was shown well tolerated and efficacious
6 Phytonutrient and Phytotherapy for Improving Health
in patients with allergic rhinitis without serious adverse effect [36]. Similarly, another formulation was also studied in clinical trial and appears to offer symptomatic relief and improvement of quality of life for some patients with seasonal allergic rhinitis [37]. The efficacy and safety of the butterbur leaf extract Ze 339 were to be safe and efficacious in the treatment of patients with seasonal allergic rhinitis [38]. All these studies clearly suggest that multi-component traditional herbals can offer a very efficacious and better therapeutic option to patients in many diseases. However, a lack of information on the phytochemistry and pharmacological section of phytochemicals, or the synergistic effects of phytotherapies may threaten and damage the customers and market [39]. Clinical trials and epidemiological studies are commonly used methods to investigate effects of phytonutrients and herbs on various health targets. However, strict clinical trials and epidemiological studies, particularly latter, require not only rationale designs, proper controls, a long time period for feeding, observation and physiological measurements, data collection, but also a large population of patients willing to cooperatively participate in the study, as well as final systematic analysis. This is largely because effects of phytonutrients are usually marginal, long-term, and individually differential. Also, other factors also can significantly affect the outcome of clinical trials and epidemiological studies, for instance, quality and quantity of herbs or phytonutrients, absorption and metabolism of phytonutrient, and drug–herbs or drug–phytonutrient interaction. Therefore, it is uneasy to obtain reliable results from clinical trial and epidemiological study on phytonutrients. For example, as one of the widely commercialized example of phytotherapeutics, Saw palmetto (Serenoa repens) combined with others is widely used for the treatment of lower urinary tract symptoms and benign prostatic hyperplasia. Although the majority of adverse events of using saw palmetto are mild, results of many different clinical trials are complicated and controversial [40, 41]. However, highquality clinical trials and epidemiological studies on phytonutrients and physiotherapies provide most close-to-realty and reliable evaluation of their biological effects on human health, and they are essential and highly needed to evaluate phytonutrients and phytotherapies for continuous and healthy development of natural resources and healing system.
53
The rapidly increasing number of such proof-of-concept studies strongly support success of some phytonutrients and their phytotherapies on improvement of health or even solve health problems.
6.6 Phytonutrients for Beauty: Weight Loss, Facial Aging, and Cosmetic Surgery An increasing prevalence of overweight and obesity has reached global proportions. Overweight and obesity generate a major risk of chronic diseases such as type 2 diabetes, cardiovascular disease, hypertension, stroke, and cancers. Overweight and obesity are dietrelated health problems, their patients, however, may not be simply and easily recovered by reducing diet consumption because overweight and obesity have changed many physiological and psychological processes to patients. Some synthetic drugs have been developed, yet their side effects and potential risks are nor ignoble. With strong belief on the potential health benefits of phytonutrients people look for herbs and phytonutrients that are effective in weight loss and diet control. Actually, plants-based foods have low saturated fats and sugar, high levels of diet fibers, and more balanced minerals and vitamins, and be eaten against many health-problems including weight and obesity [42]. Moreover, some phytonutrients from plant foods or medicinal plants have potent effects on prevention and treatment of overweight and obesity. For example, clinical studies have demonstrated that plant-derived sterols, phytosterols, can repeatedly lower bad LDL cholesterol in the blood, which is a major risk factor for coronary heart disease [43]. Hydroxycitric acid (HCA) from Garcinia cambogia is a main bioactive component in several popular Hydroxycut weight management formulation products [44]. Herbs and phytonutrients are also believed to delay facial aging, improve facial rejuvenation and facial beauty because of their rich amino acids, vitamins, antioxidants and other phytonutrients with antibacterial, antifungal, and anti-inflammatory activity that are helpful for the skin. Nowadays use of phytonutrients or herbs, effective cosmetics (many of them also contain phytonutrients), aesthetic plastic and cosmetic surgery, or combinations of them are widespread among people for various levels of beauty purposes [45, 46]. There are many claims that
54
certain herbs or phytonutrients have potent effects on reduction of weight, obesity, diabetes, facial aging and rejuvenation, or other degenerative diseases, and nutritional deficiencies, or improvement of overall health and beauty [47, 48]. However, there are also warns of negative effects on uses of herbs and natural products, particularly perioperative use of herbs and phytonutrient supplements regarding aesthetic plastic, and cosmetic surgery because these health problems on patients have a significant impact on surgical outcome and complications [49]. Although phytonutrients have beneficial effects on some aesthetic plastic and cosmetic surgeries [47, 49], some raw herbs are more complex due to multiple-components, limited information on their phytochemical, medical/toxical, or clinical researches; perioperative taking of these herbs by patients who are undergoing surgery may have unexpected influences on any surgical outcome. Many plastic or cosmetic patients are taking herbal medications or supplements, and a descriptive “top-10” list of such herbs and preoperative recommendations was compiled for the plastic surgeon [50]. Chondroitin (used to treat osteoarthritis in conjunction with glucosamine), ephedra (Ephedra sinica, used to promote weight loss, to treat respiratory tract conditions, but it has been banned by the FDA because of potential and serious side effects, active ingredients ephedrine and pseudoephedrine), echinacea (Echinacea purpurea, used for chronic wounds, immune stimulant and arthritis, active component: phenolic compounds), Ginkgo biloba (improve blood circulation and mental function, active component: ginkgoflavoneglycosides), goldenseal (Hydrastis canadensis, used for strong antibacterial regent, active ingredient: berberine), milk thistle (Silybum marianum, used for liver problems like liver cirrhosis, chronic hepatitis, etc., active ingredient: silymarin), ginseng (used to revitalize and boost energy and reduce stress and fatigue, active component: ginsenosides), kava (Piper methysticum, promotes relaxation and antidepressant, active component: kavalactones) and garlic (used to maintain healthy cholesterol and anticoagulant, or antibiotic regent, active ingredient: sulfur compound allicin), black cohosh (Cimicifuga racemosa, estrogenic activity to treat gynecological and other age-related disorders, active component: triterpenoid glycosides), valerian (Valeriana officinalis, used as mild sedative to treat insomnia and anxiety, active ingredients: sesquiterpenes and valepotriates), Saw palmetto (Serenoa repens, used for improvement of urinary
J. Zhao
symptoms and benign prostatic hyperplasia, bioactive ingredients fatty acids and phytosterols), arnica Montana (used as anti-inflammatory and antibiotic regent, active ingredient: helenalin), St. John’s Wort (Hypericum perforatum, used for mild and moderate mood disorders or depression, active ingredient hypericin), bromelain (pineapple stem, anti-inflammatory, antibacterial, and proteolytic activity), thunder god vine (Tripterygium wilfordii, root extracts used to treat rheumatoid arthritis, bioactive component: triptolide). However, some of these herbs may have negative effects on surgical procedure or recovery, such as bleeding (ginger, ginseng, Ginkgo biloba, and garlic), immunosuppression (Echinacea), inflammation (garlic, ginkgo), wound healing (Echinacea and garlic), blood pressure and/or heart rate (Ephedra, garlic, ginseng, and goldenseal), increase anesthesia effects (Kava, St. John’s Wort, Valerian) and unexpected hormone-like effects (Saw palmetto). However, just as biological activities of these herbs remain to be confirmed by more phytochemical, clinical trials, and epidemiological studies, the potential negative effects of these commonly used herbs on aesthetic plastic and cosmetic surgeries are also not well confirmed scientifically. It is still responsible and helpful for surgeons or professionals to learn the potential effects of phytonutrients that patients take and communicate well with patients to incorporate nutritional and supplementation management into their preoperative office for optimizing surgical outcome.
6.7 Absorption and Metabolism of Phytonutrients and Their Interaction with Drugs Although we take great benefits from eating plant foods and their bioactive phytonutrients, our understanding of absorption and metabolism of phytonutrients is limited. Now it is generally accepted that the bottleneck for the alleviating nutrient deficiencies may be largely due to the limited absorption of nutrients from diets. Although exact percent absorption of most phytonutrients has yet to be determined, recent studies suggest that many important phytonutrient, such as vitamins, minerals (Ca2+, Fe2+, and Zn2+), and bioactive plant products, are not fully absorbed in the human body. Unlike a synthetic drug, phytonutrients in plant foods, or a herb or its extract, normally contain low levels of bioactive ingredients, which cause difficulties
6 Phytonutrient and Phytotherapy for Improving Health
to trace their absorption and metabolism in gut intestine system. Moreover, some phytonutrients may be metabolized by microbial organisms lived in the gut systems [51]. The human gut is populated by an array of bacterial species that develop important metabolic and immune functions and markedly affect the nutritional and health status of the host. Phytonutrients from diets and their metabolic products may also affect, either positively like prebiotics or negatively, the gastrointestinal gut microbiota. The reciprocal interactions between the gut microbiota and phytonutrients influence their effects on human health. The gut microbiota transforms dietary compounds into different bioactive metabolites in vivo and, in turn, plant food bioactive compounds might influence the gut microbiota composition and its physiological effects on mammalian tissues [52]. The most extensively studied plant natural products on their absorption and metabolism by mammalian models might be flavonoids. Anthocyanins and proanthocyanidins are most abundant ones in plant diets. These flavonoids most often are found to be glucuronylated or methylated in blood plasma after ingestion [53]. However, it is not clear where (intestine cells, liver, or other organs) these flavonoids are glucuronylated or methylated which could pass blood-brain barrier. Studies are designed to investigate why anthocyanins or proanthocyanidins are modified, for uptake or physiological function? The majority of the dietary anthocyanins and proanthocyanidins were catabolized into phenolic acids. It is proposed that most likely these glucuronylated or methylated flavonoids circulated in the blood and brains may exert physiological functions [54]. Many drugs are metabolized by human Cytochrome P450 class enzymes, one of the well-studied targets on phytonutrients–drug or herb–drug interaction is how phytonutrients affect P450 enzyme activity. Gurley et al. evaluated effects of several herbs, including milk thistle, black cohosh, kava, goldenseal, St. John’s Wort, Echinacea on P450 CYP2D6 activity in vivo and found only goldenseal shows significant inhibition on drug urinary recovery [55]. By searching effective research literatures, Brazier and Levine [56] identified about 50 possible drug–herb interaction pairs. Among them, 22 drug–herb pairs were supported by randomized clinical trials, case–control studies, cohort studies, case series, or case studies. Warfarin was the most common drug and St. John’s Wort was the most common herbal product reported in drug–herb interactions. Another types of
55
targets of plant natural products in mammalians are transporters in intestine walls or throughout the gastrointestinal tract, liver, and kidney, that are responsible for drug absorption into body and their metabolism in liver and release through urinary system. Dietary flavonoids have been reported to exert mostly inhibitory effects on mammalian ABC transporters, and therefore affect drug absorption, metabolism and release [57]. A recent survey reports that about 49% of American elderly community with ages 57 through 85 used dietary supplements on a regular basis, and about 25% of them are at risk for a major drug–drug interaction [58].
6.8 Regulation, Manufacture, Consumer, Market, and Outlooks The governmental administration of food and drugs all has strict regulations on food and drugs in terms of manufacturing, servicing, and marketing, and usage. But they do not have a complete regulation on nutraceuticals, phytonutrients, functional foods, and their related therapeutic practices; such situation, however, is changing as market volume dramatically increases, in particularly nutraceutical, phytonutrients and phytotherapy. Due to increasing demands and relatively loose regulations, there exist many problems in manufacturing, marketing, and consumption of herbs and phytonutrients, as well as misled phytotherapy practices with various reasons. For examples, some commercially available herbs or herbal products are being marketed in the United States with little or no publicly available scientific validation of efficacy or consistency [59]. Not only variations in clinical trials of herbs or phytonutrients confuse patients or consumers, a significant limiting factor to our understanding of the use and effectiveness of phytotherapy may also be the lack of standardization of herbs and phytonutrient products. The bioactive components and composition of herbs can change over time of growth, collection, and storage. Measurement of herbs with their dry weight rather than bioactive components can generate huge variations. Furthermore, effectiveness of many herbs may not depend on only one chemical composition but a multi-component effect. There is growing evidence from clinical trials that phytotherapeutic agents may lead to subjective and objective symptom improvement beyond a placebo effect. Therefore, more researches on chemical compositions of herbs and
56
phytonutrients, their dynamic changes during growth, collection and storage, as well as their biological activity are very necessary for herb quality and quantity control and standardization. More regulations are being worked out through consultations with expert panels on these products and practices, Good Manufacturing Practice (GMP) compliance, Generally recognized as safe (GRAS) status, analytical methods and validation. All claims and labels on products of phytonutrients and herbs should be accurate and substantiated by scientific evidence and should not lead to misunderstanding. While advanced education and training is also necessary, professionals, patients or consumers can contribute to knowledge discovery, translation, and outreach to improve the phytonutrients and phytotherapy development and health of populations. The safety assessment of herbs and phytonutrients is complicated and involve chemical identification of bioactive composition, quantification of the material, quality control, bioactivity and toxicity tests (including acute, subacute, subchronic, chronic and long-term toxicity studies, reproductive toxicology). In addition, although phytonutrients and phytotherapy have attracted extensive attentions and are rapidly developed, still a large portion of claims on effectiveness of herbs and phytonutrients need to be tested [60]. Using advanced technologies such as mass spectrometry for identification of chemical components of herbs and metabolism of phytonutrients in human body [61], proteomics technology for testing direct targets of phytonutrients or herbs on mammalian models or human body, and transcriptomics – the global gene expression detected by using microarray technology to probe the safety and efficacy of phytonutrients or herbs, will provide more profound and precise insights into how phytonutrients or herbs affect human health [62]. These high-throughput technologies will greatly fasten various processes such as evaluation of validity, safety, effectiveness, and mechanism of phytonutrients and herbs, even though with many challenges ahead [63]. Integration of these strategies and technologies into nutrition study, also called functional nutrition genomics, which study how food nutrients or bioactive chemicals affect the expression of genetic information in an individual and how an individual’s genetic metabolizes and responds to nutrients and bioactive compounds, now emerges as a fast-g rowing
J. Zhao
and critical research area. Many hopes and great expectations on development of phytonutrients and phytotherapies might rely on functional nutrition genomics study.
References 1. Zhao J (2007) Nutraceuticals, nutritional therapy, phytonutrients, and phytotherapy for improvement of human health: a perspective on plant biotechnology application. Recent Pat Biotechnol 1(1):74–97 2. Bland JS (1996) Phytonutrition, phytotherapy, and phytopharmacology. Altern Ther Health Med 2(6):73–76 3. Eussen S, Klungel O, Garssen J, Verhagen H, van Kranen H, van Loveren H, Rompelberg C (2010) Support of drug therapy using functional foods and dietary supplements: focus on statin therapy. Br J Nutr 103(9):1260–1277 4. Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EB, Raisin CJ, Dunn-Emke S, Crutchfield L, Jacobs FN, Barnard RJ, Aronson WJ, McCormac P, McKnight DJ, Fein JD, Dnistrian AM, Weinstein J, Ngo TH, Mendell NR, Carroll PR (2005) Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 174(3):1065–1069 5. Chan JM, Holick CN, Leitzmann MF, Rimm EB, Willett WC, Stampfer MJ, Giovannucci EL (2006) Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States). Cancer Causes Control 17(2):199–208 6. Ornish D, Magbanua MJ, Weidner G, Weinberg V, Kemp C, Green C, Mattie MD, Marlin R, Simko J, Shinohara K, Haqq CM, Carroll PR (2008) Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci USA 105(24):8369–8374 7. Schmidt B, Ribnicky DM, Poulev A, Logendra S, Cefalu WT, Raskin I (2008) A natural history of botanical therapeutics. Metabolism 57(7 suppl 1):S3–S9 8. Graziose R, Lila MA, Raskin I (2010) Merging traditional Chinese medicine with modern drug discovery technologies to find novel drugs and functional foods. Curr Drug Discov Technol 7(1):2–12 9. Grunberger G, Jen KL, Artiss JD (2007) The benefits of early intervention in obese diabetic patients with FBCx: a new dietary fibre. Diabetes Metab Res Rev 23(1):56–62 10. Mancuso C, Barone E (2009) Curcumin in clinical practice: myth or reality? Trends Pharmacol Sci 30(7):333–334 11. Milder IE, Arts IC, van de Putte B, Venema DP, Hollman PC (2005) Lignan contents of Dutch plant foods: a database including lariciresinol, pinoresinol, secoisolariciresinol and matairesinol. Br J Nutr 93(3):393–402 12. Pasinetti GM, Ho L (2010) Role of grape seed polyphenols in Alzheimer’s disease neuropathology. Nutr Diet Suppl 2:97–103 13. Plosch T, Kruit JK, Bloks VW, Huijkman NC, Havinga R, Duchateau GS, Lin Y, Kuipers F (2006) Reduction of cholesterol absorption by dietary plant sterols and stanols in mice is independent of the Abcg5/8 transporter. J Nutr 136(8):2135–2140 14. Kris-Etherton PM, Hecker KD, Bonanome A, Coval SM, Binkoski AE, Hilpert KF, Griel AE, Etherton TD (2002) Bioactive compounds in foods: their role in the prevention
6 Phytonutrient and Phytotherapy for Improving Health of cardiovascular disease and cancer. Am J Med 113(suppl 9B):71S–88S 15. Nöthlings U, Murphy SP, Wilkens LR, Henderson BE, Kolonel LN (2007) Flavonols and pancreatic cancer risk: the multiethnic cohort study. Am J Epidemiol 166(8):924–931 16. Duncan JL, Aleman TS, Gardner LM, De Castro E, Marks DA, Emmons JM, Bieber ML, Steinberg JD, Bennett J, Stone EM, MacDonald IM, Cideciyan AV, Maguire MG, Jacobson SG (2002) Macular pigment and lutein supplementation in choroideremia. Exp Eye Res 74(3):371–381 17. Hallund J, Bugel S, Tholstrup T, Ferrari M, Talbot D, Hall WL, Reimann M, Williams CM, Wiinberg N (2006) Soya isoflavone-enriched cereal bars affect markers of endothelial function in postmenopausal women. Br J Nutr 95(6):1120–1126 18. Kong KW, Khoo HE, Prasad KN, Ismail A, Tan CP, Rajab NF (2010) Revealing the power of the natural red pigment lycopene. Molecules 15(2):959–987 19. Zhao J (2007) Plant troponoids: chemistry, biological activity, and biosynthesis. Curr Med Chem 14(24):2597–2621 20. Balint GA (2001) Artemisinin and its derivatives: an important new class of antimalarial agents. Pharmacol Ther 90(2–3):261–265 21. Marangoni F, Poli A (2010) Phytosterols and cardiovascular health. Pharmacol Res 61(3):193–199 22. Rideout TC, Harding SV, Jones PJ (2010) Consumption of plant sterols reduces plasma and hepatic triglycerides and modulates the expression of lipid regulatory genes and de novo lipogenesis in C57BL/6 J mice. Mol Nutr Food Res 54(suppl 1):S7–S13 23. Heinrichs SC (2010) Dietary omega-3 fatty acid supplementation for optimizing neuronal structure and function. Mol Nutr Food Res 54(4):447–456 24. Lopez-Huertas E (2010) Health effects of oleic acid and long chain omega-3 fatty acids (EPA and DHA) enriched milks. A review of intervention studies. Pharmacol Res 61(3):200–207 25. Psota TL, Gebauer SK, Kris-Etherton P (2006) Dietary omega-3 fatty acid intake and cardiovascular risk. Am J Cardiol 98(4A):3i–8i 26. Nagao K, Yanagita T (2010) Medium-chain fatty acids: functional lipids for the prevention and treatment of the metabolic syndrome. Pharmacol Res 61(3):208–212 27. Martena B, Pfeuffer M, Schrezenmeir J (2006) Mediumchain triglycerides. Int Dairy J 16:1374–1382 28. Fürst P, Stehle P (2004) What are the essential elements needed for the determination of amino acid requirements in humans? J Nutr 134(6 suppl):1558S–1565S 29. McDougall J (2002) Plant foods have a complete amino acid composition. Circulation 105(25):e197 30. Bhathena SJ, Velasquez MT (2002) Beneficial role of dietary phytoestrogens in obesity and diabetes. Am J Clin Nutr 76(6):1191–1201 31. Lotito SB, Frei B (2006) Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: cause, consequence, or epiphenomenon? Free Radic Biol Med 41(12):1727–1746 32. Chen ZY, Peng C, Jiao R, Wong YM, Yang N, Huang Y (2009) Anti-hypertensive nutraceuticals and functional foods. J Agric Food Chem 57(11):4485–4499 33. Rosch W, Liebregts T, Gundermann KJ, Vinson B, Holtmann G (2006) Phytotherapy for functional dyspepsia: a review of
57 the clinical evidence for the herbal preparation STW5. Phytomedicine 13(suppl 5):114–121 34. Hijikata Y, Yasuhara A, Yoshida Y, Sento S (2006) Traditional Chinese medicine treatment of epilepsy. J Altern Complement Med 12(7):673–677 35. Rosenbaum CC, O’Mathúna DP, Chavez M, Shields K (2010) Antioxidants and antiinflammatory dietary supplements for osteoarthritis and rheumatoid arthritis. Altern Ther Health Med 16(2):32–40 36. Saxena VS, Venkateshwarlu K, Nadig P, Barbhaiya HC, Bhatia N, Borkar DM, Gill RS, Jain RK, Katiyar SK, Nagendra Prasad KV, Nalinesha KM, Nasiruddin K, Rishi JP, Roy Chowdhury J, Saharia PS, Thomas B, Bagchi D (2004) Multicenter clinical trials on a novel polyherbal formulation in allergic rhinitis. Int J Clin Pharmacol Res 24(2–4):79–94 37. Xue CC, Thien FC, Zhang JJ, Da Costa C, Li CG (2003) Treatment for seasonal allergic rhinitis by Chinese herbal medicine: a randomized placebo controlled trial. Altern Ther Health Med 9(5):80–87 38. Kaufeler R, Polasek W, Brattstrom A, Koetter U (2006) Efficacy and safety of butterbur herbal extract Ze 339 in seasonal allergic rhinitis: postmarketing surveillance study. Adv Ther 23(2):373–384 39. Wagner H (2006) Multitarget therapy – the future of treatment for more than just functional dyspepsia. Phytomedicine 13(suppl 5):122–129 40. Agbabiaka TB, Pittler MH, Wider B, Ernst E (2009) Serenoa repens (saw palmetto): a systematic review of adverse events. Drug Saf 32(8):637–647 41. Tacklind J, MacDonald R, Rutks I, Wilt TJ. (2009) Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2:CD001423 42. Roy S, Rink C, Khanna S, Phillips C, Bagchi D, Bagchi M, Sen CK (2004) Body weight and abdominal fat gene expression profile in response to a novel hydroxycitric acid-based dietary supplement. Gene Expr 11(5–6):251–262 43. Demonty I, Ras RT, van der Knaap HC, Duchateau GS, Meijer L, Zock PL, Geleijnse JM, Trautwein EA (2009) Continuous dose-response relationship of the LDLcholesterol-lowering effect of phytosterol intake. J Nutr 139(2):271–284 44. Stohs SJ, Preuss HG, Ohia SE, Kaats GR, Keen CL, Williams LD, Burdock GA (2009) No evidence demonstrating hepatotoxicity associated with hydroxycitric acid. World J Gastroenterol 15(14):4087–4089 45. Shiffman MA (2001) Warning about herbals in plastic and cosmetic surgery. Plast Reconstr Surg 108(7):2180–2181 46. Shiffman MA (2007) Facial aging: a clinical classification. Indian J Plast Surg 40(2):178–180 47. Rahm D (2005) Perioperative nutrition and nutritional supplements. Plast Surg Nurs 25(1):21–28 48. Ang-Lee MK, Moss J, Yuan CS (2001) Herbal medicines and perioperative care. J Am Med Assoc 286(2):208–216 49. Rowe DJ, Baker AC (2009) Perioperative risks and benefits of herbal supplements in aesthetic surgery. Aesthet Surg J 29(2):150–157 50. Heller J, Gabbay JS, Ghadjar K, Jourabchi M, O’Hara C, Heller M, Bradley JP (2006) Top-10 list of herbal and supplemental medicines used by cosmetic patients: what the plastic surgeon needs to know. Plast Reconstr Surg 117(2):436–445
58 51. Manach C, Williamson G, Morand C, Scalbert A, Rémésy C (2005) Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81(1 suppl):230S–242S 52. Laparra JM, Sanz Y (2010) Interactions of gut microbiota with functional food components and nutraceuticals. Pharmacol Res 61(3):219–225 53. Spencer JP, Schroeter H, Kuhnle G, Srai SK, Tyrrell RM, Hahn U, Rice-Evans C (2001) Epicatechin and its in vivo metabolite, 3’-O-methyl epicatechin, protect human fibroblasts from oxidative-stress-induced cell death involving caspase-3 activation. Biochem J 354(Pt 3):493–500 54. McGhie TK, Walton MC (2007) The bioavailability and absorption of anthocyanins: towards a better understanding. Mol Nutr Food Res 51(6):702–713 55. Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F, Tong Y, Carrier DJ, Cheboyina S, Battu SK (2008) Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St John’s Wort, and Echinacea. Mol Nutr Food Res 52(7):755–763 56. Brazier NC, Levine MA (2003) Drug-herb interaction among commonly used conventional medicines: a compendium for health care professionals. Am J Ther 10(3): 163–169 57. Brand W, Schutte ME, Williamson G, van Zanden JJ, Cnubben NH, Groten JP, van Bladeren PJ, Rietjens IM
J. Zhao (2006) Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients. Biomed Pharmacother 60(9):508–519 58. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST (2008) Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. J Am Med Assoc 300(24):2867–2878 59. Ribnicky DM, Poulev A, Schmidt B, Cefalu WT, Raskin I (2008) Evaluation of botanicals for improving human health. Am J Clin Nutr 87(2):472S–475S 60. Blundell J (2010) Making claims: functional foods for managing appetite and weight. Nat Rev Endocrinol 6(1):53–56 61. Bino RJ, Hall RD, Fiehn O, Kopka J, Saito K, Draper J, Nikolau BJ, Mendes P, Roessner-Tunali U, Beale MH, Trethewey RN, Lange BM, Wurtele ES, Sumner LW (2004) Potential of metabolomics as a functional genomics tool. Trends Plant Sci 9(9):418–425 62. Gibney MJ, Walsh M, Brennan L, Roche HM, German B, van Ommen B (2005) Metabolomics in human nutrition: opportunities and challenges. Am J Clin Nutr 82(3): 497–503 63. Astle J, Ferguson JT, German JB, Harrigan GG, Kelleher NL, Kodadek T, Parks BA, Roth MJ, Singletary KW, Wenger CD, Mahady GB (2007) Characterization of proteomic and metabolomic responses to dietary factors and supplements. J Nutr 137(12):2787–2793
7
Skin Imaging in Aesthetic Medicine Peter M. Prendergast
7.1 Introduction Several procedures in aesthetic medical practice focus on improving the appearance and texture of the skin. Homogeneity of skin texture and color play an important role in facial attractiveness [1]. Intense pulsed light devices and certain lasers target brown and red chromophores to clear the skin by reducing unwanted melanin and hemoglobin, respectively. Resurfacing chemical peels and lasers ablate epidermal and dermal layers, improving skin texture and clarity. Recently, nonablative laser rejuvenation and tissue tightening using light and radiofrequency have emerged as useful treatment modalities that heat the dermis and improve skin texture by remodeling and increasing collagen [2, 3]. These less aggressive methods usually require multiple treatments and show gradual, subtle improvement. Although “naked eye” assessment and color photography of the skin remain important for skin examination and documenting changes before and after aesthetic procedures, they do not highlight individual chromophores or provide quantitative information and are prone to significant interobserver variability [4]. Skin imaging devices that visualize and display information on epidermal and dermal chromophores, skin texture, and wrinkles have emerged as valuable tools for skin analysis in aesthetic medicine [5]. Using cross-polarized diffuse reflectance imaging and appropriate algorithmic computer software, quantitative assessments of hemoglobin and melanin can be made [6]. P.M. Prendergast Venus Medical, Heritage House, Dundrum Office Park, Dublin 14, Ireland e-mail:
[email protected]
Images define the nature and extent of the problem being treated, document before-and-after comparisons, and facilitate the monitoring of skin changes over time. They also have a role as evidence in medical legal scenarios. Newer skin imaging devices produce excellent threedimensional images and provide quantitative information on melanin, hemoglobin, skin roughness, and wrinkle depth. Novel devices that perform quantitative analyses are likely to play an increasingly important role in research and in studies that compare treatment modalities or devices in aesthetic medicine. A comparison of skin imaging devices useful in aesthetic medicine is provided in Table 7.1.
7.2 Digital Photography Digital photography has largely replaced film photography in medical and skin imaging since the development of single lens reflex (SLR) cameras (Fig. 7.1). Although they are more bulky than compact cameras, SLR cameras are capable of producing exquisite images, and allow the user customize image capturing with different lenses, auxiliary flashes, and by optimizing settings such as optical zoom and white balance [7]. For detailed imaging of the skin’s surface, a macro lens with a focal length of 60–100 mm is appropriate, whereas a focal length of about 18–55 mm is sufficient for full-face imaging. All beforeand-after photographs in aesthetic medicine should be taken with consistent positioning and lighting to ensure comparisons are accurate. Although flash photography provides excellent lighting consistency, a point flash rather than ring flash should be used so that some shadowing is possible. Shadows improve the perception of the skin’s surface texture, and depth of wrinkles and folds.
P.M. Prendergast and M.A. Shiffman (eds.), Aesthetic Medicine, DOI 10.1007/978-3-642-20113-4_7, © Springer-Verlag Berlin Heidelberg 2011
59
60
P.M. Prendergast
Table 7.1 Comparison of devices for skin imaging in aesthetic medicine
Portable Data collection Full facial imaging Hemoglobin visualization Hemoglobin measurement Melanin visualization Melanin measurement Collagen visualization Rhytid measurement Independent of lighting conditions 3D capabilities Easy report printing
FotoFinder Dermoscope Yes Yes No No
PRIMOS 3D
VISIA
3D Lifeviz Aesthetic
Clarity Pro Advanced
Antera 3D
Yes Yes No No
No Yes Yes Yes
Yes Yes Yes No
No Yes Yes Yes
Yes No Yes Yes
No
No
No
No
Yes
Yes
Yes
No
Yes
No
Yes
Yes
No
No
No
No
Yes
Yes
No
No
No
No
No
No
No Yes
Yes Yes
Yes No
Yes No
Yes No
Yes Yes
No Yes
Yes Yes
No Yes
Yes Yes
No Yes
Yes Yes
and cross-polarized viewers enable clear visualization of pigmentation, pigment structure, vascular pattern, and the border of lesions under scrutiny. Dermoscopy is particularly useful for the differentiation of benign and malignant skin lesions and to monitor pigmented lesions for the early detection of skin cancer. Several dermoscopes are available including the FotoFinder Dermoscope (FotoFinder Systems, Inc., Columbia, MD, USA) and the LiteScope (Quantificare S.A., Cedex, France).
7.3.2 Spectrophotometric Intracutaneous Analysis (SIA)
Fig. 7.1 Single lens reflex (SLR) camera for high-quality photographic documentation before and after aesthetic procedures
The SIAscope delivers harmless radiation at wavelengths of 400–950 nm into the skin. The reflected light is measured, analyzed, and displayed as a graphical representation of the amount of melanin, hemoglobin, and collagen in the epidermis or papillary dermis. The SIAscope is portable and easy to use and is used with various software applications, such as MoleMate and MoleView to aid in the diagnosis of melanoma and nonmelanoma skin cancers [8, 9].
7.3 Skin Imaging Modalities 7.3.1 Dermoscopy
7.3.3 Optical Profilometry
Dermoscopy, or epiluminescence microscopy, is useful for the evaluation of cutaneous lesions by imaging surface and subsurface structures using polarized light. Magnification
This technique is used to measure the roughness of skin or size of fine lines and wrinkles. A silicone or rubber dental impression material is used to make a cast of the
7 Skin Imaging in Aesthetic Medicine
skin’s surface. Then tangential lighting is cast across the replica such that the shadows created reveal the microtopography of the skin. A digital camera, scanner, or stereomicroscope captures the shadows and changes the negative appearance of the replica into a positive one [10]. Although this method of measuring wrinkle size and depth is accurate, the technique can take up to an hour and has largely been replaced by more efficient methods, such as 3D computerized imaging.
61
coupled device (CCD) chip of a high-resolution camera [14]. It is used to measure skin topography and provide quantitative analysis of wrinkles and roughness [15]. Although the PRIMOS device is regarded as more accurate than the commonly used silicon replica technique [16], it does not measure chromophores in the skin and therefore its use in aesthetic medicine is limited.
7.4.2 Visia 7.3.4 Reflectance Confocal Microscopy Reflectance confocal microscopy and confocal laser scanning microscopy allow detailed high-resolution images of the skin to be taken noninvasively. The Vivascope 1500 (Lucid, Rochester, NY, USA) uses a diode laser with an 830-nm wavelength to image epidermal and dermal structures. In practice, this allows accurate characterization of pigmented and nonpigmented skin lesions, greatly assisting diagnosis. The near histologic resolution of reflectance confocal microscopy also identifies features associated with aging and UV damage, including spongiosus, sunburn cells, micro-vesicles, and vascular dilatation [11].
The Visia Complexion Analysis system (Canfield Scientific Inc., NJ, USA) utilizes photography and imaging software to provide full facial visualization of hemoglobin and melanin, and a quantitative analysis of skin texture and facial wrinkles. Canfield systems are designed to produce consistently positioned beforeand-after images by using chin and forehead rests as well as a guide light. The VISIA system has multiple applications in aesthetic medicine including the evaluation of outcomes following skin rejuvenation with lasers [17, 18].
7.4.3 3D Lifeviz Aesthetic 7.3.5 High Frequency Ultrasound High frequency ultrasound can be used to image the topography and intradermal structures of sliced or in vivo skin using ultrasound impedance imaging and 3D ultrasound imaging, respectively [12]. In aesthetic medicine, skin-targeted ultrasound represents a noninvasive means of imaging pores, surface irregularities, and age-related dermal changes [13]. Features associated with photoaging, such as a subepidermal low-echogenic band, can be monitored before and after aesthetic medical procedures to determine their efficacy.
7.4 Optical Imaging Devices 7.4.1 PRIMOS PRIMOSlite (GFMesstechnik GmbH, Berlin, Germany) is a 32 × 32 mm microtopography imaging system that projects light onto the surface of the skin with a Digital Micromirror Device (DMD; Texas Instruments, Irving, TX, USA) and records the image on the charged
3D Lifeviz Aesthetic (Quantificare S.A., Cedex, France) uses plain photography, stereovision technology, and patented DermaPix® software to produce full facial 3D images for comparison of volume, contours, and wrinkles before and after aesthetic procedures. A newer product produced by Quantificare, 3D Lifeviz Micro, is a portable system for the visualization and measurement of wrinkles, scars, and roughness in localized regions. This technology provides no information on melanin or hemoglobin.
7.4.4 Clarity Pro Advanced This system provides full facial imaging in front, left, and right profile positions using multi-spectral lighting to produce white light and blue light images. As well as providing visualization and quantitative information on rhytids, redness, UV damage, and pigmentation, fluorescence spectroscopy is utilized to identify porphyrins produced by Propionibacterium acnes in oily and acne prone skin. Clarity Pro Advanced is a product of Brigh Tex Bio-Photonics (BTBP), located in California, USA.
62 Fig. 7.2 (a) Antera 3D portable hand-held imaging device. (b) Images are captured instantly and displayed on a computer monitor or laptop
P.M. Prendergast
a
b
7.4.5 Antera 3D The Antera 3D skin imaging system (Miravex, Dublin, Ireland) uses a hand-held, portable camera and software with complex algorithms to convert light reflected from the skin’s surface into digital images that display topography, hemoglobin, and melanin (Fig. 7.2). The camera uses various light-emitting diodes and polarizers to illuminate a 60 × 60 mm area of the face and capture reflected light independent of surrounding lighting conditions (Fig. 7.3). Once captured, the
image can be manipulated in several ways using the user-friendly interface (Fig. 7.4). The image is first selected as either flat or 3D. The contour of the captured area is visualized by selecting the Contour tab and filtering for small, medium, or large wrinkles (Fig. 7.5). The roughness of skin or size of individual wrinkles and folds is measured using clickable tools that allow selection of any area of the image (Fig. 7.6). Melanin and hemoglobin are visualized and measured in a similar way. The imaging serves to highlight the nature and extent of skin surface and pigment irregularities and guide treatment accordingly (Fig. 7.7).
7 Skin Imaging in Aesthetic Medicine
63
a
b
c
d
Fig. 7.3 (a–d) Images displayed independent of surrounding lighting conditions. A directional light tool allows light and shadows to be changed and manipulated
A matching tool incorporated into the Antera 3D interface allows accurate before-and-after comparisons. Improvement in facial redness, roughness, and melanin homogeneity is measured following resurfacing, collagen stimulating, and laser vascular therapies (Fig. 7.8). Using the report tool, comparisons between images are presented in a graphic format.
7.5 Conclusions Skin imaging technologies have become more sophisticated in recent years. Multiphoton microscopy has emerged as a sophisticated method of imaging the detailed morphology of epithelial and dermal structures [19]. In aesthetic medical practice, however, hand-held, portable devices are likely to be more useful [20].
64
P.M. Prendergast
a
a
b
b
c
c
d Fig. 7.4 The user-friendly Antera 3D interface. (a) Filters for small, medium, and large wrinkles. (b) Main selection panel for normal color image, contour (topography), melanin, and hemoglobin. (c) Directional light tool. (d) Main controls for selecting an area for quantitative evaluation, matching before-and-after images, creating a report, and saving an image
Fig. 7.5 Filters for contour analysis. (a) Small wrinkles. This highlights superficial rhytids and skin texture as well as pores and acne scarring. (b) Medium wrinkles. This filter is useful to show deeper lines such as nasolabial folds. (c) The large wrinkle filter is more appropriate to visualize facial contours and volume loss
7 Skin Imaging in Aesthetic Medicine
a
65
c
b
Fig. 7.6 Quantitative skin analysis. (a) Individual wrinkles are selected to measure the overall size, width, and depth of the line. (b) Any area can be measured using a rectangular selection tool.
The selection in the after image is automatically matched using the anchor tool. (c) A circular selection tool is also available
By analyzing the wavelengths of light reflected from the skin’s surface using detailed algorithmic software, quantitative information on surface and subsurface structures is obtained. By measuring the topography of the skin, melanin distribution and content, and extent of hemoglobin, a plan of targeted skin rejuvenation can be implemented with definite goals in mind. Moreover,
measuring changes with serial imaging guides treatment programs and helps determine the efficacy of different procedures and different technologies. Providing patients with quantitative reports that illustrate the beneficial effects of treatments encourages them to continue with maintenance programs that improve results further over time.
66
P.M. Prendergast
a
b
c
d
Fig. 7.7 3D skin imaging of an area of active acne and acne scarring. (a) Color image. (b) Contour image showing the topography of the skin with deeper scars represented in purple. (c)
Melanin view showing areas of hypopigmentation within scars. (d) Hemoglobin view with increased vascularity in area of inflammation
7 Skin Imaging in Aesthetic Medicine
67
a
b
c
d
Fig. 7.8 (a) Melanin view before. (b) Two weeks after fractional CO2 laser skin resurfacing. (c) Contour view before. (d) After fractional CO2 laser skin resurfacing. Using the Antera 3D
system, quantitative analysis is possible so that an absolute and percentage improvement can be shown following treatments
68
References 1. Fink B, Grammer K, Thornhill R (2001) Human (Homo sapiens) facial attractiveness in relation to skin texture and color. J Comp Psychol 115(1):92–99 2. Kaplan H, Gat A (2009) Clinical and histopathological results following TriPollar radiofrequency skin treatments. J Cosmet Laser Ther 11(2):78–84 3. Dierickx CC (2006) The role of deep heating for noninvasive skin rejuvenation. Lasers Surg Med 38(9):799–807 4. Stefanowska J, Zakowiecki D, Cal K (2010) Magnetic resonance imaging of the skin. J Eur Acad Dermatol Venereol 24(8):875–880 5. Bargo PR, Kollias N (2010) Measurement of skin texture through polarization imaging. Br J Dermatol 162(4):724–731 6. Jung B, Choi B, Durkin AJ, Kelly KM, Nelson JS (2004) Characterization of port wine stain skin erythema and melanin content using cross-polarized diffuse reflectance imaging. Lasers Surg Med 34(2):174–181 7. Bhatia AC, Molenda MA, Heffernan MP, Roach D (2009) Imaging. In: Kaminer MS, Arndt KA, Dover JS, Rohrer TE, Zachary CB (eds) Atlas of cosmetic surgery. Saunders Elsevier, Philadelphia, p 46 8. Moncrieff M, Cotton S, Claridge E, Hall P (2002) Spectrophotometric intracutaneous analysis: a new technique for imaging pigmented skin lesions. Br J Dermatol 146(3):448–457 9. Tehrani H, Walls J, Price G, Cotton S, Sassoon E, Hall P (2006) A novel imaging technique as an adjunct to the in vivo diagnosis of nonmelanoma skin cancer. Br J Dermatol 155(6):1177–1183 10. Hatzis J (2004) The wrinkle and its measurement—a skin surface profilometric method. Micron 35(3):201–219 11. Ulrich M, Rüter C, Astner S, Sterry W, Lange-Asschenfeldt B, Stockfleth E, Röwert-Huber J (2009) Comparison of
P.M. Prendergast UV-induced skin changes in sun exposed vs. sun-protected skin—preliminary evaluation by reflectance confocal microscopy. Br J Dermatol 161(suppl 3):46–53 12. Saijo Y, Kobayashi K, Okada N, Hozumi N, Hagiwara Y, Tanaka A, Iwamoto T (2008) High frequency ultrasound imaging of surface and subsurface structures of fingerprints. Conf Proc IEEE Eng Med Biol Soc 2008:2173–2176 13. Lacarrubba F, Tedeschi A, Nardone B, Micali G (2008) Mesotherapy for skin rejuvenation: assessment of the subepidermal low-echogenic band by ultrasound evaluation with cross-sectional B-mode scanning. Dermatol Ther 21(suppl 3):S1–5 14. Friedman PM, Skover GR, Payonk G, Geronemus RG (2002) Quantitative evaluation of nonablative laser technology. Semin Cutan Med Surg 21(4):266–273 15. Hsu J, Skover G, Goldman MP (2007) Evaluating the efficacy in improving facial photodamage with a mixture of topical antioxidants. J Drugs Dermatol 6(11):1141–1148 16. Gold MH, Goldman MP, Biron J (2007) Human growth factor and cytokine skin cream for facial skin rejuvenation as assessed by 3D in vivo optical skin imaging. J Drugs Dermatol 6(10):1018–1023 17. Lee MC, Hu S, Chen MC, Shih YC, Huang YL, Lee SH (2009) Skin rejuvenation with 1,064-nm Q-switched Nd:YAG laser in Asian patients. Dermatol Surg 35(6):929–932 18. Kulick MI, Gajjar NA (2007) Analysis of histologic and clinical changes associated with Polaris WR treatment of facial wrinkles. Aesthet Surg J 27(1):32–46 19. Lin SJ, Jee SH, Dong CY (2007) Multiphoton microscopy: a new paradigm in dermatological imaging. Eur J Dermatol 17(5):361–366 20. Fisk NA, Jensen K, Knaggs H, Ferguson S (2010) The clinical utility of a hand-held computerized optical imaging system at assessing skin discoloration. J Cosmet Dermatol 9(2):103–107
8
Cosmeceutical Treatment of the Aging Face Jennifer Linder
8.1 Introduction The increased consumer interest in skin health and appearance combined with a confusing and expansive cosmetic marketplace has led patients to seek educated product recommendations from their physicians. To effectively and ethically deliver on this patient expectation, physicians must understand the intricacies of the skin’s aging process and be aware of the topical ingredients currently available, their mechanisms of action and their efficacy. Clinically proven topical therapies can work to correct many of the visible signs of aging skin and support and enhance the outcomes of more invasive procedures.
8.2 Common Presentations of Visible Aging Structural breakdown of the skin occurs as a result of both intrinsic and extrinsic aging and involves multiple pathological processes. Topical cosmeceuticals are typically formulated to address specific agerelated cutaneous challenges. Identifying the most effective and proven ingredient blends allows the physician to provide patients with topical solutions to correct and prevent the foremost causes of visible facial aging. This can be accomplished by addressing extracellular matrix degradation, textural variances,
J. Linder 6710 Camelback Road, Suite 230, Scottsdale, AZ 85251, USA e-mail:
[email protected]
and dyschromias. This chapter will review these common causes of visible aging and the proven cosmeceuticals for their correction. The primary cause of cutaneous aging is a result of matrix degradation, which presents as sagging, laxity, rhytids, atrophy, and enlarged pores. Effective therapies are usually designed to protect the existing matrix with sunscreens, antioxidants, and matrix metalloproteinase inhibitors (MMPi) while triggering new matrix production with collagen-building ingredients like retinoids, vitamin C, and peptides. Another common feature of aging skin is textural variances, which present as dryness, dehydration, and coarsening of the skin. These can be reversed with alpha hydroxy acids (AHA), mechanical exfoliators, humectants, and occlusives. The dyschromias typically seen as a result of aging can be effectively addressed with the use of melanogenesis inhibitors. All of these presentations of aging and their possible treatments must be considered when evaluating a patient and making specific recommendations for skin care.
8.3 Matrix Degradation The majority of a healthy dermis is the extracellular matrix (ECM), which is a complex framework of bio molecules designed to support and protect the dermal cells. The structural proteins (collagen and elastin), adhesive proteins (laminins and fibronectin), glycosa minoglycans (GAG), and proteoglycans that comprise the ECM degrade naturally due to chronological intrinsic aging. Degradation is accelerated by the exogenous causes of extrinsic aging – primarily UV exposure and the resultant oxidative stress and matrix
P.M. Prendergast and M.A. Shiffman (eds.), Aesthetic Medicine, DOI 10.1007/978-3-642-20113-4_8, © Springer-Verlag Berlin Heidelberg 2011
69
70
etalloproteinase (MMP) upregulation [1]. MMP m enzymes, such as collagenase, elastase and hyaluronidase are responsible for the natural recycling and destroying of the ECM’s components that are no longer useful. MMP also play a role in tumorigenesis [2]. Although a small amount of these enzymes are necessary for healthy skin, an overproduction occurs in response to external damaging factors – particularly UV radiation – accelerating matrix breakdown. The expression of MMP is increased with as little as 0.1 minimal erythema dose (MED) (1/10 of the dose of UV exposure required to develop erythema) [3]. It has been demonstrated that the degeneration of dermal collagen fiber bundles (DCFB) is more acute and severe in photodamaged skin [4]. Aged skin as a result of ECM degradation presents with varying degrees of visible sagging and laxity, rhytids, epidermal and dermal atrophy, and enlargement of pores.
8.4 Sagging and Laxity Many factors contribute to the lax appearance of aged skin. Over time, the effects of gravity certainly play a role [5], yet loss of facial volume [6, 7] as a result of the resorption of facial bones [8] and the atrophy of adipose tissue [9], compounded by the degradation of the critical structural components of the dermis, plays a larger role. This occurs due to chronological aging; however, it is exacerbated dramatically by extrinsic factors, particularly UV exposure. The structural and elastic components of the dermis provide youthful skin with support, volume and the ability to stretch and return to its original form. This well-organized framework develops a decreased functionality in aged skin. Sun-protected dermal skin typically decreases in thickness by about 20% after 80 years of age. Sun-exposed skin, in contrast, thins significantly earlier [10, 11]. This strongly supports the daily use of broad-spectrum UV protection as a critical step to preserving a youthful facial appearance. Photodamage is a clear and well-documented cause of premature skin aging and matrix degradation [1, 12, 13]. This can be attributed to an increase of UVB-induced radicals as well as an intensification of MMP activity [14, 15]. Radicals are highly reactive species due to unpaired electrons in their outer shell. There are many types of free radicals, yet reactive oxygen species (ROS) are widely studied due to their damaging effects in the skin. ROS include hydroxyl radicals, nitric oxide,
J. Linder
peroxynitrite, superoxide anions, peroxide, triplet oxygen, and singlet oxygen. An increase of MMP-1 causes collagen fibrils to cleave. Collagen is then increasingly weakened by MMP-3 and MMP-9 activity. These degenerated collagen fibrils are re-stabilized through the formation of intermolecular crosslinks [1]. In addition to crosslinks between collagen fibrils, it has been demonstrated that while the collagen fibers develop indistinct outlines and a smaller diameter with age, the elastic fibers become shorter and thicker, resulting in a general loss of dermal integrity [4]. Additionally, the increase of the MMP elastase negatively affects the elastic fibers’ ability to maintain youthful facial turgor.
8.5 Rhytids: Fine Lines and Deeper Wrinkling Estrogen contributes in the skin as a modulator of connective tissue components, namely collagen and hyaluronic acid (HA). As estrogen production diminishes with age, collagen and HA are not replaced as readily as in young skin [16], making wrinkling a common visible presentation of aging skin. Superficial rhytids begin to form due to this slowing of collagen production [17]. The reduction of HA production results in skin dehydration that further exacerbates the appearance of fine lines [18]. Decreased estrogen levels with advancing age also slow cell regeneration and the production of ECM components. This degeneration of the skin’s matrix is, as stated previously, exacerbated by UV exposure over a patient’s lifetime. More advanced, deeper wrinkling is primarily a result of overexposure to extrinsic factors. UVA-induced breakdown and crosslinking of collagen has been well-demonstrated, as is the escalated degeneration of collagen and elastic fibers due to an increase in elastase and collagenase expression [17, 19]. In addition, the repeated muscular contractions demonstrated in facial expressions lead to dynamic wrinkling, including lines in the glabella, forehead and crows’ feet as well as perioral vertical lines due to aging and smoking [20, 21].
8.6 Epidermal and Dermal Atrophy The loss of facial volume that contributes to an aged appearance is compounded by the atrophy of both the epidermis and the dermis. As mentioned, the
8 Cosmeceutical Treatment of the Aging Face
age-dependent drop in estrogen levels during perimenopause and menopause slows the production of matrix components [16, 22, 23]. It is also evident that UV exposure not only degrades mature collagen but also impedes the formation of new collagen by downregulating both type I and type II procollagen gene expression [24]. This dermal atrophy contributes substantially to visible facial aging. Age-related degeneration of the epidermis includes: enlarged corneocyte surface area, flattening and reduced adherence of the keratinocytes, and an overall slowing of cell turnover [25–27]. Additionally, the flattening of the rete ridges leads to an epidermis that appears thin and fragile and is nourished less effectively [5].
8.7 Enlarged Pores Another common visible characteristic of aged skin is enlarged pores. This is due to a disorganized and degenerated collagen and elastin network providing reduced support to the follicle walls [28]. In advanced age, and with cumulative ultraviolet exposure, these enlarged pores can progress to solar comedones [29].
71
8.9 Broad-Spectrum UV Protection Because sunscreens can limit UV-induced skin damage and MMP production, they are accepted as the most active and beneficial of the anti-aging products [30]. Understanding the variety of ingredients available and their individual advantages and disadvantages will allow a physician to make more informed recommendations regarding the use of sunscreens. Sunscreens can have either chemical or physical ingredients or a combination of both. It is critical for skin health and age-controlling benefits that the product protects against both UVB and UVA wavelengths, as UVA has the ability to penetrate into the dermis and breakdown the ECM due to its longer wavelength. Unfortunately, only four of the ingredients currently approved by the FDA provide true broad-UVA-spectrum protection. For this reason, a broad-spectrum sunscreen should include one of the following: avobenzone, ecamsule, zinc oxide, or titanium dioxide. A blend of multiple ingredients is typically necessary to provide “ideal” sunscreen protection. Sunscreen ingredient regulations differ around the world. Refer to Table 8.1 for a list of FDA-approved sunscreen ingredients and their corresponding wavelength-absorbing/reflecting capabilities.
8.8 Topical Therapies for Collagen and Matrix Protection
8.10 Chemical Sunscreen Agents
One must consider that each patient’s skin represents a unique combination of their DNA, environment, lifestyle choices, and product usage. Patients that exhibit dramatic degeneration of critical matrix components, due to overexposure to UV rays, smoking and other exogenous offenders, may require more invasive therapies to ameliorate their visible facial degradation. That said, even patients with advanced matrix breakdown can benefit from the use of proven topicals to impede further destruction. The most efficacious treatment plans for aging skin typically combine potent protection of the existing matrix in addition to the use of topical therapies to promote the deposition of new matrix components. A combination of broad-spectrum sunscreens, MMPi and a range of proven antioxidants provide the skin with excellent matrix-protecting benefits. When used with collagen-building ingredients like vitamin C, retinoids and peptides, dramatic improvements in the ECM can be demonstrated. The final outcome is healthier and more attractive skin.
A chemical sunscreen is an organic substance that penetrates the corneocytes and absorbs UV rays before they affect the skin. Although some patients avoid chemical sunscreens out of concern for skin sensitivities, these concerns are typically misdirected, as most reactions are due to a product’s base rather than its OTC active ingredients [31, 32]. Para-aminobenzoic acid (PABA) was among the first chemical sunscreens to be approved by the FDA. While it is an effective UVB absorber, PABA has become nearly extinct in current sunscreen preparations due to photoallergy concerns [33]. Octyl dimethyl PABA, or Padimate O, is an aminobenzoic acid derivative that was introduced as a less sensitizing alternative to PABA. Other PABA derivatives, such as glyceryl PABA (glyceryl aminobenzoate) and padimate A (amyldimethyl PABA) are available in other countries but are not FDA-approved [34]. PABA-free marketing claims have ultimately led to decreased use of PABA derivatives throughout the industry.
72
J. Linder
Table 8.1 UV attenuation of commonly used FDA-approved sunscreen agents. Adapted from [176] UVA
UVB
400
390
380
370
360
350
340
330
320
310
300
290
Ensulizole Octisalate Homosalate Octyldimethyl PABA Octinoxate Octocrylene Oxybenzone Meradimate Titanium dioxide Zinc oxide Ecamsule Avobenzone Attenuated UV Peak absorbency
Cinnamates are the most widely used chemical sunscreen agents on the market [35]. This category of sunscreens encompasses UVB shielding ingredients octinoxate (octyl methoxycinnamate) and cinoxate. Allergic reactions are uncommon with cinnamates, which has led to their popularity; however, they typically must be used in conjunction with other UVB absorbers in order to provide adequate protection [36]. Octocrylene (2-ethylhexyl-2-cyano-3,3 diphenylacrylate) offers weak UVB-absorbency yet has impressive stability. Octocrylene is often used to prolong the activity of other sunscreen agents and also to improve water resistance [34, 35]. Salicylates include octisalate (octyl salicylate) and homosalate (homomenthyl salicylate). These agents offer UVB protection and are considered nonsensitizing sunscreens [37]. Salicylates are often referred to as weak sunscreen agents; however, their excellent safety profile contributes to their sustained use in the industry [38]. Like cinnamates, salicylates are most often used in conjunction with other UV filters. Phenylbenzimidazole sulfonic acid is typically referred to as ensulizole. The use of ensulizole in topical preparations is relatively rare despite a decent safety record and a light feel [39]. Ensulizole is one of many UVB absorbing agents and it offers virtually no UVA attenuation, which may explain the rarity of its use [40]. Benzophenones are unique in that they offer UVB absorbency as well as weak UVA protection. Several benzophenones are available, including oxybenzone, dioxybenzone and sulisobenzone. Benzophenones are now considered the most sensitizing of the chemical sunscreens, although reactions are still relatively
rare [41]. While these agents do expand narrowly into the UVA spectrum, products containing benzophenones should not be considered truly broadspectrum [42]. Anthranilates are salts or esters of anthranilic acid. Meradimate (menthyl anthranilate) is the only FDAapproved anthranilate. It maintains a high safety and stability profile; however, an unappealing texture limits its use in cosmetic preparations [43]. Camphor derivative ecamsule (terephthalylidene dicamphor sulfonic acid) was the most recent sunscreen agent to receive FDA approval. Ecamsule’s absorbency peak is in the short-end of the UVA spectrum [44]. While it is effective and photostable, ecamsule must be formulated in conjunction with other sunscreening agents, such as avobenzone and titanium dioxide, in order to provide optimal protection. Oil-soluble forms of camphor derivatives are also available in countries outside of the United States [43]. Dibenzoylmethanes are a group of UVA-absorbing sunscreens. Avobenzone (butyl methoxydibenzoylmethane) is the only dibenzoylmethane used in the United States. While it is an effective UVA screening agent, photo-instability has raised concerns in the industry [45]. Formulary considerations, such as the addition of salicylates, benzophenones, octocrylene, bemotrizinol or ecamsule, can be made to prolong the activity of avobenzone [36, 46]. Certain products employ 2-6 diethylexhyl naphthalate as a means to stabilize avobenzone. Although concerns with the potential carcinogenicity of phthalates have surfaced within recent years, more research is necessary in order to conclude whether this is a valid concern [47].
8 Cosmeceutical Treatment of the Aging Face
Tinosorbs include methylene-bis-benzotriazolyl tetramethylbutylphenol (Tinosorb M or Bemotrizinol) and bis-ethylhexyloxyphenol methoxyphenoltriazine (Tinosorb S or Bemotrizinol). Although neither of these ingredients has received FDA-approval as of 2010, they are widely used throughout Europe. Tinosorb M and S are unique in that they are said to offer the reflective and absorbent benefits of both physical and chemical sunscreens [36]. Both ingredients have been found to provide UVA and UVB protection, with Tinosorb M being a water-soluble form and Tinsorb S oil-soluble. Their safety profiles combined with their photostability makes them good options for sunscreen formulations [48].
8.11 Physical Sunscreen Agents A physical sunscreen agent is comprised of inorganic molecules that sit on the surface of the skin and reflect or scatter UV radiation before it can induce cellular damage. In the past, although physical sun protection was effective, it was often associated with thicker product consistency and a white appearance on the skin. Proper formulation and smaller particle sizes can alleviate these concerns, leading to a lighter, more appealing product feel. Zinc oxide offers broad-spectrum protective benefits with a high safety and stability profile. It is considered the more cosmetically elegant of the physical sunscreens, as zinc formulas typically cause less of a white appearance on the skin compared to titanium dioxide formulas when micronized [49]. Zinc is naturally anti-inflammatory, which gives it additional benefits when used to prevent the erythema of sun exposure [50]. Titanium dioxide is an inert sunscreen ingredient with no record of photosensitization. The large particle sizes of titanium dioxide can leave a white hue on the skin when applied, limiting their use in darker-skinned patients. Titanium dioxide, like zinc oxide, is often formulated with micronized particles to overcome this cosmetic concern [51]. Zinc oxide and titanium dioxide, as well as nearly all of the chemical sunscreen ingredients may induce cellular oxidation in response to UV radiation [52, 53]. Certain physical sunscreen products use a stabilized, coated particle to overcome this potentially damaging effect [54]. Additional means of counteracting this
73
type of reaction include formulating sunscreens with supportive antioxidants and/or incorporating topical antioxidant serums into a patients’ morning skin care routine along with sunscreen products [37, 55].
8.12 Antioxidants Although the body has its own endogenous free radical-quenching mechanisms, daily application of topical antioxidants provides significantly heightened protection against matrix breakdown and the visible signs of facial aging [56, 57]. Antioxidants function in three ways: primary antioxidants, or electron donors; secondary antioxidants, which chelate metal ions; and co-antioxidants, which facilitate other antioxidants. Many offer multiple protective benefits [58]. The following are some of the most effective and accepted antioxidants. Resveratrol is a natural constituent of certain colored berries, grapes, red wine, and parts of the peanut plant. It is a potent polyphenolic compound that exhibits both primary and secondary antioxidant benefits. Topical application prior to UVB exposure has been shown to suppress the production of hydrogen peroxide radicals and lipid peroxidation [59, 60]. Resveratrol has also demonstrated antiproliferative and preventative effects on tumorigenesis within the skin [61]. Silymarin is a powerful flavanoid antioxidant found in milk thistle whose most active component is the primary and secondary antioxidant, silybin. Research suggests that silymarin inhibits lipid peroxidation, nitric oxide and hydrogen peroxide production, and increases the amount of the skin’s natural glutathione [62, 63]. Protection against UV-induced immunosuppression, carcinogenesis and cellular degradation has also been attributed to topical application of silymarin [64–66]. Caffeine is believed to play a significant role in the antioxidant behavior of several potent antioxidants, including coffea Arabica and green tea [67–69]. Studies comparing caffeinated and decaffeinated beverages demonstrate a clear increase in the antioxidant activity of those containing caffeine [67]. Caffeine is considered a primary and secondary antioxidant that is capable of scavenging hydroxyl radicals, hydrogen peroxide, peroxyl radicals, and singlet oxygen [70]. Research also suggests that topical application of caffeine can reduce UV-induced carcinogenesis by inducing cellular apoptosis in UV-exposed keratinocytes [68, 70].
74
Coffea Arabica extract is a polyphenol that has demonstrated a clear quenching of free radicals in vitro. The exact antioxidant mechanism has not been clearly elucidated, although it could be attributed to its coantioxidant capability to increase endogenous glutathione reductase, superoxide dismutase, and catalase content [71–73]. Ergothioneine is newer to the cosmeceutical market. Research indicates strong primary antioxidant, free radical scavenging capabilities [74].1 Scientific studies suggest that ergothioneine reduces several forms of ROS, including hydrogen peroxide, hydroxyl radicals, singlet oxygen, peroxynitrite, lipid peroxides, and nitric oxides [74–77]. Chemopreventive benefits have also been demonstrated with topical ergothioneine use [74]. Ferulic acid is a polyphenol whose mechanisms of action include prevention of nitric oxide production and lipid peroxidation [78]. Ferulic acid is a primary antioxidant that is also able to absorb UV radiation, although it is not considered a sunscreen agent [79]. Comparative studies suggest that while ferulic acid surpasses idebenone in photoprotection, its scavenging effects are not as potent as green tea polyphenols [80, 81]. Green tea is the source of several potent polyphenol antioxidants. Epigallocatechin gallate (EGCG) is found in abundance in camellia sinensis and is thought to provide green tea’s primary antioxidant, antiinflammatory, and chemoprotective benefits [82]. EGCG has been shown to inhibit lipid peroxidation and prevent the formation of nitric oxide, hydroxyl radicals, and singlet oxygen [82, 83]. Research also indicates that topically applied EGCG is able to reverse the immunosuppressive effects of UV rays [84] and induce degradation of cutaneous carcinogenic cells [85]. Idebenone is an engineered analog of coenzyme Q-10 that serves as a potent primary antioxidant. Clinical trials preformed on the topical benefits of idebenone suggest an impressively well-rounded radical scavenging capacity when compared to traditional antioxidant agents such as alpha lipoic acid, kinetin, tocopherol, and ascorbic acid [86]. In vivo tests showed a decrease in lipid peroxidation and an inhibition of UVB-induced DNA damage and erythema [86]. Further research, however, indicates a lack of photoprotection when compared to other topical antioxidants [81, 87].
J. Linder
Genistein is an isoflavone derivative of soybeans that increases the activity of the skin’s endogenous antioxidants [88]. Studies suggest that genistein prevents lipid peroxidation and hydrogen peroxide production. Genistein also interferes with UV-induced DNA damage and mutation [58, 89]. In vivo studies involving genistein indicate short- and long-term UV damage prevention, including erythema, skin cancer, and visible photoaging [90]. l-Ascorbic acid is the only true bioavailable form of vitamin C, and it is the only ingredient to provide all of vitamin C’s topical benefits. Topically applied l-ascorbic acid serves as a primary, secondary, and coantioxidant that effectively quenches ROS in the aqueous environment of the skin [91]. Because vitamin C is easily oxidized, products must be stabled by one of three methods. Products with an aqueous base should have a pH of 3.5 or lower [92]. An impressively stable, and therefore effective, method of protecting the l-ascorbic acid molecule is to use encapsulation and an anhydrous product base [93]. Esterification is another method of stabilization; however, ester versions of vitamin C, such as ascorbyl palmitate and magnesium ascorbyl phosphate, have been shown in clinical studies to provide only the antioxidant capabilities of vitamin C and they do not offer the collagen synthesis, anti-inflammatory, and photoprotective activities [94]. Therefore, esterification is not the preferred method of stabilization. Glutathione is part of the body’s endogenous antioxidant systems. Many of the most commonly used topical antioxidants work by regenerating this essential protective component. Research indicates that glutathione provides primary antioxidant capabilities by neutralizing current and preventing future oxidation [95]. In addition, glutathione serves as a co-antioxidant that supports l-ascorbic acid and vitamin E [96]. Studies also indicate that topically applied glutathione reduces UV-induced erythema to a higher degree than superoxide dismutase, ascorbyl palmitate, and tocopherol [97].
8.13 Matrix Metalloproteinase Inhibitors (MMPi) While the term MMP inhibitor has recently seen increased use in the marketing of cosmeceuticals, most MMPi ingredients have been used for decades throughout the industry.
8 Cosmeceutical Treatment of the Aging Face
Retinoids describe all members of the vitamin A family, including retinoic acid and its analogues and derivatives (e.g., adapalene, tazarotene, retinol). Cosmeceutical vitamin A products containing retinol or retinaldehyde are successfully converted into retinoic acid within the skin [98]. Retinoids are responsible for multiple matrix-protecting actions within the skin, including decreasing collagenase and elastase levels [99]. Vitamin E ingredients include tocopherol, tocotrienols, and tocopheryl acetate. Research shows that tocopherol inhibits the activity of fibroblastic protein kinase C and the production of collagenase [100]. Studies have also found that tocotrienols are capable of decreasing nuclear factor-kB activation, which is responsible for the production of several MMP enzymes [101]. Aloe vera has been used topically for centuries, and its anti-inflammatory effects are well-documented [9, 102, 103]. Research on the individual constituents of aloe found that aloin effectively downregulates collagenase levels as well as granulocyte MMP [104]. Soy extracts are used throughout the industry. The most topically active components, though, have shown to be soy-derived isoflavones, such as genistein and daidzein. They are typically used as antioxidants, although research on the effects of oral soy isoflavones demonstrated a decrease in UV-induced MMP production [105, 106]. Further studies are needed to verify whether these effects are also achieved through topical application. Resveratrol is a powerful antioxidant, and research indicates that resveratrol effectively decreases UV-induced MMP production and downregulates nuclear factor-kB activity [59, 79, 107]. Beta-carotene is a carotenoid found in yellow/ orange fruits and vegetables and some dark leafy greens. When beta-carotene is applied topically, this vitamin A precursor inhibits MMP expression in both UV-exposed and un-irradiated tissue [108]. Epigallocatechin gallate (EGCG) is a green and black tea polyphenol responsible for multiple protective benefits. Studies show that EGCG reduces the production of various MMP enzymes and the activation of nuclear factor-Kb [109, 110]. l-Ascorbic acid is bioavailable vitamin C. Rather than directly inhibiting the expression of a particular MMP, vitamin C upregulates levels of the endogenous tissue inhibitor of matrix metalloproteinase-1 [111].
75
8.14 Collagen and Matrix Producers Gradual breakdown of the skin’s structural components is inevitable for most patients, particularly those with excessive UV exposure. Once degradation occurs, use of clinically proven topical ingredients works to trigger the synthesis of such matrix proteins as collagen and elastin to improve the health and appearance of the skin. l-Ascorbic acid, bioavailable vitamin C, is a cofactor for collagen-stabilizing enzymes prolyl and lysyl hydroxylase and activates transcription of and stabilizes procollagen mRNA [91, 111, 112]. Although esters such as ascorbyl palmitate and magnesium ascorbyl phosphate are beneficial when administered orally, the acids in the skin are not strong enough to cleave the ester’s covalent bonds to free the l-ascorbic acid. Therefore topically, l-ascorbic acid is preferred to maximize collagen production. Retinoids encompass retinol, retinaldehyde, vitamin A esters, retinoic acid, and its analogues. While retinoic acid is the biologically active and most potent retinoid, it is potentially irritating to some patients. Retinol effectively binds with cellular retinol binding protein (CRBP) and is ultimately converted to retinoic acid in the skin [113]. Retinol, retinaldehyde, and retinoic acid are proven to stimulate dermal fibroblast production, increase mRNAs for types I and III collagen and trigger glycosaminoglycan production when applied topically [99, 114]. In addition, retinoids are thought to be one of the only topical methods for encouraging proliferation of elastin [115]. Peptides are the key building blocks of nearly all living tissues. Peptides encompass a large category of topical ingredients; however, very few have been legitimized in scientific studies. The topical use of peptides is still relatively new to the industry and, as of now, while many are being marketed, the most substantiated agents are used in the treatment of aging skin. Neurotransmitter-affecting peptides, carrier peptides, and signal peptides work in different ways to improve the integrity of matrix proteins.
8.15 Neurotransmitter-Affecting Peptides Acetyl hexapeptide-8 is a chain of six amino acids that inhibits soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNARE) complex. In
76
vivo studies found that twice daily application of acetyl hexapeptide-8 for 30 days resulted in a 30% decrease in the depth of dynamic rhytids [116].
8.16 Carrier Peptides Copper peptides are considered carrier peptides, as they increase the uptake of copper by the cells when paired with a tripeptide (glycyl-I-histidyl-l-lysine). Copper is used due to its involvement in collagen deposition through the activation of lysyl oxidase. Research suggests that the copper peptide increases collagen, gylcosaminoglycan, and adhesive protein production [117].
8.17 Signal Peptides Signal peptides are used to initiate specific responses within the skin. Several age-control signal peptides are currently available yet only a few are backed by legitimate studies. Palmitoyl pentapeptide-4 refers to lysine-therinetherine-lysine-serine paired with palmitic acid. In vitro studies show a stimulation of types I and III collagen as well as enhanced production of fibronectin [118]. Palmitoyl oligopeptide is a combination of valineglycine-valine-alanine-proline-glycine and palmitic acid. Studies suggest that this long-chain peptide stimulates the production of multiple dermal fibroblasts [119]. Palmitoyl oligopeptide can be used alone or in conjunction with other peptides.
8.18 Textural Variances The texture of the skin’s surface is another key indicator of a patient’s age and lifestyle choices. Varying degrees of dryness, dehydration, coarsening, and epidermal keratinization are hallmarks of aged skin.
J. Linder
highly compacted, leading to a flaky, dull, and rough appearance. These factors in conjunction with a natural slowing in the production of moisture-binding glycosaminoglycans, and the UV-induced increase in the MMP hyaluronidase, leads to intensified dryness and dehydration [5, 120, 121]. Many patients experiment with topical products in an attempt to minimize the visual signs of their age. Aggressive topicals, improper cleansing habits, and insufficient moisturization often compound age-related and UV-exacerbated dryness [122].
8.18.2 Coarsening The time it takes a keratinocyte to travel from the basal layer to the stratum corneum increases from about 20 days in young skin to approximately 30 in aged skin [123]. This extended cellular lifespan, in addition to aged keratinocytes being more resistant to apoptosis [79], leads to skin that is more prone to DNA damage and oncogenesis. Additionally, the process of desquamation slows with time and with exposure to the elements, leaving the flattened corneocytes to build up, making the skin appear dry, flaky, and coarse [121]. In addition, patients who have experienced extended actinic exposure over their lifetime may present with solar elastosis, which clinically appears as a thickening of the skin that can lead to a yellow tone and a “leather-like” appearance [124]. Histologically, solar elastosis is a result of deposition of large amounts of abnormal elastic material that replaces the more normal collagen-rich ECM. It is triggered by UV radiation or free radicals that activate elastin promoters, which in turn elevate elastin mRNAs resulting in solar elastosis [125, 126]. In cases of advanced extrinsic aging with extensive textural changes, cosmeceuticals are typically used in tandem with more invasive procedures to work toward improvement.
8.19 Cosmeceutical Ingredients for Texture Improvement 8.18.1 Dryness and Dehydration An age-related decrease in the stratum corneum’s natural moisturizing factor (NMF) reduces barrier function, increases transepidermal water loss (TEWL), and contributes to slowed desquamation. As a result the corneocytes flatten and the stratum corneum becomes more
The textural changes associated with visible skin aging can be addressed in multiple fashions. Regular exfoliation and maintaining optimal skin hydration levels with humectants and occlusive agents can significantly decrease the appearance of coarsening, xerosis, and fine lines.
8 Cosmeceutical Treatment of the Aging Face
8.19.1 Exfoliation with Alpha Hydroxy Acids (AHA) AHA are a class of water-soluble carboxylic acids that can be naturally derived or synthetically produced for topical use. They have the ability to break down intracellular desmosomal bonds to allow for easier exfoliation of impacted cells. Although the exact mechanism of action is not fully elucidated, this may be a result of chelation of calcium ions [127]. AHAs are also thought to stimulate fibroblasts to produce collagen and elastin to strengthen the matrix and firm the skin. AHAs can either be used as active ingredients in daily skin care products like washes, moisturizers and serums or they can be used in medical treatments such as superficial chemical peels. There are multiple AHA; however, only glycolic acid, lactic acid, and citric acid have significant research regarding their topical use. Each of these acids offers unique secondary and tertiary benefits. Glycolic acid has a very low molecular weight, which allows for hastened penetration and epidermolysis [128]. The fast penetration often induces higher instances of inflammation and stimulation than is associated with other AHA. Glycolic acid also has demonstrated pigment reducing benefits and has strong degreasing properties, making it ideal for oily, acneic skin but potentially dehydrating for drier skin types [129]. Lactic acid is a relatively larger molecule in comparison to glycolic acid, which allows it to penetrate into the skin slowly [128], reducing the chances of irritation and inflammation. Lactic acid has been shown to reduce bacteria [130], act as a humectant [131] and suppress the formation of tyrosinase. Lower concentrations (up to 5%) are recommended for daily use to promote cellular exfoliation of the corneocytes without causing sensitization or visible flaking [132]. Citric acid has demonstrated an ability to increase the thickness of viable epidermal cells. In addition, testing also showed topical use increased epidermal and dermal hyaluronic acid levels [133].
8.19.2 Mechanical Exfoliants Mechanical exfoliation is a method of physically removing skin cells through friction and abrasive media. This type of exfoliation can be utilized in-office with microdermabrasion or in cosmeceuticals, such as
77
granular exfoliation products. While these can be effective in smoothing the skin’s surface, over-use by the patient often leads to sensitization. Gentle products with rounded beads as the exfoliating media may reduce the occurrence of over-treatment.
8.19.3 Humectants Humectants are used to increase hydration of the stratum corneum by drawing water from the dermis and, in locales with high humidity levels, the air. Enhancing topical hydration helps to improve the appearance of the skin’s texture and may also temporarily decrease the depth of rhytids. Humectants should not be used alone in topical preparations, as not occluding the area may increase surface dehydration [134]. Hyaluronic acid is a naturally occurring glycosaminoglycan used topically for its impressive moisture-attracting capabilities. Although hyaluronic acid does not penetrate intact skin, it moisturizes the epidermis by holding up to 1,000 times its molecular weight in water [135]. Sodium PCA is the salt of pyrrolidone carboxylic acid and is part of the skin’s NMF. When applied topically, sodium PCA showed greater hygroscopic activity than glycerin and sorbitol [136]. Sorbitol is often used as a more cost-effective alternative to sodium PCA and hyaluronic acid. Sorbitol is a unique humectant in that it is also able to chelate metal ions, allowing for potential antioxidant capabilities [137]. Honey has exhibited humectant properties in multiple wound-healing studies. In addition to being hygroscopic, honey also offers antibacterial and antiinflammatory benefits [138, 139]. Glycerin is one of the most effective humectants, as it is able to hydrate on many levels. Glycerin has been shown to penetrate through intercellular aquaporins, thereby enhancing surface and intercellular skin hydration [140]. Glycerin also has optimal sustainability and repeated application increases its moisture-binding benefits [141]. Urea is often used for its keratolytic benefits [142] as well as its hygroscopic properties. Like glycerin, urea is capable of entering and hydrating the skin cells by way of aquaporin-3 [141]. The exfoliation and hydration provided by urea make it especially effective for moderate to severe xerosis and keratinization [142].
78
8.19.4 Occlusive Agents Occlusive agents’ function is to create an invisible barrier on the skin to maintain moisture levels. When used alone, occlusive agents merely retain hydration, rather than significantly increasing moisture levels in the skin. Moisturizing products that employ both humectants to draw water from the dermis to the epidermis and occlusive ingredients to trap it within can heighten moisture content throughout the epidermis [143]. Petrolatum is considered the most effective occlusive agent available [144]. Many find petrolatum-based products to have an unappealing, greasy texture and studies indicate possible comedogenicity [145]. Petrolatum products are often used immediately following deeper chemical peels or laser resurfacing treatments, as they serve as an effective barrier replacement during re-epithelialization [146]. Lanolin acts as an effective occlusive agent derived from the sebaceous glands of sheep [145]. Although lanolin is considered safe, research has indicated that lanolin alcohols are potential allergens and contributors to various types of dermatitis [147, 148]. Silicones, such as dimethicone and cyclomethicone, are polymers that provide occlusion with a light, powder-like texture. Silicones are often used in hydrating products designed for daily use on any skin type, including acne and oily skin. This group of occlusive ingredients is not associated with comedogenicity or allergenicity [149]. Shea butter, or butyrospermum parkii, has been used in cosmetic products for decades due to its occlusive capabilities. Its rich texture typically makes shea butter more appropriate for drier skin types. Studies on wound healing suggest that shea butter also may decrease the risk of infection and accelerate healing time [150]. Niacinamide, also referred to as nicotinamide, serves as an occlusive agent, based on its ability to increase the skin’s natural barrier components. Research indicates that topical niacinamide triggers the production of epidermal free fatty acids, ceramides, and cholesterol [151]. Plant oils, such as squalane, vegetable oils and jojoba oil provide mild occlusion as well. In addition, certain plant oils, specifically rosehip seed, borage and evening primrose, among others, may also provide secondary skin health benefits because of their content of essential fatty acids (EFA). EFA have been shown to
J. Linder
be beneficial in the inhibition of inflammatory skin conditions [152]. A reduction of inflammation may also decelerate the extrinsic aging process.
8.20 Dyschromias An easily apparent and common sign of aged skin is a visibly mottled and uneven skin tone. These dyschromias are due to a degeneration of the vascular system and melanogenesis. Both blood and melanin-related dyschromias are intensified by ultraviolet exposure and are more apparent in highly photodamaged patients due to the thinning of skin [153, 154]. Although there is a lessening in the dermal vascularity of intrinsically aged skin, UV exposure and cigarette smoke are both known to stimulate angiogenesis [155]. Telangiectasias can develop due to congenital factors, but much of the facial telangiectasias that are seen in older skin are due to environmental causes. Exposure to UVA rays causes necrosis of endothelial cells leading to dermal blood cell damage [79]. UVBinduced free radical formation causes a dilation of capillaries [153, 154]. Additionally, as the skin thins with age, this vascularity is more readily visible [154]; therefore, telangiectasias and increased vascularity are frequent presentations of aging. Poikiloderma of Civatte, which presents as reticulated hyperpigmented patches associated with telangiectasias and mild atrophy on the lateral aspects of the neck on fair skinned people, is a classic example of the changes seen in chronically photodamaged skin. Cosmeceuticals can assist with vascular dyschromias by protecting and promoting the collagen around damaged vessels and by limiting inflammation and dilation. Sun avoidance and daily broad-spectrum protection are critical and they can also help to mitigate vascular changes, but once facial telangiectasias have developed, there are no great cosmeceutical options for their resolution. Use of laser therapy for their removal is recommended. Hyperpigmentation is one of the most common skin concerns world-wide. Hyperpigmentation is deposited in the skin as a result of UV exposure, hormonal stimuli, or inflammation [156, 157]. In general, the density of melanocytes should decrease as a result of intrinsic aging [157, 158]. However, the hormonal shifts that occur as a result of menopause can cause an increase in the number and activity level of the melanocytes [159].
8 Cosmeceutical Treatment of the Aging Face
Actinic damage, pregnancy, and menopause will increase the number of melanocytes and increase pigment deposits in the keratinocytes [157, 158]. As with all visible signs of facial aging discussed, hypermelanosis is exacerbated in photoaged skin. The process of melanogenesis is comprised of many interconnected reactions, providing the physician with multiple opportunities to interrupt melanin production through the use of a variety of proven OTC and cosmeceutical ingredients. The use of several topical pigment-reducing ingredients with different mechanisms of action typically leads to accelerated results compared with the use of a single tyrosinase inhibitor.
8.21 Melanogenisis Inhibitors Hydroquinone (HQ) is the most prescribed skin-lightening agent world-wide [160]. HQ inhibits tyrosinase activity by suppressing the binding of copper and tyrosinase. In addition, studies show that HQ decreases the formation and promotes the degradation of melanosomes and induces melanocyte-specific cytotoxicity [156, 161, 162]. HQ is the most potent option of the melanogenesis inhibitors. Cosmeceuticals can contain up to 2% of HQ. These lower concentrations assist in the avoidance of inflammation and potential postinflammatory hyperpigmentation (PIH) that can be experienced as a result of irritation from higher percentages of HQ. Further, one study comparing the efficacy of 2% and 5% HQ found that there was no significant difference in lightening benefits; however, there was an increased risk of sensitivities with the higher percentage preparation [163]. Due to the potential of irritation, patch tests should be considered to determine patient tolerance prior to product use. Kojic acid acts by chelating the copper bound to the tyrosinase [156, 162, 164]. In addition, kojic acid decreases the number of melanosomes and melanocytic dendrites [165] while inhibiting nuclear factorkappa B (NF-kB) activation in keratinocytes, mitigating the inflammatory response [166]. There is a potential for contact dermatitis following kojic acid application; therefore, highly sensitive patients should be patchtested to ensure no undue inflammation is caused during treatment [166]. Lactic acid is a hydrophilic AHA that increases exfoliation of melanin-filled keratinocytes, ultimately fading dyschromias. In addition, lactic acid suppresses
79
the formation of tyrosinase, contributing to the inhibition of melanogenesis [156, 167]. l-Ascorbic acid is able to convert dopaquinone back to l-DOPA during melanogenesis, preventing melanin formation [161, 168]. l-Ascorbic acid’s antioxidant, anti-inflammatory, and photoprotective capabilities may also help to avert the stimulation of melanogenesis. Retinoids, such as retinoic acid, retinol and retinaldehyde, assist in the reduction and hindrance of hyperpigmentation by inhibiting tyrosinase, enhancing cell turnover, and limiting melanosomal phagocytosis [114, 156, 168]. Retinol is typically used in cosmeceutical preparations, as it is successfully converted to retinoic acid within the skin [98]. Similar results may be achieved with retinol without the heightened irritant risk commonly associated with retinoic acid [113]. Azelaic acid provides melanocyte-specific antiproliferative and cytotoxic effects while also inhibiting tyrosinase activity. Further, azelaic acid is thought to be able to reduce DNA synthesis and mitochondrial activity in hyperactive and abnormal melanocytes [156, 169]. Arbutin is a natural b-d-glucopyranoside derivative of HQ that allows controlled release of HQ [156, 170]. Arbutin also suppresses the activity of tyrosinase, inhibits melanosome maturation, and provides antioxidant protection [161, 168]. Resorcinol derivatives, such as phenylethyl resorcinol and 4-n-butylresorcinol have demonstrated inhibition of the conversion of tyrosinase to l-DOPA [171, 172] during the melanogenesis process. Resorcinol derivatives have also demonstrated antioxidant benefits. Undecylenoyl phenylalanine is thought to prevent the synthesis of the melanocyte-stimulating hormone (MSH) and, as a result, prevent the formation of tyrosinase, melanin, and melanosome transfer [173–175].
8.22 Conclusions An understanding of the primary visible signs of aging skin, including matrix degradation, textural variances and dyschromias, and their individual causes allows the physician to make informed product choices for their patients. With the plethora of new anti-aging cosmeceuticals available to the physician, and the consumer, product recommendations based on science, not marketing, are what patients need. This overview is intended to provide the physician with the information necessary for selecting the best topical therapies
80
for their patients working to prevent and reverse the visible signs of aging. Physicians may also develop cosmeceutical strategies to support more invasive procedures for patients with advanced dermal degradation.
References 1. Fisher G, Kang S, Varani J, Bata-Csorgo Z, Wan Y, Datta S, Voorhees JJ (2002) Mechanisms of photoaging and chronological skin aging. Arch Dermatol 138(11):1462–1470 2. Kerkelä E, Saarialho-Kere U (2003) Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol 12(2):109–125 3. Fisher GJ, Datta SC, Talwar HS, Wang ZQ, Varani J, Kang S, Voorhees JJ (1996) Molecular basis of sun-induced premature skin aging and retinoid antagonism. Nature 379(6563): 335–339 4. Nishimori Y, Edwards C, Pearse A, Matsumoto K, Kawai M, Marks R (2001) Degenerative alterations of dermal collagen fiber Bundles in photodamaged human skin and UV-irradiated hairless mouse skin: possible effect on decreasing skin mechanical properties and appearance of wrinkles. J Invest Dermatol 117(6):1458–1463 5. Herschthal J, Kaufman K (2007) Cutaneous aging: a review of the process and topical therapies. Expert Rev Dermatol 2:753–761 6. Coleman S, Grover R (2006) The anatomy of the aging face: volume loss and changes in 3-dimensional topography. Aesthet Surg J 26(1S):S4–S9 7. Donath AS, Glasgold RA, Glasgold MJ (2007) Volume loss versus gravity: new concepts in facial aging. Curr Opin Otolaryngol Head Neck Surg 15(4):238–243 8. Ramirez OM, Robertson KM (2001) Comprehensive approach to rejuvenation of the neck. Facial Plast Surg 17(2):129–140 9. Thakur ND, Batheja P, Kaushik D, Michniak B (2008) Structural and biochemical changes in aging skin and their impact on skin permeability barrier. In: Dayan N (ed) Skin aging handbook: an integrated approach to biochemistry and product. William Andrew Inc., Norwich, NY, pp 55–90. 10. de Rigal J, Escoffier C, Querleux B, Faivre B, Agache P, Lévêque JL (1989) Assessment of aging of the human skin by in vivo ultrasonic imaging. J Investig Dermatol 93(5): 621–625 11. El-Domyati M, Attia S, Saleh F, Brown D, Birk DE, Gasparro F, Ahmad H, Uitto J (2002) Intrinsic aging vs. photoaging: a comparative histopathological, immunohistochemical, and ultrastructural study of the skin. Exp Dermatol 11(5):398–405 12. Stoebner PE, Meunier L (2008) Photoaging of face. Ann Dermatol Venereol 135(1 Pt 2):1S21–1S26 13. Kang S, Fisher GJ, Voorhees JJ (2001) Photoaging: pathogenesis, prevention, and treatment. Clin Geriatr Med 17(4):643–659 14. Murphy G, Cockett M, Ward RV, Docherty AJ (1991) Matrix metalloproteinase degradation of elastin, type IV collagen
J. Linder and proteoglycan: a quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J 277 (Pt 1):277–279 15. Fuchs J (1992) Oxidative injury in dermopathology. Springer, Berlin, p 360 16. Gendimenico G, Mack V, Siock PA, Mezick JA (2002) Topical estrogens: their effects on connective tissue synthesis in hairless mouse skin. Arch Dermatol Res 294(5):231–236 17. Lochner K, Gaemlich A, Südel KM, Venzke K, Moll I, Knott A, Stäb F, Wenck H, Döring O, Böttger M, Gallinat S (2007) Expression of decorin and collagens I and III in different layers of human skin in vivo: a laser capture microdissection study. Biogerontology 8(3):269–282 18. Wilhelm KP, Cua AB, Maibach HI (1991) Skin aging: effect on transepidermal water loss, stratum corneum hydration, skin surface pH, and casual sebum content. Arch Dermatol 127(12):1806–1809 19. Brenneisen P, Briviba K, Wlaschek M, Wenk J, ScharffetterKochanek K (1997) Hydrogen peroxide (H2O2) increases the steady-state mRNA levels of collagenase/MMP-1 in human dermal fibroblasts. Free Radical Biol Med 22(3):515–524 20. Koh JS, Kang H, Choi SW, Kim HO (2002) Cigarette smoking associated with premature facial wrinkling: image analysis of facial skin replicas. Int J Dermatol 41(1):21–27 21. Fagien S (1999) Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery. Plast Reconstr Surg 103(2):701–713 22. Soldano S, Montagna P, Brizzolara R, Sulli A, Parodi A, Seriolo B, Paolino S, Villaggio B, Cutolo M (2010) Effects of estrogens on extracellular matrix synthesis in cultures of human normal and scleroderma skin fibroblasts. Ann NY Acad Sci 1193(1):25–29 23. Shah MG, Maibach HI (2001) Estrogen and skin: an overview. Am J Clin Dermatol 2(3):143–150 24. Fisher GJ, Datta S, Wang Z, Li XY, Quan T, Chung JH, Kang S, Voorhees JJ (2000) c-Jun dependent inhibition of cutaneous procollagen transcription following ultraviolet irradiation is reversed by all-trans retinoic acid. J Clin Invest 106(5):663–670 25. Kligman AM (1979) Perspectives and problems in cutaneous gerontology. J Invest Dermatol 73(1):L39–L46 26. Neerken S, Lucassen GW, Bisschop MA, Lenderink E, Nuijs TA (2004) Characterization of age-related effects in human skin: a comparative study that applies confocal laser scanning microscopy and optical coherence tomography. J Biomed Opt 9(2):274–281 27. Guinot C, Malvy D, Ambroisine L, Latreille J, Mauger E, Tenenhaus M, Morizot F, Lopez S, Le Fur I, Tschachler E (2002) Relative contribution of intrinsic vs extrinsic factors to skin aging as determined by a validated skin age score. Arch Dermatol 138(11):1454–1460 28. Zouboulis CC, Boschnakow A (2001) Chronological ageing and photoageing of the human sebaceous gland. Clin Exp Dermatol 26(7):600–607 29. Patterson WM, Fox M, Schwartz RA (2004) FavreRacouchot disease. Int J Dermatol 43(3):167–169 30. Draelos ZD (2010) Active agents in common skin care products. Plast Reconstr Surg 125(2):719–724 31. Nixon RL, Frowen KE, Lewis AE (1997) Skin reactions to sunscreens. Australas J Dermatol 38(suppl 1):S83–S85
8 Cosmeceutical Treatment of the Aging Face 32. Ortiz KJ, Yiannias JA (2004) Contact dermatitis to cosmetics, fragrances, and botanicals. Dermatol Ther 17(3): 264–271 33. Gasparro FP, Mitchnick M, Nash JF (1998) A review of sunscreen safety and efficacy. Photochem Photobiol 68(3): 243–256 34. Levy SB (2009) UV filters. In: Barel AO, Paye M, Maibach HI (eds) Handbook of cosmetic science and technology, 3rd edn. Informa Healthcare, New York, pp 311–322 35. Lim HW, Thomas L et al (2004) Photoprotection. In: Rigal DS, Weiss RA, Lim HW, Dover JS (eds) Photoaging. Marcel Dekker, New York, pp 73–88 36. Kullavanijaya P, Lim HWJ (2005) Photoprotection. J Am Acad Dermatol 52(6):937–958 37. Baumann L, Avashia N, Castanedo-Tardan MP (2009) Sunscreens. In: Baumann L (ed) Cosmetic dermatology principals and practice, 2nd edn. McGraw Hill Companies Inc., Columbus, OH, pp 245–255 38. Fisher AA (1992) Sunscreen dermatitis: part IV – the salicylates, the anthranilates, and physical agents. Cutis 50(6): 397–398 39. Levy SB (1997) Sunscreens for photoprotection. Dermatol Ther 4:59–71 40. Rai R, Srinivas CR (2007) Photoprotection. Indian J Dermatol Venereol Leprol 73(2):73–79 41. Darvay A, White IR, Rycroft RJ, Jones AB, Hawk JL, McFadden JP et al (2001) Photoallergic contact dermatitis is uncommon. Br J Dermatol 145(4):597–601 42. Lim H, Draelos Z, Rigel DS, Ruenger TM (2006) Shedding light on complete UV protection. J Cosmet Dermatol 19:3–8 43. Draelos ZD (2007) Cosmeceuticals. In: Goldberg DJ (ed) Facial rejuvenation: a total approach. Springer, Berlin, p 172 44. Jancin B (2009) Two UVA sunscreen filters are better than one. Skin & Allergy News 19 45. Schwack W, Rudolph T (1995) Photochemistry of dibenzoyl methane UVA filters part 1. J Photochem Photobiol B Biol 28:229–234 46. Chatelain E, Gabard B (2001) Photostabilization of butyl methoxydibenzoylmethane (avobenzone) and ethylhexyl methoxycinnamate by bis-ethylhexyloxyphenol methoxyphenyl triazine (tinosorb S), a new UV broadband filter. Photochem Photobiol 74(3):401–406 47. David RM, Gans G (2003) Summary of mammalian toxicology and health effects of phthalate esters. In: Staples CA (ed) Phthalate esters. Springer, Berlin, pp 299–316 48. Reisch MS (2005) New-wave sunscreen. Chem Eng News 83:18–22 49. Pinnell SR, Fairhurst D, Gillies R, Mitchnick MA, Kollias N (2000) Microfine zinc oxide is a superior sunscreen ingredient to microfine titanium dioxide. Dermatol Surg 26(4): 309–314 50. Agren MS (1990) Studies on zinc in wound healing. Acta Derm Venereol Suppl 154:1–36 51. DeBuys HV, Levy SB, Murray JC, Madey DL, Pinnell SR (2000) Modern approaches to photoprotection. Dermatol Clin 18(4):577–590 52. Brezova V, Gabčová S, Dvoranová D, Stasko A (2005) Reactive oxygen species produced upon photoexcitation of sunscreens containing titanium dioxide (an EPR study). J Photochem Photobiol B 79(2):121–134
81 53. Hansen KM, Gratton E, Bardeen CJ (2006) Sunscreen enhancement of UV-induced reactive oxygen species in the skin. Free Radic Biol Med 41:1205–1212 54. González S, Fernández-Lorente M, Gilaberte-Calzada Y (2008) The latest on skin photoprotection. Clin Dermatol 26(6):614–626 55. Edlich RF, Winters KL, Lim HW, Cox MJ, Becker DG, Horowitz JH, Nichter LS, Britt LD, Long WB (2004) Photoprotection by sunscreens with topical antioxidants and systemic antioxidants to reduce sun exposure. J Long Term Eff Med Implants 14:317–340 56. Dreher F, Maibach H (2001) Protective effects of topical antioxidants in humans. Curr Probl Dermatol 29:157–164 57. Burke KE (2004) Photodamage of the skin: protection and reversal with topical antioxidants. J Cosmet Dermatol 3(3):149–155 58. Pinnell SR (2003) Cutaneous photodamage, oxidative stress, and topical antioxidant protection. J Am Acad Dermatol 48(1):1–19 59. Baxter R (2008) Anti-aging properties of resveratrol: review and report of a potent new antioxidant skin care formulation. J Cosmet Dermatol 7(1):2–7 60. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275(5297):218–220 61. Aziz MH, Reagan-Shaw S, Wu J, Longley BJ, Ahmad N (2005) Chemoprevention of skin cancer by grape constituent resveratrol: Relevance to human disease? FASEB J 19(9): 1193–1195 62. Katiyar SK (2005) Silymarin and skin cancer prevention: anti-inflammatory, antioxidant and immunomodulatory effects. Int J Oncol 26(1):1213–1222 63. Kaur M, Agarwal R (2007) Silymarin and epithelial cancer chemoprevention: How close we are to bedside? Toxicol Appl Pharmacol 224(3):350–359 64. Katiyar SK (2002) Treatment of silymarin, a plant flavonoid, prevents ultraviolet light-induced immune suppression and oxidative stress in mouse skin. Int J Oncol 21(6): 1213–1222 65. Singh RP, Agarwal R (2002) Flavonoid antioxidant silymarin and skin cancer. Antioxid Redox Signal 4(4): 655–663 66. Li LH, Wu LJ, Zhou B, Wu Z, Tashiro S, Onodera S, Uchiumi F, Ikejima T (2004) Silymarin prevents UV irradiation-induced A375-S2 cell apoptosis. Biol Pharm Bull 27(7):1031–1036 67. Huang MT, Xie JG, Wang ZY, Ho CT, Lou YR, Wang CX, Hard GC, Conney AH (1997) Effects of tea, decaffeinated tea, and caffeine on UVB light-induced complete carcinogenesis in SKH-1 mice: demonstration of caffeine as a biologically important constituent of tea. Cancer Res 57(13): 2623–2629 68. Richelle M, Tavazzi I, Offord E (2001) Comparison of the antioxidant activity of commonly consumed polyphenolic beverages (coffee, cocoa, and tea) prepared per cup serving. J Agric Food Chem 49(7):3438–3442 69. Devasagayam TPA, Kamat JP, Mohan H, Kesavan PC (1996) Caffeine as an antioxidant: inhibition of lipid peroxidation induced by reactive oxygen species. Biochim Biophys Acta 1282(1):63–70
82 70. Heffernan TP, Kawasumi M, Blasina A, Anderes K, Conney AH, Nghiem P (2009) ATR-CHK1 pathway inhibition promotes apoptosis after UV treatment in primary human keratinocytes: potential basis for the UV protective effects of caffeine. J Invest Dermatol 129(7):1805–1815 71. Farris P (2007) Idebenone, green tea, and Coffeeberry® extract: new and innovative antioxidants. Dermatol Ther 20(5):322–329 72. Baumann LS (2007) Less-known botanical cosmeceuticals. Dermatol Ther 20:330–342 73. Gomes RA, Moldes CA, Delite FS, Gratäo PL, Mazzafera P, Lea PJ, Azevedo RA (2006) Nickel elicits a fast antioxidant response in coffea arabica cells. Plant Physiol Biochem 44:420–429 74. Asmus KD, Bensasso RV, Bernier JL, Houssin R, Land EJ (1996) One-electron oxidation of ergothioneine and analogues investigated by pulse radiolysis: redox reaction involving ergothioneine and vitamin C. Biochem J 315(Pt 2):625–629 75. Chaudieá Re J, Ferrari-Iliou R (1999) Intracellular antioxidants: from chemical to biochemical mechanisms. Food Chem Toxicol 37(9–10):949–962 76. Akanmu D, Cecchini R, Aruoma OI, Halliwell B (1991) The antioxidant action of ergothioneine. Arch Biochem Biophys 288(1):10–16 77. Aruoma OI, Spencer JPE, Mahmood N (1999) Protection against oxidative damage and cell death by the natural antioxidant ergothioneine. Food Chem Toxicol 37(11): 1043–1053 78. Saija A, Tomaino A, Lo Cascio R, Trombetta D, Proteggente A, De Pasquale A, Uccella N, Bonina F (1999) Ferulic and caffeic acids as potential protective agents against photooxidative skin damage. J Sci Food Agric 79:476–480 79. Svobodová A, Psotová J, Walterová D (2003) Natural phenolics in the prevention of UV-induced skin damage. a review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 147(2):137–145 80. Scott BC, Butler J, Halliwell B, Aruoma OI (1993) Evaluation of the antioxidant actions of ferulic acid and catechins. Free Radic Res Commun 19(4):241–253 81. Tournas JA, Lin FH, Burch JA, Selim MA, Monteiro-Riviere NA, Zielinski JE, Pinnell SR (2006) Ubiquinone, idebenone, and kinetin provide ineffective photoprotection to skin when compared to a topical antioxidant combination of vitamins C and E with ferulic acid. J Invest Dermatol 126(5): 1185–1187 82. Afaq F, Mukhtar H (2006) Botanical antioxidants in the prevention of photocarcinogenesis and photoaging. Exp Dermatol 15(9):678–684 83. F’guyer S, Afaq F, Mukhtar H (2003) Photochemoprevention of skin cancer by botanical agents. Photodermatol Photo immunol Photomed 19(2):56–72 84. Katiyar SK, Challa A, McCormick TS, Cooper KD, Mukhtar H (1999) Prevention of UVB-induced immunosuppression in mice by the green tea polyphenol (−)-epigallocatechin-3-gallate may be associated with alterations in IL-10 and IL-12 production. Carcinogenesis 20(11): 2117–2124 85. Lu YP, Lou YR, Xie JG, Peng QY, Liao J, Yang CS, Huang MT, Conney AH (2002) Topical applications of caffeine or (−)-epigallocatechin gallate (EGCG) inhibit carcinogenesis
J. Linder and selectively increase apoptosis in UVB-induced skin tumors in mice. Proc Natl Acad Sci 99(19):12455–12460 86. McDaniel DH, Neudecker BA, DiNardo JC, Lewis JA 2nd, Maibach HI (2005) Idebenone: a new antioxidant – part I. Relative assessment of oxidative stress protection capacity compared to commonly known antioxidants. J Cosmet Dermatol 4(1):10–17 87. Huang C, Miller T (2007) The truth about over-the-counter topical anti-aging products: a comprehensive review. Aesthet Surg J 27(4):402–412 88. Cai Q, Wei H (1996) Effect of dietary genistein on antioxidant enzyme activities in SENCAR mice. Nutr Cancer 25(1):1–7 89. Salvi M, Brunati AM, Clari G, Toninello A (2002) Interaction of genistein with the mitochondrial electron transport chain results in opening of the membrane transition pore. Biochim Biophys Acta 1556(2–3):187–196 90. Burke KE (2005) Nutritional antioxidants. In: Draelos ZD (ed) Procedures in cosmetic dermatology series: cosmeceuticals, 1st edn. Elsevier, Philadelphia, PA, pp 125–132 91. Farris PK (2005) Topical vitamin C: a useful agent for treating photoaging and other dermatologic conditions. Dermatol Surg 31(7 Pt 2):814–818 92. Pinnell SR, Yang HS, Omar M, Omar M, Monteiro-Riviere N, DeBuys HV, Walker LC, Wang Y, Levine M (2001) Topical L-ascorbic acid: percutaneous absorption studies. Dermatol Surg 27(2):137–142 93. Heber GK, Markovic B, Hayes A (2006) An immunohistological study of anhydrous topical ascorbic acid compositions on ex vivo human skin. J Cosmet Dermatol 5(2): 150–156 94. Traikovich SS (1999) Use of topical ascorbic acid and its effects on photodamaged skin topography. Arch Otolaryngol Head Neck Surg 125(10):1091–1098 95. Glutathione, reduced (GSH) (2001) Monograph. Altern Med Rev 6(6):601–607 96. Chan AC (1993) Partners in defense, vitamin E and vitamin C. Can J Physiol Pharmacol 71(9):725–731 97. Montenegro L, Bonina F, Rigano L, Giogilli S, Sirigu S (2007) Protective effect evaluation of free radical scavengers on UVB induced human cutaneous erythema by skin reflectance spectrophotometry. Int J Cosmet Sci 17:91–103 98. Kang S (2005) Mechanism of action of retinol. J Cosmet Dermatol 18:6–8 99. Varani J, Warner RL, Gharaee-Kermani M, Phan SH, Kang S, Chung J, Wang Z, Datta SC, Fisher GJ, Voorhees JJ (2000) Vitamin A antagonizes decreased cell growth and elevated collagen-degrading matrix metalloproteinases and stimulates collagen accumulation in naturally aged human skin. J Invest Dermatol 114:480–486 100. Riwcciarelli R, Maroni P, Ozer N, Zingg JM, Azzi A (1999) Age-dependent increase of collagenase expression can be reduced by a-tocopherol via protein kinase C inhibition. Free Radic Biol Med 27(7–8):729–737 101. Ahn KS, Sethi G, Krishnan K, Aggarwal BB (2007) Gamma-tocotrienol inhibits nuclear factor-kB signaling pathway through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis. J Biol Chem 282(1):809–820
8 Cosmeceutical Treatment of the Aging Face 102. Davis RH, Rosenthal KY, Cesario LR, Rouw GA (1989) Processed Aloe vera administered topically inhibits inflammation. J Am Podiatr Med Assoc 79(8):395–397 103. Klein AD, Penneys NS (1988) Aloe vera. J Am Acad Dermatol 18(4 Pt 1):714–720 104. Barrantes E, Guinea M (2003) Inhibition of collagenase and metalloproteinases by aloins and aloe gel. Life Sci 72(7):843–850 105. Kim SY, Kim SJ, Lee JY, Kim WG, Park WS, Sim YC, Lee SJ (2004) Protective effects of dietary soy isoflavones against UV-induced skin-aging in hairless mouse model. J Am Coll Nutr 23(2):157–162 106. Shao ZM, Wu J, Shen ZZ, Barsky SH (1998) Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res 58(21):4851–4857 107. Woo JH, Lim JH, Kim YH, Suh SI, Min DS, Chang JS, Lee YH, Park JW, Kwon TK (2004) Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC signal transduction. Oncogene 23(10):1845–1853 108. Wertz K, Hunziker PB, Seifert N, Riss G, Neeb M, Steiner G, Hunziker W, Goralczyk R (2005) Beta-Carotene interferes with ultraviolet light a-induced gene expression by multiple pathways. J Invest Dermatol 124(2):428–434 109. Ahmed S, Wang N, Lalonde M, Goldberg VM, Haqqi TM (2004) Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes. J Pharmacol Exp Ther 308(2):767–773 110. Song XZ, Xia JP, Bi ZG (2004) Effects of (−)-epigallocatechin-3-gallate on expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in fibroblasts irradiated with ultraviolet A. Chin Med J 117(12):1838–1841 111. Nusgens BV, Humbert P, Rougier A, Colige AC, Haftek M, Lambert CA, Richard A, Creidi P, Lapière CM (2001) Topically applied vitamin C enhances the mRNA level of collagens I and III, their processing enzymes and tissue inhibitor of matrix metalloproteinase 1 in the human dermis. J Invest Dermatol 116(6):853–859 112. Dreher F, Denig N, Gabard B, Schwindt DA, Maibach HI (1999) Effect of topical antioxidants on UV-induced erythema formation when administered after exposure. Dermatology 198(1):52–55 113. Kang S, Duell EA, Fisher GJ, Datta SC, Wang ZQ, Reddy AP, Tavakkol A, Yi JY, Griffiths CE, Elder JT et al (1995) Application of retinol to human skin In vivo induces epidermal hyperplasia and cellular retinoid binding proteins characteristic of retinoic acid but without measurable retinoic acid levels or irritation. J Invest Darmatol 105(4):549–556 114. Draelos ZD (2005) Retinoids in cosmetics. J Cosmet Dermatol 18:3–5 115. Stratigos AJ, Katsambas AD (2005) The role of topical retinoids in the treatment of photoaging. Drugs 65(8): 1061–1072 116. Blanes-Mira C, Clemente J, Jodas G, Gil A, FernándezBallester G, Ponsati B, Gutierrez L, Pérez-Payá E, FerrerMontiel A (2002) A synthetic hexapeptide (argireline) with antiwrinkle activity. Int J Cosmet Sci 24(5):303–310 117. Lupo MP, Cole AL (2007) Cosmeceutical peptides. Dermatol Ther 20(5):343–349
83 118. Katayama K, Armendariz-Borunda J, Raghow R, Kang AH, Seyer JM (1993) A pentapeptide from type I procollagen promotes extracellular matrix production. J Biol Chem 268(14):9941–9944 119. Robinet A, Fahem A, Cauchard JH, Huet E, Vincent L, Lorimier S, Antonicelli F, Soria C, Crepin M, Hornebeck W, Bellon G (2005) Elastin-derived peptides enhance angiogenesis by promoting endothelial cell migration and tubulogenesis through upregulation of MT1-MMP. J Cell Sci 118(pt 2):343–356 120. Ghersetich I, Lotti T, Campanile G, Grappone C, Dini G (1994) Hyaluronic acid in cutaneous intrinsic aging. Int J Dermatol 33(2):119–122 121. Grove GL, Klingman AM (1983) Age-associated changes in human epidermal cell renewal. J Gerontol 38(2):137–142 122. Grunewald AM, Gloor M, Gehring W, Kleesz P (1995) Damage to the skin by repetitive washing. Contact Dermat 32(4):225–232 123. Kligman AM (1979) Perspectives and problems in cutaneous gerontology. J Invest Dermatol 73(1):39–46 124. Moloney SJ, Edmonds SH, Giddens LD, Learn DB (1992) The hairless mouse model of photoaging: evaluation of the relationship between dermal elastin, collagen, skin thickness and wrinkles. Photochem Photobiol 56(4):505–511 125. Kligman LH (1989) Photoaging: manifestations, prevention, and treatment. Clin Geriatr Med 5(1):235–251 126. Bernstein EF, Chen YQ, Tamai K, Tamai K, Shepley KJ, Resnik KS, Zhang H, Tuan R, Mauviel A, Uitto J (1994) Enhanced elastin and fibrillin gene expression in chronically photoaged skin. J Invest Dermatol 103(2):182–186 127. Wang X (1999) A theory for the mechanism of action of the a-hydroxy acids applied to the skin. Med Hypotheses 53(5):380–382 128. Brody HJ (1992) Superficial peeling. In: Brody HJ (ed) Chemical peeling and resurfacing, 2nd edn. Mosby-Year Book, Inc., St. Louis, pp 73–108 129. Effendy I, Kwangsukstith C, Lee JY, Maibach HI (1995) Functional changes in human stratum corneum induced by topical glycolic acid: comparison with all-trans retinoic acid. Acta Derm Venereol 75(6):455–458 130. Orth DS, Kabara JJ, Denyer Stephen P, Tan SK (2005) Cosmetic and drug microbiology. Informa Healthcare, New York, pp 163–184 131. Leyden JJ, Rawlings AV (2002) Skin moisturization. Marcel Dekker, Inc, New York, pp 323–352 132. Helms RA, Quan DJ (2006) Textbook of therapeutics: drug and disease management, 8th edn. Lippincott Williams & Wilkins, Philadelphia, pp 203–256 133. Bernstein EF, Underhill CB, Lakkakorpi J, Ditre CM, Uitto J, Yu RJ, Scott EV (1997) Citric acid increases viable epidermal thickness and glycosaminoglycan content of sun-damaged skin. Dermatol Surg 23(8):659–694 134. Draelos ZD (2000) Therapeutic moisturizers. Dermatol Clin 18(4):597–607 135. Bhat SV, Nagasampagi BA, Suvakumar M (2005) Mucopolysaccharides. In: Bhat SV, Nagasampagi BA, Suvakumar M (eds) Chemistry of natural products. Narosa Publishing House, New Delhi, pp 523–524 136. Takahashi M, Yamada M, Machida Y (1984) A new method to evaluate the softening effect of cosmetic ingredients on the skin. J Soc Cosmet Chem 35:171–181
84 137. Gesslein B (1999) Humectants in personal care formulation: a practical guide. In: Schueller R, Romanowski P (eds) Conditioning agents for hair and skin, vol 21, Cosmetic science and technology series. Marcel Dekker, Inc, New York, NY, pp 95–110 138. Marshall C (2002) The use of honey in wound care: a review article. Br J Podiatry 5:47–49 139. Biswal BM, Zakaria A, Ahmad NM (2003) Topical application of honey in the management of radiation mucositis. a preliminary study. Support Care Cancer 11(4): 242–248 140. Hara-Chikuma M, Verkman AS (2005) Aquaporin-3 functions as a glycerol transporter in mammalian skin. Biol Cell 97(7):479–496 141. Draelos ZD (2008) New channels for old cosmeceuticals: aquaporin modulation. J Cosmet Derm 7(2):83 142. Fluhr JW, Cavallotti C, Berardesca E (2008) Emollients, moisturizers, and keratolytic agents in psoriasis. Clin Dermatol 26(4):380–386 143. Kraft JN, Lynde CW (2005) Moisturizers: what they are and a practical approach to product selection. Skin Ther Lett 10(5):1–8 144. Krivda MS (2004) Making the choice. Skin & Aging 12(6). http://www.skinandaging.com/article/2766. Accessed 6/11/10 145. Fluhr J, Holleran WM, Berardesca E (2002) Clinical effects of emollients on skin. In: Leyden JJ, Rawlings AV (eds) Cosmetic science and technology series: skin moisturization. Marcel Dekker, Inc., New York, pp 223–243 146. Eaglstein WH (2001) Moist wound healing with occlusive dressings: a clinical focus. Dermatol Surg 27(2): 175–182 147. Schlossman ML, McCarthy JP (1979) Lanolin and derivatives chemistry: relationship to allergic contact dermatitis. Contact Dermat 5(2):65–72 148. Giorgini S, Melli MC, Sertoli A (1983) Comments on the allergenic activity of lanolin. Contact Dermat 9(5):425–426 149. Draelos ZK (1995) Patient compliance: enhancing clinician abilities and strategies. J Am Acad Dermatol 32(5 Pt 3):S42–S48 150. Ezema DO, Ozoiko ZO (1992) Butyrospermum lipids as an ointment base. Pharm Biol 30:117–123 151. Gehring W (2004) Nicotinic acid/niacinamide and the skin. J Cosmet Dermatol 3(2):88–93 152. Horrobin DF (1989) Essential fatty acids in clinical dermatology. J Am Acad Dermatol 20(6):1045–1053 153. Takema Y, Yorimoto Y, Kawai M, Imokawa G (1994) Agerelated changes in the elastic properties and thickness of human facial skin. Br J Dermatol 131(5):641–648 154. Glogau RG (1997) Physiologic and structural changes associated with aging skin. Dermatol Clin 15(4): 555–559 155. Chung JH, Eun HC (2007) Angiogenesis in skin aging and photoaging. J Dermatol 34(9):593–600 156. Lotti T, Thiers BH (2007) Dermatologic clinics. Pigmentary disorders, vol 25(3). Elsevier Saunders, Philadelphia 157. Ortonne J, Bissett DL (2008) Latest insights into skin hyperpigmentation. J Investig Dermatol Symp Proc 13(1):10–14 158. Whiteman DC, Parsons PG, Green AC (1999) Determinants of melanocyte density in adult human skin. Arch Dermatol Res 291(9):511–516
J. Linder 159. Tadokoro T, Itami S, Hosokawa K, Terashi H, Takayasu S (1997) Human genital melanocytes as androgen target cells. J Invest Dermatol 109(4):513–517 160. Picardo M, Carrera M (2007) New and experimental treatments of cloasma and other hypermelanoses. Dermatol Clin 25(3):353–362 161. Badreshia-Bansal S, Draelos ZD (2007) Insight into skin lightening cosmeceuticals for women of color. J Drugs Dermatol 6(1):32–39 162. Bennett S, Chaudhuri RK, Closs B, Draelos ZD, Loiseau A, Maibach HI et al (2006) Anti-aging: physiology to formulation. Allured Publishing Corporation, IL 163. Arndt KA, Fitzpatrick TB (1965) Topical use of hydroquinone as a depigmenting agent. J Am Med Assoc 194(9):965–967 164. Kim YM, Yun J, Lee CK, Lee H, Min KR, Kim Y (2002) Oxyresveratrol and hydroxystilbene compounds: inhibitory effect on tyrosinase and mechanism of action. J Biol Chem 277(18):16340–16344 165. James AJ (2006) “Skin Lightening and Depigmenting Agents” emedicine from WebMD. http://www.emedicine. com/derm/topic528.htm 166. Zhu WY, Zhang RZ (2006) Skin care skin lightening agents. In: Draelos ZD, Thaman L (eds) Cosmetic formulation of products. Taylor and Francis Group LLC, New York, pp 205–218 167. Ando S, Suemoto Y, Mishima Y, Suemoto Y, Mishima Y (1993) Tyrosinase gene transcription and its control by melanogenic inhibitors. J Invest Dermatol 100(2 suppl): 150s–155s 168. Rendon MI, Gaviria JI (2005) Review of skin lightening agents. Dermatol Surg 31(7 Pt 2):886–890 169. Fitton A, Goa KL (1991) Azelaic acid. a review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary disorders. Drugs 41(5):780–798 170. Maeda K, Fukuda M (1996) Arbutin: mechanism of its depigmenting action in human melanocyte culture. J Pharmacol Exp Ther 276(2):265–269 171. SymRise AG (2007) Symwhite product information. Frankfurt, Germany 172. Katagtri T, Okubo T, Oyobikawa M, Futaki K, Shaku M, Kawai M (1998) Novel melanogenic enzymes inhibitor for controlling hyperpigmentation. 20th IFSCC International Congress 1:1–11 173. Seppic SA (2003) Sepiwhite product information. Paris, France 174. Katoulis AC, Alevizou A, Bozi E, Makris M, Zafeiraki A, Mantas N, Kousta F, Mistidou M, Kanelleas A, Stavrianeas NG (2009) A randomized double-blind vehicle-controlled study of a preparation containing undecylenoyl phenylalanine 2% in the treatment of solar lentigines. Clin Exp Dermatol 4:69–72 175. Bissett DL, Robinson LR, Raleigh PS, Miyamoto K, Hakozaki T, Li J, Kelm GR (2009) Reduction in the appearance of facial hyperpigmentation by topical N-undecyl-10enoyl-L-phenylalanine and its combination with niacinamide. J Cosmet Dermatol 8(4):260–266 176. Diffey BL, Tanner PR, Matts PJ, Nash JF. In vitro assessment of the broad-spectrum ultraviolet protection of sunscreen products. J Am Acad Dermatol. 2000;43: 1024–1035
Part III Cutaneous Procedures
9
Local Regional Anesthesia Peter M. Prendergast
9.1 Introduction As less invasive, ambulatory aesthetic procedures have become more popular over the last decade, so too has the use of local and regional anesthesia. Using nerve blocks, procedures such as injectable lip enhancement, facial contouring, laser skin resurfacing, chemical peels, suture lifts, and autologous fat transfer can be performed painlessly without general anesthesia, oral, or intravenous sedation. As well as obvious benefits to the patient by avoiding unnecessary general anesthesia or sedation, nerve blocks are quick, reliable, and safe, and may obviate the need for extensive infiltrative anesthesia. The learning curve for basic nerve block techniques is short. Once mastered, they afford the physician and surgeon the opportunity to provide a comprehensive range of facial procedures in an officebased setting. The first step in performing accurate nerve block technique is to study the anatomy of the sensory nerves, the foramina from which they arise, and their relationship to surrounding and underlying structures (Fig. 9.1). The sensory innervation of the face is via the three divisions of the trigeminal nerve: ophthalmic, maxillary, and mandibular nerves (Fig. 9.2). Regional anesthesia in the face is achieved by blocking these nerves and their branches and allows most injectable, minimally invasive, and laser resurfacing procedures to be performed easily and without pain or discomfort for
P.M. Prendergast Venus Medical, Heritage House, Dundrum Office Park, Dublin 14, Ireland e-mail:
[email protected]
the patient. There are several advantages for using nerve blocks in aesthetic medicine (Table 9.1). They allow large areas to be anesthetized without infiltrating the entire treatment area. This is particularly relevant for full-face treatments such as laser skin resurfacing. Regional nerve blocks typically require less anesthetic solution and produce less local distortion of tissues than local infiltrative anesthesia and are preferred for soft tissue augmentation using fillers where a careful assessment of the volume and architecture of the tissues is required during the procedure. Injecting smaller volumes of anesthetic around main nerve branches, compared to local infiltrative anesthesia using larger volumes, may reduce the chance of lignocaine toxicity, particularly if epinephrine is used. This chapter describes nerve block techniques for the commonly performed procedures in aesthetic medicine described in this book. These include blocks of the sensory nerves of the face, wrist block, and ankle block. Although the techniques are straightforward, a thorough knowledge of the anatomy of the nerves and their location in relation to bony landmarks is essential. It is important also to keep in mind that anatomic variations exist, such as the presence of multiple foramina for a single named nerve [1]. In the face, the ophthalmic nerve supplies the forehead, upper eyelid, and dorsum of the nose via the supraorbital, supratrochlear, infratrochlear, and external nasal nerves. The maxillary nerve supplies the lower eyelid, cheek, upper lip, ala of the nose, and part of the temple through the infraorbital, zygomaticofacial, and zygomaticotemporal nerves. The sensory fibers of the mandibular nerve supply the skin over the mandible, lower cheek, part of the temple and ear, and the lower lip through the buccal and auriculotemporal nerves. The greater auricular
P.M. Prendergast and M.A. Shiffman (eds.), Aesthetic Medicine, DOI 10.1007/978-3-642-20113-4_9, © Springer-Verlag Berlin Heidelberg 2011
87
88
P.M. Prendergast
a
b
Fig. 9.2 Sensory innervation of the face. The trigeminal nerve (Cranial nerve V) has three main branches: ophthalmic division (V1), maxillary division (V2), and mandibular division (V3)
nerve, derived from the primary rami of the second and third cervical nerves, innervates the angle of the mandible. Nerve blocks of the median, ulnar, and radial nerves anesthetize the skin of the hand and allow injectable procedures to be performed on the sensitive palmar surface without pain. An ankle block allows similar injections on the plantar surface of the foot. Nerve blocks can also be used in conjunction with infiltrative local anesthesia where procedures are more vigorous or extensive such as suture facelift techniques or autologous fat grafting.
9.2 Indications Fig. 9.1 (a) Frontal view. (b) Lateral view of skull showing foramina and location of sensory nerves where they are blocked: (1) Supraorbital notch. (2) Supratrochlear notch. (3) Infratrochlear notch. (4) Site of dorsal nasal nerve. (5) Infraorbital foramen. (6) Zygomaticofacial foramen. (7) Mental foramen. (8) Separate foramen of deep branch of supraorbital nerve. (9) Site of zygomaticotemporal nerve. (10) Mandibular nerve posterior to lateral pterygoid plate (marked X)
There are numerous indications for regional nerve blocks in the face in aesthetic medicine (Table 9.2). An infraorbital nerve block allows painless injection of filler below the eye in the tear trough area and along the nasolabial fold. To anesthetize the malar and anterior cheek area, a combined infraorbital and zygomaticofacial nerve block is used. In the authors view, lip enhancement with
9 Local Regional Anesthesia
89
Table 9.1 Advantages of nerve blocks in aesthetic medicine Small volumes sufficient to anesthetize large areas Injection sites distant to treatment areas avoid tissue distortion Anesthesia of the entire face is achieved using multiple facial blocks Avoid general anesthesia and sedation where invasive treatments are performed Quick onset of local anesthesia (5–10 min) Safe and reliable with correct technique Table 9.2 Indications for nerve blocks in aesthetic medicine Indication Lip enhancement Cheek enhancement Nose contouring Augmentation of tear trough Laser skin resurfacing (full face)
Chin enhancement Botulinum toxin for palmar hyperhidrosis Botulinum toxin for plantar hyperhidrosis
Nerve block Infraorbital, mental Infraorbital, zygomaticofacial Infraorbital, dorsal nasal Infraorbital, zygomaticofacial Supraorbital, supratrochlear, infratrochlear, infraorbital, zygomaticofacial, zygomaticotemporal, mandibular, mental Mental plus mylohyoid augmentation Median, ulnar, radial Posterior tibial, sural, saphenous
hyaluronic acid injections into the vermilion border and body of the lip should not be performed without nerve blocks. Topical anesthesia only for the lips provides insufficient pain relief, whereas infiltrative local anesthesia can distort the tissues and interfere with the assessment of a satisfactory aesthetic outcome. Infraorbital and mental nerve blocks allow painless injections into the lips within seconds. Complementary injections into the frenulum of the upper and lower lips are sometimes required to ensure complete anesthesia of the central portion of the lips. Occasionally, fillers are used to define or shape the tip of the nose. Blocking the dorsal nasal nerve makes these otherwise painful injections completely tolerable. Collagen stimulating and panfacial volumizing procedures such as those using poly-L-lactic acid are best performed following multiple nerve blocks, including infraorbital, mental, zygomaticofacial, zygomaticotemporal, buccal, and auriculotemporal nerve blocks. For laser skin resurfacing, these blocks, as well as blocks to the supraorbital, supratrochlear, and
infratrochlear nerves, provide anesthesia to the entire face. Augmentation of facial features using autologous fat employs similar anesthesia with multiple regional nerve blocks. The injection of botulinum toxin into the palms of the hands for palmar hyperhidrosis is a painful procedure unless a wrist block is performed. For plantar hyperhidrosis, an ankle block allows injections of botulinum toxin into the sole of the foot without the need for additional anesthesia.
9.3 Materials In current practice, the amide local anesthetics are most commonly used because they are stable in solution and rarely produce hypersensitivity reactions. They include lignocaine, prilocaine, mepivacaine, and bupivacaine, and act by blocking sodium channels in the nerve cell membrane (Table 9.3). This depolarization prevents the development of an action potential and blocks nerve impulses. Although equal success can be achieved with most of these agents [2], the author uses lignocaine, with or without epinephrine, almost exclusively. Lignocaine is excellent for minor nerve blockade and is presented as a dilute solution in 0.5, 1.0, 1.5, and 2% concentrations. The addition of epinephrine results in local vasoconstriction that reduces the systemic absorption of the anesthetic, improves the quality of the block, and prolongs the duration of anesthesia. A sufficient epinephrine concentration to achieve these effects is 5 mg/mL, or a concentration in solution of 1:200,000 [3]. Although guidelines exist for the maximum recommended dosages of local anesthetic agents, both with and without epinephrine, the evidence to support the guidelines is lacking [4]. Calculating maximum dosages of local anesthesia should take into account the location of the nerve block, age of the patient, medications, and any concurrent illness. The rate of absorption and peak plasma concentration of local anesthetic depends on the location of the block and especially on the vascularity of the tissues [5]. A reduction in 10–20% should be made for the maximum dosage in elderly patients or those with renal, hepatic, or cardiac dysfunction. Local anesthetic with epinephrine should never be used for blocks where there are end-arteries, such as the nose, fingers, or penis, where intense vasoconstriction could compromise perfusion and lead to ischemia or necrosis. For the nerve blocks described in this chapter, the following materials are required (Fig. 9.3):
90
P.M. Prendergast
Table 9.3 Properties and dosage guidelines of amide local anesthetic agents Agent Lignocaine
Duration of actiona (min) 30–60
Prilocaine
30–90
Mepivacaine Bupivacaine
50–90 120–240
Maximum dosageb 4.5 mg/kg without epinephrine or max 300 mg 7 mg/kg with epinephrine 500 mg without epinephrine 600 mg with epinephrine 7 mg/kg or max 400 mg 2.5 mg/kg or max 175 mg without epinephrine 225 mg with epinephrine
Duration of action without epinephrine Dosage should be reduced in presence of chronic or acute illness, in the elderly and pediatric population, and in patients with renal, liver, and cardiovascular disease
a
b
Fig. 9.3 Materials required for minor nerve blocks
1 . Syringes: 3 mL and 5 mL 2. Needles: 30 gauge, 27 gauge, 25 gauge 3. Needle: 22 gauge spinal 4. Lignocaine 1–2% plain 5. Lignocaine 1–2% with 1:200,000 epinephrine 6. Sodium chloride for injection (for dilution if necessary) 7. Sterile gauze 8. Isopropyl alcohol pads
9.4 Anatomy and Technique 9.4.1 Infraorbital Nerve (Fig. 9.4) The infraorbital nerve is the largest cutaneous branch of the maxillary nerve. It emerges onto the face at the infraorbital foramen, along a vertical line between the pupil and medial limbus, about 7 and 6 mm below the inferior orbital rim in men and women, respectively. The foramen
9 Local Regional Anesthesia
a
91
opens downward and medially, so the most accurate nerve block approach is from below and medially, either intraorally or percutaneously [6]. For the intraoral approach, a 27- or 30-gauge needle is passed through the vestibule between the canine and first premolar, aiming the needle toward the infraorbital foramen. The index finger of the non-injecting hand rests on the inferior orbital rim to prevent inadvertent passage of the needle beyond the rim. About 1.5 mL of anesthetic is injected around the foramen. The anesthetized area includes the lower eyelid, side of the nose, medial cheek, and upper lip. Alternatively, the nerve can be approached through the skin by injecting between the ala of the nose and the upper part of the nasolabial fold, directing the needle toward the infraorbital foramen.
9.4.2 Dorsal Nasal Nerve (Fig. 9.5)
b
This nerve represents one or more dorsal branches of the ethmoid nerve. It passes under the nasal bone about 6 to 9 mm from the midline and passes under the nasalis muscle toward the tip of the nose [7]. The dorsal nasal nerve supplies sensory innervation to the tip of the nose via its 1–3 branches. The block is made at the level of the periosteum at the junction of the nasal and cartilaginous parts of the nose on either side of the midline.
9.4.3 Mental Nerve (Fig. 9.6)
c
The mental nerve arises from the inferior alveolar nerve, a branch of the mandibular nerve, and exits the mental foramen between the apices of the lower premolar teeth, usually in line vertically with the infraorbital foramen, although it is sometimes slightly anterior or posterior to this position [8]. It usually exists as several fascicles that are visible or palpable through stretched oral mucosa. The mental nerve supplies skin over the lower lip and
Fig. 9.4 Infraorbital nerve block. (a) The nerve (dot) emerges below the inferior orbital rim and supplies the shaded area. (b) Percutaneous approach to the nerve from below and medially. The entry point is between the ala of the nose and the nasolabial fold. Note the finger protecting the orbit along the orbital rim. (c) More commonly performed intraoral approach. The needle enters the vestibule between the canine and first premolar (red dot) and aims toward the infraorbital foramen
92
a
P.M. Prendergast
a
b b
Fig. 9.5 Dorsal nasal nerve block. (a) Location of nerve (dot) on either side of the midline as it emerges from underneath the nasalis muscle and supplies the tip of the nose (shaded). (b) The nerve block is performed by injecting at the junction of the nasal bone and cartilage on either side of the midline
chin. Occasionally, a branch of the mylohyoid nerve innervates the central chin pad. To block the mental nerve, 1 ml of anesthetic is injected just under the mucosa between the premolars or around the nerve fibers if they are visible. Reaching the nerve percutaneously is also
Fig. 9.6 Mental nerve block. (a) Nerve location (dot) as it emerges from its foramen on the mandible and area of the chin and lower lip it innervates (shaded). (b) The nerve is approached intraorally by injecting under the mucosa at the root of the second premolar tooth
9 Local Regional Anesthesia
possible but is not frequently performed and may be more painful [9]. To anesthetize the central part of the chin, this block is augmented by injecting a further 2–3 mL preperitoneally over the mental protuberance using a 27-gauge 1.5-in. needle.
93
a
9.4.4 Supraorbital, Supratrochlear, Infratrochlear Nerves (Fig. 9.7) The supraorbital nerve emerges from the orbit at the supraorbital notch (or foramen) 2.3–2.7 cm from the midline in men and 2.2–2.5 cm from the midline in women [10]. The nerve has superficial and deep branches. The superficial branch passes through the corrugator and frontalis muscles to innervate most of the forehead over the eyebrows and the anterior scalp. Sometimes the deep branch arises from a separate foramen up to 1 cm above the orbital rim and as far as 3–4 cm lateral to the medial branch. The deep branch usually runs superiorly between the galea and the periosteum of the forehead 0.5–1.5 cm medial to the superior temporal crest line. The supratrochlear nerve arises about 1 cm medial to the supraorbital nerve at the orbital rim and branches to supply the skin over the medial lower forehead and medial eyelid. The infratrochlear nerve arises medial and inferior to the supratrochlear nerve and supplies a small area of skin on the medial aspect of the upper eyelid and bridge of the nose. All three nerves can be blocked together. A 1.5-in. needle is passed from a point just lateral to the midline in the brow, along the orbital rim until the needle touches the nasal bone medially. The index finger of the noninjecting hand protects the globe. About 2 mL of local anesthetic is injected as the needle is withdrawn. Immediately after the needle exits, firm pressure is placed over the orbital rim with gauze to minimize bleeding and ecchymosis. A second horizontal injection is made under the frontalis muscle about 1 cm above the orbital rim to block a separate deep branch of the supraorbital nerve.
Fig. 9.7 Supraorbital, supratrochlear, and infratrochlear nerve blocks. (a) The sites of the foramina or notches from which the nerves appear on the face are represented by dots along the brow. From medial to lateral, the infratrochlear, supratrochlear, and supraorbital nerves innervate the shaded area. (b) The three nerves are blocked by passing the needle along the rim from the middle of the brow as far as the nasal bone and injecting on the way out. Note the finger protects the globe. (c) A second injection is made under the frontalis 1 cm above the brow to block an aberrant deep branch of the supraorbital nerve
b
c
94
9.4.5 Zygomaticofacial Nerve (Fig. 9.8)
P.M. Prendergast
a
The zygomaticofacial nerve exits its foramen just below and lateral to the junction of the inferior and lateral orbital rim. It provides sensory innervation to the skin over the malar eminence. The nerve is blocked by injecting 1–2 mL of anesthetic on the periosteum at the estimated location of the foramen just inferolateral to the bony rim.
9.4.6 Zygomaticotemporal Nerve (Fig. 9.9) The zygomaticotemporal nerve arises from its foramen behind the posterior aspect of the lateral orbital rim just above the point where the zygomatic arch meets the lateral orbital rim. It innervates the temple area. To block this nerve, the needle enters the skin behind the lateral orbital rim about 10–12 mm behind and just below the palpable zygomaticofrontal suture and passes deeply until it hits the posterior part of the orbital rim. The needle is slid down the posterior part of the rim to a point about 1 cm below the level of the lateral canthus near the zygomatic arch. On withdrawal, 2 mL are injected behind the lateral orbital rim where the nerve arises from its foramen [11]. b
9.4.7 Mandibular Nerve (Fig. 9.10) For procedures requiring anesthesia of the entire face, blocking the mandibular nerve proximally is beneficial because the buccal and auriculotemporal nerves innervate parts of the cheek and temple not covered by the nerves described above. The mandibular nerve passes about 1 cm posterior to the pterygoid plate, deep to the lateral pterygoid muscle. To block the nerve, first mark the location of the sigmoid notch, the depression below the zygomatic arch between the coronoid process and condyle of the mandible. Pass a 1.5-in. 27-gauge needle perpendicularly to infiltrate the skin first, and then continue through the fascia and masseter until the needle hits the lateral pterygoid plate. Remove the needle and pass a 22-gauge spinal needle attached to a 5 mL syringe in the same
Fig. 9.8 Zygomaticofacial nerve block. (a) The position of the zygomaticofacial nerve (dot) is shown just inferolateral to the lateral part of the inferior orbital rim. It innervates the skin over the zygomatic bone and arch (shaded). (b) The nerve block is easily performed by injecting on the periosteum over the foramen, while the non-injecting hand feels for the rim
9 Local Regional Anesthesia
a
95
way until it tips the pterygoid plate. Use the plastic guard on the needle to mark the depth of the needle in this location. Then withdraw the needle partly and redirect it about 1 cm posteriorly until it reaches the depth marked on the needle. Advance the needle a few millimeters further, aspirate, and inject about 4 mL of anesthetic. This blocks the buccal and auriculotemporal nerves and anesthetizes the lateral part of the face and temple.
9.4.8 Greater Auricular Nerve (Fig. 9.11)
b
The greater auricular nerve arises from the anterior primary rami of the second and third cervical nerves. It pierces the deep cervical fascia at the posterior border of sternocleidomastoid and runs on the muscle toward the angle of the jaw. Below the ear it divides into anterior and posterior branches and innervates the skin of the inferior part of the ear, the area below the ear, and the angle of the jaw. The nerve can be blocked at its location 6.5 cm inferior to the external acoustic meatus, midway between the anterior and posterior borders of sternocleidomastoid. About 2 mL of anesthetic is injected on the muscle at this point.
9.4.9 Wrist Block (Fig. 9.12)
Fig. 9.9 Zygomaticotemporal nerve block. (a) The nerve (shown as dot) arises from behind the posterior aspect of the lateral orbital rim near the zygomatic arch and supplies the skin over the temple (shaded). (b) The needle enters just behind and below the zygomaticofrontal suture and passes behind the posterior lateral orbital rim toward the zygomatic arch. Just below the level of the lateral canthus (and behind the lateral orbital rim) 2 mL of local anesthetic are injected as the needle is slowly withdrawn
Nerve blocks to the hand, especially the palmar surface, facilitate the injection of botulinum toxin into the dermis to treat palmar hyperhidrosis. Topical anesthesia only is usually insufficient as injections into the sensitive dermis of the palms are painful. To anesthetize the palmar surface of the hand, the median nerve, ulnar nerve, and radial nerves are blocked. The sensory innervation to the palm of the hand is shown in Fig. 9.12. The median nerve lies just deep to the palmaris longus tendon proximal to the wrist crease and continues under the flexor retinaculum to innervate the palmar surface of the radial three and a half digits and part of the thenar eminence. In about 10% of individuals the palmaris longus tendon is absent. A palmar cutaneous branch of the median nerve arises up to 10 cm proximal to the wrist crease, passes superficially over the retinaculum,
96
P.M. Prendergast
a
b
c
d
Fig. 9.10 Mandibular nerve block. (a) The mandibular nerve (green) lies just posterior to the lateral pterygoid plate (black shaded). The auriculotemporal and buccal branches of the mandibular nerve innervate the skin over the side of the face (yellow shaded). The distribution of the mental nerve is not depicted here. (b) The sigmoid notch is marked between the mandibular condyle and coronoid process which are palpable below the zygomatic arch.
(c) A 1.5-in. 27-gauge needle passed perpendicularly through the center of the notch will reach the lateral pterygoid plate (shaded). Local anesthetic is infiltrated along this tract. (d) A 22-gauge spinal needle is then passed along the same course to the pterygoid plate. The depth on the needle is noted and it is then redirected 1 cm posteriorly to the same depth. In this position, the tip of the needle lies close to the nerve. After aspirating, 4 mL of anesthetic are injected
and innervates the central and proximal part of the palm of the hand. To block the median nerve, a 27-gauge needle is passed under the palmaris longus tendon 3 cm proximal to the distal wrist crease. At a depth of about 1 cm, 3–5 mL of anesthetic without epinephrine is injected slowly, after aspiration to avoid intravascular injection. With all nerve blocks at the wrist, advise the patient to report any “electric shock”-type sensations along the distribution of the nerves. If this occurs, withdraw the needle a few millimeters to avoid intraneural injection. As the needle is withdrawn, inject a further 2 mL subcutaneously to block the palmar branch.
Massage this bleb of anesthetic medially and laterally over the tendon to ensure the nerve is not missed. If the palmaris longus tendon is not present, simply inject deep to the fascia medial to the flexor carpi radialis tendon. If present, the palmaris longus is clearly visible when the thumb is opposed against the little finger and the wrist slightly flexed. The ulnar nerve lies deep and a little to the radial side of the flexor carpi ulnaris tendon. On the palmar surface it supplies sensory innervation to the ulnar one and a half fingers and the hypothenar eminence. To block the nerve, pass the needle just deep to the tendon
9 Local Regional Anesthesia
Fig. 9.11 Greater auricular nerve block. The nerve is found 6.5 cm below the external acoustic meatus in the midpart of sternocleidomastoid. It innervates the lower part of the ear, behind and below the ear, and the angle of the jaw (shaded area). The nerve is blocked by injecting on the fascia of the muscle at its predicted location (dot)
about 3 cm from the distal wrist crease and inject 3–5 mL. If the needle passes into the substance of the tendon, tough resistance will be felt and the needle should be partially withdrawn and redirected. The radial nerve supplies sensation to a small area on the thenar eminence through its superficial branches. It courses alongside the cephalic vein proximal to the anatomical snuff box on the radial side of the forearm and can be felt or rolled on the underlying fascia and bone. To block the radial nerve, a small area around the nerve is isolated with the non-injecting hand and 2–3 mL of anesthetic is injected onto the fascia adjacent to the cephalic vein. The trapped solution bathes the nerve to ensure adequate blockade.
9.4.10 Plantar Block (Fig. 9.13) Blocking the sensory innervation to the sole of the foot is indicated before injections of botulinum toxin for plantar hyperhidrosis. Without nerve blocks, the patient does not easily tolerate the procedure. This technique requires nerve blocks to the posterior tibial, sural, and saphenous nerves. The sensory supply to the sole of the foot is shown in Fig. 9.13. The posterior tibial nerve is found between the medial malleolus and Achilles
97
tendon where it is related to the posterior tibial artery before it divides to form the lateral and medial plantar nerves. To block the posterior tibial nerve, a 25-gauge needle is passed on the medial side of the Achilles tendon at the level of the superior border of the medial malleolus. The needle is advanced until it touches the posterior border of the tibia, then withdrawn 5 mm, and 5 mL of plain lignocaine is injected. The nerve lies just posterior to the posterior tibial artery in this location. The sural nerve runs behind the lateral malleolus to innervate skin over the lateral aspect of the ankle, lateral foot, and a small area on the lateral plantar surface. An injection is made at the level of the superior malleolus on the lateral aspect of the Achilles tendon. The needle is advanced until it reaches the fibula, withdrawn 5 mm, and 5 mL is injected around the nerve. The saphenous nerve runs with the great saphenous vein on the anterior aspect of the medial malleolus. It innervates the medial ankle and a small area on the medial plantar surface of the foot. To block the nerve, injections are made just medial and lateral to the great saphenous vein anterior to the medial malleolus.
9.5 Complications Immediate complications following the injection of local anesthesia include pain, bleeding, hematoma, edema, nerve damage, and adverse drug reactions due to overdosage or allergy [12]. Vasoconstriction occurs when local anesthetic agents with epinephrine are inadvertently injected intravascularly, leading to a range of phenomena from local blanching of tissues and necrosis to transient loss of vision, diplopia, and amaurosis [13–16]. The positive chronotropic effects of epinephrine also result in transient tachycardia that may be uncomfortable for some patients. Systemic toxicity from local anesthesia following nerve blocks is possible if an excessive dosage is used, if the injection site is particularly vascular, or if the threshold for toxicity is lower due to advanced age or a comorbid condition. Systemic toxicity manifests first as central nervous system signs and symptoms, including tremor, twitching, dizziness, circumoral paresthesia, tinnitus, blurred vision, and progresses to convulsions and coma in severe cases. At higher plasma concentrations, cardiovascular toxicity occurs, leading to bradycardia, vasodilatation and
98
a
P.M. Prendergast
b
d
c
e
Fig. 9.12 Wrist block. This requires blocks of the radial, median, and ulnar nerves. (a) Area on the palm innervated by the radial nerve. (b) The radial nerve (green) lies adjacent to the cephalic vein (blue) on the radial side of the forearm and can sometimes be felt if it is rolled against the underlying bone. (c) The non-injecting hand traps the nerve between two fingers proximal to the anatomical snuff box as the injection is made on the fascia. (d) Palmar surface innervated by the median nerve. (e) The visible flexor carpi radialis proximal to the wrist crease (marked) as the wrist is flexed against resistance. The palmaris longus tendon is absent in this patient (as it is in 10% of the population). When present, the median nerve is located deep to the palmaris longus tendon. If the tendon is absent, the nerve can be predicted to lie on the ulnar side of the flexor carpi radialis.
f
(f) The block is made 3 cm proximal to the wrist crease by injecting 1 cm deep, after aspirating. (g) In this patient, the palmaris longus tendon is clearly visible when the thumb is opposed. In 90% of the population, where the tendon is present, the median nerve is found deep to the tendon 3 cm proximal to the wrist crease where it can be blocked by passing a needle at 45° about 1 cm under the tendon. (h) A palmar cutaneous branch of the median nerve (green) arises up to 10 cm proximal to the wrist crease and supplies an area on the proximal part of the palm (shaded). This nerve is blocked by injecting 3 mL subcutaneously over the site of the median nerve. (i) Sensory innervation of the ulnar nerve on the palm. (j) The nerve is blocked by injecting 3 cm proximal to the wrist crease, deep to and slightly radial to the flexor carpi ulnaris tendon
9 Local Regional Anesthesia
99
g
h
i
j
Fig. 9.12 (continued)
hypotension, arrhythmias and even asystole. Severe acute toxicity secondary to local anesthetics is rare if recommended dosages are used. Toxicity should be managed according to the clinical scenario. The airway should be maintained and oxygen delivered as required. Intravenous atropine is appropriate for bradyarrhythmias although volume expansion with colloid may be required if there is hypotension secondary to vasodilatation. In severe cases, epinephrine may be necessary, or cardioversion for cases of ventricular fibrillation.
9.6 Conclusions Nerve block techniques are simple to learn and invaluable to the practitioner of aesthetic medicine. Small or large areas of the face can be anesthetized in
a few minutes allowing most non-surgical and minimally invasive procedures to be performed without the need for adjuvant anesthesia. Successful nerve block requires that a sufficient volume and concentration of local anesthetic surround the regional nerve at its origin or at a site proximal to the area it innervates. However, the maximum dosage should not be exceeded to avoid the risk of toxicity. Complications secondary to nerve blocks are uncommon but can occur if the maximum dosage is exceeded or if the solution is injected intravascularly. Simple measures to ensure safe technique and maximum comfort for the patient include aspiration prior to injection, slow injection of solution at room temperature, use of plain anesthetic without epinephrine for extremities, and protecting the orbit with the non-injecting hand for blocks around the eye.
100
a
P.M. Prendergast
b
d
c
Fig. 9.13 Plantar block. (a) The plantar surface of the foot receives innervation from the posterior tibial nerve, sural nerve, and saphenous nerve: (blue dash) calcaneal branches of posterior tibial nerve; (black dots) medial plantar nerve; (black dash) lateral plantar nerve; (red dash) sural nerve; (green dash) saphenous nerve. (b) Ankle showing the medial malleolus (M), posterior tibial artery and nerve
posterior to the malleolus. (c) The sural nerve is blocked by injecting the needle at the superior level of the lateral malleolus (M), advancing toward the fibula until it is reached. About 5 mL local anesthetic is injected slowly as the needle is withdrawn. (d) The saphenous nerve is blocked by injecting just anterior to the medial malleolus alongside the great saphenous vein
9 Local Regional Anesthesia
References 1. Loukas M, Owens DG, Tubbs RS, Spentzouris G, Elochukwu A, Jordan R (2008) Zygomaticofacial, zygomaticoorbital and zygomaticotemporal foramina: anatomical study. Anat Sci Int 83(2):77–82 2. McClean C, Reader A, Beck M, Meryers WJ (1993) An evaluation of 4% prilocaine and 3% mepivacaine compared with 2% lidocaine (1:100,000 epinephrine) for inferior alveolar nerve block. J Endod 19(3):146–150 3. Scott DB, Jebson PJR, Braid DP, Oertengren B, Frisch P (1972) Factors affecting plasma levels of lignocaine and prilocaine. Br J Anaesth 44(10):1040–1049 4. Rosenberg PH, Veering BT, Urmey WF (2004) Maximum recommended doses of local anesthetics: a multifactorial concept. Reg Anesth Pain Med 29(6):564–575 5. Tucker GT, Mather LE (1988) Absorption and disposition of local anesthetics: pharmacokinetics. In: Cousins MJ, Bridenbaugh PO (eds) Neural blockade in clinical anesthesia and management of pain. Williams & Wilkins, Baltimore, pp 61–63 6. Lynch MT, Syverud SA, Schwab RA, Jenkins JM, Edlich R (1994) Comparison of intraoral and percutaneous approaches for infraorbital nerve block. Acad Emerg Med 1(6): 514–519 7. Zide BM (2006) Nerve blocks 101. In: Zide BM, Jelks GW (eds) Surgical anatomy around the orbit. The system of zones. Lippincott Williams & Wilkins, Philadelphia, p 116
101 8. Haribhakti VV (1996) The dentate adult human mandible: an anatomic basis for surgical decision-making. Plast Reconstr Surg 97(3):536–541 9. Syrverud SA, Jenkins JM, Schwab RA, Lynch MT, Knoop K, Trott A (1994) A comparative study of the percutaneous versus intraoral technique for mental nerve block. Acad Emerg Med 1(6):509–513 10. Zide BM (2006) Supraorbital nerve. Nuances/dissections from above. In: Zide BM, Jelks GW (eds) Surgical anatomy around the orbit. The system of zones. Lippincott Williams & Wilkins, Philadelphia, p 77 11. Zide BM, Swift R (1998) How to block and tackle the face. Plast Reconstr Surg 101(3):840–851 12. Lustig JP, Zusman SP (1999) Immediate complications of local anesthetic administered to 1007 consecutive patients. J Am Dent Assoc 130(4):496–499 13. Blaxter P, Britten M (1967) Transient amaurosis after mandibular nerve block. Br Med J 1(5541):681 14. Webber B, Orlansky H, Lipton C, Stevens M (2001) Complications of an intra-arterial injection from an inferior alveolar nerve block. J Am Dent Assoc 132(12):1702–1704 15. Torrente-Castells E, Gargallo-Albiol J, Rodriguez-Baeza A, Berini-Aytes L, Gay-Escoda C (2008) Necrosis of the skin of the chin: a possible complication of inferior alveolar nerve block injection. J Am Dent Assoc 139(12):1625–1630 16. Choi EH, Seo JY, Jung BY, Park W (2009) Diplopia after inferior alveolar nerve block anesthesia: report of 2 cases and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107(6):e21–e24
Botulinum Toxins
10
Peter M. Prendergast
10.1 Introduction
10.2 History
Botulinum toxin (BTX) is a powerful, naturally occurring exotoxin produced by the anaerobic, spore-forming bacterium, Clostridium botulinum. Although there are seven distinct serotypes (A–G), BTX type A is the most potent in humans and is the most widely used botulinum toxin in clinical and aesthetic medicine. In minute doses, purified BTX-A injected into facial muscles causes temporary chemodenervation. Partial or complete paralysis of selected muscles of facial expression reduces hyperdynamic wrinkles, improves the position or shape of the brow and mouth, and even contours the face. The explosion in popularity of BTX-A treatments over the last two decades is a testament to its safety and efficacy. In the USA, chemodenervation with BTX-A was the number one non-surgical procedure every year since 2000, with a 3,824% increase in the number of BTX-A treatments from 1997 to 2009 [1]. Although the treatment of glabellar frown lines is currently the only approved cosmetic indication for certain preparations of BTX-A, off-label use in muscle groups in the upper face, lower face, and neck yield excellent results with minimal complications in experienced hands. This chapter describes the most effective and appropriate use of botulinum toxin type A in aesthetic medicine for face and neck rejuvenation, and its use in the treatment of hyperhidrosis.
Botulism, derived from “botulus,” the Latin word for sausage, is an intoxication from food poisoning with visual disturbance, nausea, vomiting, dizziness that progresses to a symmetric descending neuroparalysis. Justinus Kerner, a German physician, originally described the symptoms of botulism between 1817 and 1822 but did not identify the pathogen [2]. In 1895, an outbreak of botulism in Ellezelles, Belgium, associated with contaminated smoked ham left 34 people ill and three dead. Van Ermengem at the University of Ghent identified the bacterium responsible as bacillus botulinus. This was later renamed Clostridium botulinum. His studies revealed that the toxin produced by the bacteria is heat-sensitive but quite resistant to alcohol, certain enzymes, and acidic environments [3]. Sommer and Snipe purified the toxin in the early 1920s [4]. In 1946, Shantz identified and isolated botulinum toxin type A, the most potent of the serotypes in humans. Burgen et al. [5] elucidated the physiology and mechanism of action of botulinum toxin. Scott [6] was the first to use the toxin experimentally in animals and showed that it effectively weakened extraocular muscles in monkeys. In 1977, the toxin was used in humans for the same purpose. From this work, protocols were developed for the use of botulinum toxin for the treatment of strabismus. This led to the approval of BTX-A by the Food and Drug Administration (FDA) for the treatment of strabismus in 1989, and for blepharospasm in 1989 [7]. In 1987, Carruthers made the serendipitous discovery that BTX-A injections improve the appearance of frown lines. She was using BTX-A to treat patients with benign essential blepharospasm and noticed that spread
P.M. Prendergast Venus Medical, Heritage House, Dundrum Office Park, Dublin 14, Ireland e-mail:
[email protected]
P.M. Prendergast and M.A. Shiffman (eds.), Aesthetic Medicine, DOI 10.1007/978-3-642-20113-4_10, © Springer-Verlag Berlin Heidelberg 2011
103
104
P.M. Prendergast
Fig. 10.1 Commonly used botulinum toxins
of some of the toxins into the adjacent glabellar muscles improved hyperdynamic wrinkles in this area. Although Clark and Berris published a paper on the use of BTX-A to treat facial asymmetry in 1989 [8], it was Carruthers’ landmark paper in 1992 [9] describing its efficacy in treating frown lines that heralded the modern era of botulinum toxin in aesthetic medicine. In 2003, the FDA approved Botox® (Allergan, CA, USA) for the treatment of glabellar lines. In 2009, FDA approval was also granted for Dysport® (Ipsen, Berkshire, UK), another type A botulinum toxin, for the treatment of glabellar folds.
10.3 Available Botulinum Toxins Several botulinum toxin type A products are available from the USA, the UK, Germany, Korea, and China. Botox and Dysport are the market leaders worldwide and currently the only two type A botulinum toxins approved by the FDA. Their aestheticindication counterparts are Botox Cosmetic and Azzalure, respectively. These products are produced from cultures of Clostridium botulinum that yield the neurotoxin itself surrounded by a protective protein complex. Although the complexes, consisting mostly of hemagglutinins, may vary in mass between products, the neurotoxin itself is identical, consisting of a light chain and a heavy chain (HC) joined by a disulfide bond. The compound is prepared with excipients that include human albumin, then vacuum freeze dried and presented as a white powder in vials for reconstitution with sterile saline before use (Fig. 10.1). Botox and Dysport should be stored at 2–8°C and ideally used within 48 h following reconstitution,
although potency is probably preserved for up to 2 weeks [10]. Botox is presented in vials of 100 U and Dysport in vials of 500 U or 300 U. It is important to understand that the units of Botox and Dysport are not interchangeable [11]. One biological unit (U) of Botox or Dysport is the dose required (LD50) to kill 50% of 20 g Swiss-Webster (CFW®) mice when injected intraperitoneally. However, the effects on mice cannot be extrapolated to other species, so 1 U Botox does not exhibit the same effect in humans as 1 U Dysport. The literature on dose equivalence between Dysport and Botox is confusing, with different authors concluding ratio conversions from 4:1 to 2:1 [12]. In the author’s experience, a conversion of 1 U Botox to 2.5 U Dysport is appropriate for most aesthetic indications. However, if a physician chooses to use both products, experience dictates dosage requirements for satisfactory outcomes rather than simply converting from one to another using a simple and largely unsubstantiated ratio. 1. Azzalure® is adapted from Dysport and branded and marketed by Galderma (Lausanne, Switzerland). The two products are identical in activity and the units are interchangeable. Azzalure is presented in vials of 125 U and approved for glabellar lines. 2. Xeomin® (Merz, Frankfurt, Germany) was introduced to the market in 2005 and is now available throughout Europe presented as 100 U vials. It differs in structure to the other BTX-A products by consisting of the 150 kDa neurotoxin only without the surrounding protein complex [13]. For practical purposes, a conversion ratio of 1:1 between Xeomin and Botox is considered appropriate. 3. Bocouture® is Xeomin’s sister toxin, presented in 50 U vials and licensed for aesthetic use. Inactive
10 Botulinum Toxins
ingredients also differ between products; Botox/ Botox Cosmetic contains sodium chloride. 4. Dysport/Azzalure contains lactose, and Xeomin/ Bocouture contains sucrose. Other products include Neuronox® (Medy-Tox, Seoul, South Korea) and Prosigne® (Lanzhou Institute of Biological Products, China). Although these products are presented as 100 U vials of lyophilized botulinum toxin type A complex and reportedly have 1:1 conversion rates to Botox®, efficacy and safety studies and trials are lacking compared to the market leading products [14].
10.4 Mechanism of Action Botulinum toxin causes a flaccid paralysis of striated muscle by blocking the release of the neurotransmitter acetylcholine at the neuromuscular junction. Normally, an action potential along a nerve terminal stimulates fusion of acetylcholine-containing vesicles with the cell membrane at the synaptic cleft, releasing acetylcholine to act on cholinergic receptors in striated muscle. This fusion is mediated by two groups of SNARE (soluble N-ethylmale imide-sensitive factor attachment protein receptors) proteins: synaptobrevin on the acetylcholine-containing vesicle; syntaxin 1A and SNAP-25 on the plasma membrane at the neuromuscular junction (Fig. 10.2). Any interference with one or more of these proteins prevents formation of the so-called synaptic fusion complex and blocks release of acetylcholine [15]. Most botulinum toxin A products consist of the neurotoxin surrounded by a protective protein complex. The complex is resistant to acidic environments and protects the toxin from the harsh environment of the digestive tract. In tissues with a higher pH, such as subcutaneous, intramuscular, or intravascular compartments, the covalent bonds binding the complex quickly dissociate, releasing the neurotoxin. After injection, the neurotoxin is probably released in less than a minute [16]. BTX-A consists of three 50 kDa segments, designated L, HN, and HC [17]. The HC binds to the cholinergic nerve cell membrane, leading to endocytosis of the toxin into the intracellular compartment. The intermediate chain (HN) facilitates the translocation of the light chain (L) from the vesicle into the cytosol of the nerve. The light chain of BTX-A cleaves the SNAP25 protein at the neuromuscular junction and blocks the neuroexocytosis of acetylcholine into the synaptic cleft (Fig. 10.2). Botulinum toxin type B (Myobloc®)
105
cleaves the vesicle-associated membrane protein (VAMP), synaptobrevin, rather than SNAP-25, but both type A and type B toxins ultimately block the release of acetylcholine leading to temporary paralysis of striated muscle. Clinically, the effects of botulinum toxin injections begin 2–3 days following treatment and are maximal at 10–14 days. After approximately 1 month, new unmyelinated nerve “sprouts” begin to grow from the nerve endings to re-establish functional connections within the motor units. Normal muscular activity slowly returns within 3–4 months. Following repeated injections over several years of treatment, disuse atrophy of denervated muscle may prolong the effects of subsequent treatments, to 6 months or longer in some cases. The release of sweat from eccrine sweat glands is also mediated by acetylcholine. Intradermal injections of BTX-A block this release through the same mechanisms described above and effectively reduce unwanted sweating. This application has led to the treatment of axillary, palmar, and plantar hyperhidrosis with anhidrosis typically lasting longer than the effect of acetylcholine blockade in striated muscle.
10.5 Clinical Effects When botulinum toxin is injected subcutaneously or intramuscularly, it exhibits effects at the injection site and over an area 1–2 cm in diameter around the point of injection. The spread of toxin in the tissues is termed the “action halo.” A number of factors may influence the size of the action halo: manipulation or manual spreading following injection, volume of solution injected, dose, and type of toxin used [18]. Even without forceful or deliberate contraction, the mimetic muscles of the face have a resting tone that determines the position of the tissues they act upon (Fig. 10.3). Frontalis, a brow elevator, works in opposition to the brow depressors, which include procerus, corrugators, and fibers of orbicularis oculi. Unopposed activity of the elevators will therefore elevate the brow (Fig. 10.4). To achieve this, the brow depressors are treated with BTX, whilst preserving frontalis. Similarly, unopposed action of the depressors will drop the brow and forehead. For this reason, treating frontalis alone without the depressors will result in a heavy ptotic brow and should never be performed. Around the mouth, denervating depressor anguli oris results in reduced
106 Fig. 10.2 Mechanism of action of botulinum toxin A. (Left) Normal release of acetylcholine. (Right) Botulinum toxin blocks neuromuscular transmission by cleaving the SNAP-25 component of the synaptic fusion complex. HC heavy chain, LC light chain, Ach acetylcholine
P.M. Prendergast HC
LC
Nerve cell receptor
Endocytosis of botulinum toxin
Translocation of LC
ACh-containing vesicle
Synaptobrevin
SNAP-25 Syntaxin-1A
opposition to the lateral lip elevators (Fig. 10.5). Denervating one part of a muscle with BTX and preserving other fibers of the same muscle also increases the activity of the preserved fibers. For example, treatment of the medial part of frontalis with preservation of the lateral part increases the activity of lateral frontalis and creates a lateral brow lift. An understanding of the dynamics and behavior of the mimetic muscles and their response to chemodenervation allows them to be manipulated to achieve a variety of aesthetic results.
Cleavage
10.6 Anatomy A thorough knowledge of facial anatomy and musculature is necessary for injectable treatment with BTXA. Imprecise injections will at best lead to suboptimal results and at worst to complications such as brow or lid ptosis, mouth asymmetries, or even visual disturbance. The muscles of facial expression are thin, flat muscles that act either as sphincters of facial orifices, as dilators, or as elevators and depressors of the
10 Botulinum Toxins
107
Fig. 10.3 Superior and inferior vectors on the brow and mouth produced by normal resting tone and activity of the facial muscles
Fig. 10.5 Selective denervation of depressor anguli oris produces a reduced opposition to the mouth corner elevators. This activity lifts the mouth corners
Fig. 10.4 Brow elevation is produced by denervating the depressors and sparing the frontalis
e yebrows and mouth (Table 10.1). Many of these muscles are intimately related to or mingle with fibers of the muscles around them. Inadvertent injection or spread of botulinum toxin into the “wrong” muscle can lead to complications. Frontalis, corrugator supercilii, depressor supercilii, procerus, and orbicularis oculi represent the periorbital facial muscles. The perioral muscles include the levator muscles, zygomaticus major and minor, risorius, orbicularis oris, depressor anguli oris, depressor labii, and mentalis. The nasal group includes compressor naris, dilator naris, and depressor septi. In the neck, the platysma muscle lies superficially and extends into the lower face (Fig. 10.6). Frontalis represents the anterior belly of the occipitofrontalis muscle and is the main elevator of the brows. It arises from the epicranial aponeurosis and passes forwards over the forehead to insert into fibers of orbicularis oculi, corrugators, and dermis over the brows. Contraction raises the eyebrows and creates horizontal furrows across the forehead. Orbicularis oculi acts as a sphincter around the eye. It consists of three parts, the orbital, preseptal, and pretarsal parts. The orbital part arises from the nasal part of the frontal
108
P.M. Prendergast
Table 10.1 Mimetic facial muscles Brow elevator Brow depressors
Lower lid elevator Mouth and lip elevators
Mouth and lip depressors
Nose
Neck
Frontalis Procerus Corrugator supercilii Depressor supercilii Orbicularis oculi (orbital part) Orbicularis oculi (pretarsal part) Levator labii Levator anguli oris Levator labii superioris alaeque nasi Zygomaticus major and minor Mentalis (lower lip) Depressor labii Depressor anguli oris Platysma Compressor naris Dilator naris Depressor septi Platysma
Frontalis (medial) Depressor supercilli Levator labii superioris alaeque nasi
bone, the frontal process of the maxilla, and the anterior part of the medial canthal tendon. Its fibers pass in concentric loops around the orbit, well beyond the confines of the orbital rim. Contraction causes the eyes to squeeze closed forcefully. Superior fibers also depress the brow. Preseptal orbicularis oculi arises from the medial canthal tendon, passes over the fibrous orbital septum of the orbital rim, and inserts into the lateral palpebral raphe. The pretarsal portion, involved in blinking, overlies the tarsal plate of the eyelid and has similar origins and insertions to its preseptal counterpart. In some individuals, contraction of the pretarsal part results in fine lines under the eye or bulging of the lid itself. Corrugator supercilii arises from the superomedial aspect of the orbital rim and passes upwards and outwards to insert into the dermis of the middle of the brow. From its origin deep to frontalis, two slips of muscle, one vertical and one transverse, pass through fibers of frontalis to reach the dermis. Corrugator supercilii depresses the brow and pulls it medially, as in frowning. Depressor supercilii is a thin slip of muscle
Frontalis (lateral) Procerus Corrugator Orbicularis oculi:
Zygomatici
Pretarsal part Preseptal part Orbital part Compressor naris Dilator naris
Orbicularis oris
Depressor anguli oris
Depressor septi
Mentalis
Depressor labii Platysma
Fig. 10.6 Anatomy of the facial muscles
10 Botulinum Toxins
that is difficult to distinguish from the superomedial fibers of orbicularis oculi. It inserts into the medial brow and acts as a depressor. Procerus arises from the nasal bone, passes superiorly, and inserts into the dermis of the glabella between the brows. It depresses the lower forehead skin in the midline to create a horizontal crease at the bridge of the nose. Zygomaticus major and minor are superficial muscles that originate from the body of the zygoma and pass downward to insert into the corner of the mouth and lateral aspect of the upper lip, respectively. Superior fibers of these muscles lie beneath the orbital part of orbicularis oculi where they are prone to denervation with injudicious injections of botulinum toxin below the lateral canthus. Zygomaticus major and minor lift the corners of the mouth. Levator labii superioris alaeque nasi (LLSAN) originates from the frontal process of the maxilla and inserts into the nasal cartilage and upper lip. This thin slip of muscle elevates the upper lip during smiling. Orbicularis oris acts as a sphincter around the mouth and its fibers interlace with all of the other facial muscles that act on the mouth. Contraction of orbicularis oris has various actions including pursing, dilation, and closure of the lips. Smokers who overuse this muscle are prone to vertical rhytids above the lip. Depressor anguli oris arises from the periosteum of the mandible along the oblique line lateral to depressor labii inferioris. Its fibers converge on the modiolus with fibers of orbicularis oris, risorius, and sometimes levator anguli oris. Depressor labii inferioris arises from the oblique line of the mandible in front of the mental foramen, where fibers of depressor anguli oris cover it. It passes upwards and medially to insert into the skin and mucosa of the lower lip and into fibers of orbicularis oris. Mentalis arises from the incisive fossa of the mandible and descends to insert into the dermis of the chin. Contraction elevates and protrudes the lower lip and creates the characteristic “peach-pit” dimpling of the skin over the chin. Nasalis consists of two parts, the transverse part (compressor naris) and alar part (dilator naris). Compressor naris arises from the maxilla over the canine tooth and passes over the dorsum of the nose to interlace with fibers from the contralateral side. It compresses the nasal aperture and contributes to the formation of “bunny lines” over the dorsum of the nose. Dilator naris originates from the maxilla just below and medial to compressor
109
naris and inserts into the alar cartilage of the nose. It dilates the nostrils during respiration. Depressor septi is a slip of muscle arising from the maxilla above the central incisor, deep to the mucous membrane of the upper lip. It inserts into the cartilaginous nasal septum and pulls the nose tip inferiorly. Platysma is a broad thin sheet of muscle that arises from the fascia of the muscles of the chest and shoulders and passes upwards over the clavicles and neck toward the lower face. Fibers insert into the border of the mandible, perioral muscles, modiolus, and dermis of the cheek. As part of aging, its fibers attenuate or thicken to create platysmal bands. Functionally, platysma depresses the mandible during deep inspiration but is probably more important as a mimetic muscle to express horror or disgust. The action of the facial muscles on the brow and mouth are shown in Table 10.1.
10.7 Indications The skin of the face is adherent to the underlying mimetic muscles through the superficial musculoaponeurotic system (SMAS) and its fibrous septae. Contraction of these facial muscles creates hyperdynamic lines, particularly in the upper face where there is very little subcutaneous fat between the muscles and the dermis. Botulinum toxin improves hyperdynamic lines by inducing a flaccid paralysis in the underlying muscles that cause them. Indications for treatment with botulinum toxin type A in aesthetic medicine are shown in Table 10.2. Although most areas of the face, including the neck, are amenable to treatment with botulinum toxin, chemodenervation in the lower face is less forgiving and should be performed only once the physician has gained experience in treating the upper face. Contraindications to treatment with BTX-A include known allergy to the product or its components, inflammation or infection at a proposed injection site, pregnancy, breast-feeding, and neuromuscular disorders such as myasthenia gravis.
10.8 Consultation It is important to ask the patient what they wish to achieve from the treatment. Some patients prefer a natural look with some movement, whilst others prefer no movement
110
P.M. Prendergast
Table 10.2 Aesthetic indications for botulinum toxin Indication Frown lines Horizontal forehead lines Brow lift
Lateral orbital lines (crow’s feet) Lower eyelid lines, lid hypertrophy Gingival show (“gummy” smile) Perioral lines (smokers lines) Downturned mouth Dimpled (“peachpit”) chin Platysmal (“turkeyneck”) bands Horizontal (“necklace”) lines Nasal (“bunny”) lines Masseteric hypertrophy (square jaw) Jawline (“Nefertiti”) lifting
Target muscle(s) Procerus, corrugators Frontalis Procerus, corrugators, orbicularis oculi (orbital part), medial frontalis (lateral brow lift) Orbicularis oculi (lateral orbital part) Orbicularis oculi (pretarsal part) Levator labii superioris alaeque nasi Orbicularis oris Depressor anguli oris Mentalis Platysma Platysma (intradermal) Nasalis (compressor part) Masseter Platysma
and a very smooth appearance. The treatment should be tailored accordingly. In female patients, the desired brow shape should be determined. Although a gentle arch in the lateral brow is aesthetically ideal for most women, some women prefer no arch, or a significant “lift.” A horizontal, lower set brow is more appropriate in the male patient (Fig. 10.7).
10.9 Facial Assessment The Glogau classification system for wrinkles and photoaging is useful when considering suitable candidates for BTX-A treatments. Younger patients with no wrinkles (Glogau I) may seek treatment to prevent lines, elevate the brow, treat a gummy smile, or reduce the appearance of a square jaw due to masseteric hypertrophy. Patients who benefit most from BTX-A injections are those who have wrinkles on animation (Glogau II). Older patients with wrinkles at rest (Glogau III) are frequently candidates for BTX-A but usually achieve superior results when chemodenervation is combined with other treatment modalities such
as soft tissue augmentation and skin resurfacing. Before any treatment is performed, a careful assessment of the proposed treatment areas should be made.
10.9.1 Upper Face First, inspect for the presence of excess skin and tissue under the brows (dermatochalasis) (Fig. 10.8). In these patients, even a drop by 1–2 mm of the brow following treatment of frontalis may be enough to cause hooding and a feeling of heaviness that many patients find distressing. Either avoid treating frontalis in these patients or treat it with very conservative doses superiorly in the forehead well away from the brows. The corrugators should also be treated conservatively in these patients as spread of the toxin into medial fibers of frontalis can lead to medial brow ptosis. Some patients with heavy upper lids compensate, often subconsciously, by constantly contracting frontalis to elevate the brows and keep the excess tissue out of the eyes. This frontalis over activity creates deep horizontal forehead lines. Treating frontalis with BTX-A in these patients can be detrimental, as they lose the ability to elevate the brows and develop a brow ptosis. To determine whether the patient is compensating, perform the following simple test: 1. Ask the patient to close their eyes and relax the forehead completely. Gently stroke the forehead downward to make sure frontalis is relaxed. 2. Focus carefully on the horizontal position of the brow. 3. Ask the patient to open their eyes and look at you. Watch the position of the brow. If the brows elevate upon opening the eyes, there is compensation. If the brow remains at the same level when the eyes open and the patient does not feel “heaviness” in this position, treating frontalis is relatively safe. Next, note the strength of the upper facial muscles, the distribution of rhytids, and the nature of the lines. Deep, etched-in lines usually improve with BTX-A treatments but will not disappear. Explain this to the patient so they have realistic expectations. Additional procedures such as dermal fillers in the glabella or laser resurfacing for crow’s feet may be suggested. Male patients typically have stronger facial muscles and require higher doses to achieve satisfactory denervation [19]. If treatment of pretarsal orbicularis oculi is being considered to improve lines in the lower eyelid, or a hypertrophic muscle, first perform the snap test. Gently pull away the lower eyelid from the globe and release. The lid
10 Botulinum Toxins Fig. 10.7 Aesthetically ideal brow shape. (a) Male, the brow should be horizontal and at the level of the supraorbital ridge. (b) Female, a gently arching brow from medial to lateral is ideal
111
a
b
10.9.2 Lower Face Inspect the patient carefully during animation at the time of consultation. Some patients habitually pull the corners of the mouth downward during speech. This over activity of depressor anguli oris may contribute to a downturned mouth, even in the resting position. Although patients may request fillers in the chin to make it smoother, chemodenervation of mentalis is usually more appropriate to soften dermal insertions of the muscle. Vertical lip lines are more appropriately treated with BTX-A if they appear primarily during animation but disappear at rest. In older patients and smokers, a combination of fillers for augmentation and BTX-A for denervation usually provides better results than each treatment on its own.
10.10 Keys for Success
Fig. 10.8 Patient with dermatochalasis. Treatment of frontalis with botulinum toxin should be conservative or avoided in this patient to avoid brow ptosis
should snap promptly back into place. A sluggish response indicates laxity of the lower lid, and contraindicates denervation of the muscle, which could cause an ectropion.
It should be remembered that the aim of treatment with botulinum toxins is facial rejuvenation and not total paralysis of treated muscles. Careful placement of appropriate doses of botulinum toxin in suitable patients enables satisfactory outcomes with a negligible incidence of complications. Some keys for success include the following: 1. Use conservative doses and accurately placed injections to selectively denervate muscles. This enhances natural-looking results and reduces complications. Adjustments or “top-ups” can be performed at follow-up visits. 2. Use low doses in the frontalis to preserve some activity and avoid brow ptosis. 3. Never treat frontalis without treating the brow depressors (corrugators and procerus).
112
P.M. Prendergast
Fig. 10.9 Insulin syringe with 30-gauge needle used for injection of botulinum toxin
4. Use miniscule doses for injections over the lateral brow where necessary, with additional denervation of the lateral orbicularis oculi in the brow to avoid lateral brow ptosis. 5. Warn the patient of transient weakness around the mouth with perioral injections. 6. Ask the patient to contract the selected muscles before injection to identify the anatomy and improve precision. 7. Increase the dose in male patients and those with stronger muscles as required. 8. Combine treatments with fillers, photorejuvenation, skin resurfacing, and suture lifting techniques for more impressive overall rejuvenation.
a
b
10.11 General Technique The technique using Dysport will be described, although the concepts of chemodenervation can be applied to any of the other botulinum toxins. For practical purposes, 2.5 U Dysport can be considered approximately equal to 1 U Botox or 1 U Xeomin. To reconstitute Dysport, 2.5 mL saline is slowly injected into the vial using a 3 mL syringe and 20-gauge needle. Saline with or without preservative can be used, although there is some evidence that saline with benzyl alcohol is associated with reduced pain on injection [20]. Although reconstitution with less or more volume is possible, a more concentrated solution requires extremely small injection aliquots and a more diluted solution may increase spread and diffusion of the toxin following injection. The 2.5 mL volume produces a solution with 2 U Dysport per 0.01 mL graduation on a 0.5 or 1 mL syringe. For injection, the author prefers a 0.5 mL insulin syringe with attached 30-gauge needle and clear 0.01 mL graduations (Fig. 10.9). Using separate syringe and needles, up to 0.08 mL product remains in the “dead space” of the 30-gauge needle hub and cannot be used. Puncturing the needle through the rubber cap on the vial will cause some blunting and increase the discomfort on injection. As
Fig. 10.10 (a) and (b) Techniques for injecting botulinum toxin. The graduations on the syringe should be clearly visible during injection
such, either the cap and rubber bung should be removed to draw up the solution or several syringes should be used for a single treatment. Before injecting, the syringe should be rotated so the graduations on the barrel are clearly visible. Anesthesia is not required for botulinum toxin injections using 30-gauge needles and is usually well tolerated. The non-injecting hand should have a sterile cotton ball ready to gently compress the injection point
10 Botulinum Toxins
a
113
b
Fig. 10.11 Assessing the glabellar area. (a) Ask the patient to frown and observe the anatomy and strength of the procerus and corrugators. (b) The procerus lies in the midline between the
brows, the belly of the corrugator usually near the medial brow. The lateral insertion should be injected where it inserts into the dermis above the brow
following withdrawal of the needle. This reduces the incidence of ecchymosis. Using the cotton ball, the tissues can also be wiped along the extent of the muscle using 2–3 gentle strokes. This maneuver allows a controlled spread of toxin within the chosen parts of the muscle, or across a broad sheet of muscle such as frontalis. Various general techniques are used to hold the syringe during injection (Fig. 10.10).
is rare if the muscle is injected carefully with conservative doses. The thin fibers of the lateral corrugator are easily denervated, and excessive doses will also denervate frontalis in this area and may create medial brow heaviness. Usually 6–8 U Dysport is sufficient. It is useful to “visualize” the anatomy under the skin and gently wipe the skin with the cotton ball from the medial to lateral injection to spread the toxin along the extent of the muscle. Five injection points should be made to treat the glabella (Fig. 10.12). Two weeks following the treatment, attempted frowning should produce no movement of the glabellar muscles (Fig. 10.13).
10.11.1 Glabella Improving hyperdynamic glabellar frown lines requires chemodenervation of procerus, and medial and lateral parts of corrugators. The patient is asked to frown to determine the strength of the muscles and identify the lateral extent of corrugator where it tethers the dermis (Fig. 10.11). These muscles are brow depressors so their treatment usually produces a subtle brow elevation. The procerus is gently pinched in the midline and an injection is made perpendicularly into the belly of the muscle. Dysport 12–14 U is usually sufficient in a female patient, but up to 20 U may be required in a male patient. To inject the medial part of corrugator, the thumb or finger is placed along the orbital rim to define the belly of the muscle. The author directs the needle along the long axis of the muscle, depositing 8–10 U Dysport in the medial part in a female patient. A perpendicular injection is then made at the lateral insertion of the muscle, deep to frontalis. This is usually at least 1 cm from the orbital margin, but the site of injection is determined by the muscle itself and should not be dictated by bony landmarks here. Ptosis
10.11.2 Forehead Horizontal forehead lines vary in prominence from subtle fine lines to deep furrows depending on the strength of frontalis. If the patient with deep lines actively contracts the muscle during speech and animation, look for dermatochalasis and consider sparing frontalis to avoid brow ptosis and hooding. Similarly, elderly patients with excess skin under the brow should be treated conservatively [21]. In a typical patient, small 4–5 U aliquots of Dysport across the superior aspect of frontalis are sufficient to smooth lines completely without creating an unnatural “plastic-like” appearance (Fig. 10.14). For stronger muscles, or when the muscle fibers extend more superiorly toward the hairline, two rows of injections can be placed (Fig. 10.15). Over the lateral frontalis, even less toxin should be used. The treatment over lateral frontalis
114
P.M. Prendergast
a
b
c
d
Fig. 10.12 Injection technique for the glabella. (a) The procerus is gently pinched and a perpendicular injection is made into the belly of the muscle. (b) The medial part of corrugator is injected into the belly of the muscle. (c) The lateral part of corrugator is injected where its most lateral fibers are seen to tether
a
the dermis. This injection is made perpendicularly just above the periosteum and deep to frontalis. (d) The thumb or finger is placed along the supraorbital ridge to protect the orbit and define the medial part of corrugator before injection
b
Fig. 10.13 (a) Before. (b) Attempted frowning 2 weeks after chemodenervation of procerus and corrugators with 40 U Dysport
10 Botulinum Toxins
Fig. 10.14 Typical treatment pattern for patient with average or weak frontalis. To maintain or achieve an arched lateral brow, the lateral frontalis is treated with low doses high in the forehead. When the forehead is treated, the glabella is always treated too to avoid overactivity of the glabellar muscles. Diagram shows units of Dysport at each injection point
depends on the morphology and strength of the muscle in this region. In patients with a very weak frontalis and almost no movement over the lateral brow, the lateral forehead can be avoided completely. By treating the medial frontalis only, resting tone in fibers of the lateral part increases, creating a slight lateral brow lift. When contraction of frontalis produces bunching of skin immediately above the lateral brow, minute doses should be placed in the area of maximal wrinkling to soften the lines and prevent “peaking” above the brow (Fig. 10.16). Although brow ptosis is less likely when extremely small doses are placed immediately above the brow, an additional injection of 3 U should be made in fibers of orbicularis oculi near the tail of the brow to encourage brow elevation in this area. If no injections are placed in a lateral frontalis that is strong, the “Mephisto” or “Spock” appearance is likely (Fig. 10.17). Dysport 2 U placed superiorly near the hairline and 1 U placed lower over the brow will partially denervate the
115
Fig. 10.15 Example of injection pattern and doses in a patient with strong frontalis. Two rows of injections are placed. Just 1 U Dysport is placed close to the lateral brow to prevent frontalis activity creating creases or “peaking” here. To maintain a lateral brow lift, a further injection is made in fibers of orbicularis oculi at the temporal crest line near the tail of the brow
Fig. 10.16 Treatment of the lateral forehead. A small dose of botulinum toxin should be placed within the area marked by the circle to soften these lines. An additional injection is placed at the X to prevent lateral brow ptosis
muscle without causing ptosis. The injection in the depressor part of orbicularis oculi serves two purposes. Firstly, it alleviates the depressor action of orbicularis
116
a
P.M. Prendergast
b
Fig. 10.17 (a) Patient at rest following chemodenervation of the forehead and frown areas. The physician avoided the area over the lateral brow, presumably to avoid the risk of lateral brow ptosis.
(b) A “Mephisto” brow is evident when the patient attempts to raise the brows. This should be corrected with a small dose injected into the area of maximal wrinkling over the lateral brow
oculi, creating a lift. Secondly, its action-halo affects fibers of frontalis just above the lateral brow, thus softening the “peaking” or wrinkle above the tail of the brow that commonly occurs when frontalis is spared. To determine the best injection point, place the index finger near the tail of the brow where it crosses the temporal crest and ask the patient to raise the eyebrows, and then forcefully shut the eyes. The finger should raise minimally but be pulled down strongly at the correct point. The pattern of injections in the male patient differs, with more aggressive chemodenervation over lateral frontalis to maintain an aesthetically ideal horizontal brow position (Fig. 10.18). Male
patients usually benefit from two rows of injections, with 6 U aliquots of Dysport typically required. Before treatment, asymmetries in the brow and muscle activity should be noted and the treatment should be tailored accordingly (Fig. 10.19). To treat frontalis, the needle is quickly placed through the dermis into the subcutaneous or intramuscular plane. A loss of resistance should be felt as the needle tip traverses the dermal-subcutaneous junction. If the needle tip remains in the dermis, excessive resistance is felt and the solution may leak onto the surface of the skin. If the needle touches the periosteum, the patient may complain of headache after the procedure.
10 Botulinum Toxins
Fig. 10.18 Typical injection pattern in the male patient. In this example, 114 U Dysport is used for treatment of the frown and forehead. Higher doses may be required, particularly in the glabellar muscles
Every effort should be made to avoid the visible veins in the forehead to avoid bruising. Bleeding should be stemmed immediately with external pressure for 90s to avoid ecchymosis.
10.11.3 Periorbital The crow’s feet or lateral orbital rhytids are commonly treated with 3–4 injections of botulinum toxin achieving excellent periorbital rejuvenation (Fig. 10.20). The patient should understand prior to treatment that the aim is to soften lateral lines, and that some “smile lines” at the upper cheek will remain. Chasing smile
117
lines with inferiorly placed injections may result in inadvertent chemodenervation of zygomaticus major or minor with ptosis of the upper lip (Fig. 10.21). Microdroplets of botulinum toxin injected intradermally in the cheeks may improve cheek lines, but the risk of mouth asymmetry still exists [22]. Although rare, lateral injections should be made at least 1 cm from the bony orbital margin to prevent spread into the globe, resulting in extraocular muscle weakness and diplopia [23]. The finger is placed on the rim as injections are made superficially, either in the dermis or subcutaneous plane between the visible blood vessels (Fig. 10.22). As a general rule, 3–4 injections can be made, keeping the inferior injection lateral to an imaginary line dropped vertically from the lateral canthus (Fig. 10.23). Denervating the preseptal portion of orbicularis oculi under the eye may allow the suborbicularis oculi fat (SOOF) pad to bulge anteriorly, worsening undereye bags. Infraorbital injections can be made in the pretarsal portion of orbicularis oculi, however, to reduce lid bulging (Fig. 10.24). One or two injections (e.g., Dysport 4 U) are made tangentially in the lid just below the lashes in the midline, with an additional injection more laterally as required (Fig. 10.25). Medial injections may interfere with the lacrimal apparatus. Before treating the lower eyelid, the snap test should be performed. With the patient gazing forwards, gently retract the lower eyelid inferiorly away from the eye. Upon release, the lid should snap back into place. If it returns sluggishly, avoid treating this area to prevent complications.
10.11.4 Brow Some patients request a brow lift using botulinum toxin. The brow elevates when the depressors are treated and the elevators, or parts of them, are preserved. Subtle elevation of the lateral brow is achieved by denervating the lateral orbicularis oculi under or in the hair of the lateral brow. Further lateral brow elevation occurs when the medial frontalis is treated and fibers of lateral frontalis are preserved (Fig. 10.26). The glabella must also be treated to
118
avoid unopposed action of the depressor muscles that act to pull the brow inferiorly. It is preferable to under treat lateral frontalis and allow the brow to lift, rather than over treat, with a risk of brow ptosis. An abnormally elevated lateral brow can easily be adjusted after 2 weeks with a further injection above the most elevated portion.
10.11.5 Nose To treat “bunny lines” over the bridge and lateral part of the nose, the compressor naris portion of nasalis is targeted with about 6 U Dysport injected under the skin on either side of the nose where there is maximal wrinkling. A third injection is placed over the dorsum
a
Fig. 10.19 Tailoring the treatment for each patient. (a) Patient at rest before treatment. The left brow is lower than the right. (b) Patient contracting frontalis. The muscle is relatively strong, with more activity over the right brow compared to the left. (c) Treatment plan. The area over the right brow is treated with one
P.M. Prendergast
to denervate inferior most fibers of procerus (Fig. 10.27). Rarely, dilator naris is injected with 4 U Dysport to reduce the flaring associated with wide nostrils. The tip of the nose can also be made to elevate in patients with active depressor septi muscles. From the side profile, observe the tip of the patient’s nose as they speak. If the tip of the nose tugs inferiorly with movement of the mouth, injecting depressor septi is appropriate. An injection is placed in the midline at the root of the nose near the origin of the muscle where it inserts into the maxilla deep to the mucous membrane of the upper lip. This may also elongate the upper lip and should be avoided in older patients where the upper lip is already lengthened. In these patients, the injection can be made at the insertion point of the muscle under the tip of the nose.
b
unit of Dysport, with 3 U in the lateral brow depressor (orbicularis oculi). Frontalis over the left lateral brow is spared since frontalis does not produce any furrows in this area. (d) The patient attempting to contract frontalis 2 weeks after treatment
10 Botulinum Toxins
c
119
d
Fig. 10.19 (continued)
a
b
Fig. 10.20 (a) Before. (b) After chemodenervation of lateral orbicularis oculi. Complete disappearance of the crow’s feet has been achieved
120
P.M. Prendergast
Fig. 10.21 An asymmetric smile following treatment of lateral orbital rhytids. The inferiorly placed toxin spread into the lateral lip elevators where they originate over the zygoma
Fig. 10.24 Treating the lower lid bulging and lines. Pretarsal orbicularis oculi is treated by placing the needle tangential to the lid and inserting it superficially in the mid-pupillary line. A small bleb is raised. A second injection can be placed more laterally in the lid, but medial injections close to the lacrimal apparatus should be avoided
10.11.6 Perioral
Fig. 10.22 Injection technique for lateral orbital rhytids. The orbital rim is palpated with the index finger. Superficial injections are made about 1 cm away from the rim. Depending on the distribution of lines, 3–6 injections are placed, avoiding superficial vessels where possible
Fig. 10.23 Injection points for treating lateral orbital rhytids. Injections medial to the red line should be avoided, unless they are in the eyelid in pretarsal orbicularis oculi. The most inferior injection should not be over the zygoma, where denervation of the lip elevators can occur
Although soft tissue augmentation using fillers or autologous fat is usually the first-line treatment for perioral lines and folds, botulinum toxin is appropriate and effective in certain cases. Chemodenervation of muscles that act on the mouth must be precise, with small doses to avoid excessive weakness or asymmetries. To treat “smokers’ lines,” four injections into orbicularis oris are made 5 mm above the vermilion border. Using Dysport, 2 U are placed just under the dermis, two on either side with two further injections in the lower lip if required (Fig. 10.28). The patient should be warned that even with conservative doses a transient subjective feeling of weakness lasting about 1 week can occur. Additional injections can be made after at least 2 weeks if no improvement is observed and the patient reports no weakness. A gummy smile results from excessive activity of the lip elevators, including levator labii and levator labii superioris alaeque nasi (LLSAN). Placing just 4 U Dysport at the superior part of LLSAN, between the nasolabial fold and nasal ala, is sufficient to drop the upper lip and reduce gingival show, even when smiling maximally (Fig. 10.29). The injections should be placed at the same depth bilaterally to avoid asymmetry.
10 Botulinum Toxins
a
Fig. 10.25 (a) Before. A hypertrophic pretarsal orbicularis oculi creates bulging of the lower lid. (b) After 4 U Dysport in
a
121
b
the mid-pupillary line just below the eyelash line. Hyaluronic acid filler was also placed in the superior orbitopalpebral sulci
b
Fig. 10.26 (a) Before. (b) After chemodenervation to raise the lateral brow. By preserving fibers of lateral frontalis, and/or treating the lateral brow depressor, the brow elevates
The “peachpit” chin, or cobblestone appearance results from activity of dermal insertions of mentalis (Fig. 10.30). Softening the chin is achieved with two injections into each head of the muscle. Each injection (8–10 U Dysport) is placed deeply into the body of the muscle (Fig. 10.31). The patient should be advised not to rub or massage the chin for up to a week to avoid spread into the adjacent depressor labii muscles. Depressor anguli oris acts to depress the lateral corners of the mouth, giving the mouth a sad or sullen look (Fig. 10.32). To elevate the corners of the mouth, particularly in combination with dermal fillers in the oral commisures, place about 8 U Dysport into the
muscle where it inserts into the periosteum at the border of the mandible. Although the muscle can be felt to contract when the patient is asked to pull the mouth corners downward, if in doubt, place the injection more laterally to avoid inadvertent chemodenervation of depressor labii (Fig. 10.33).
10.11.7 Jawline The “Nefertiti lift” to contour the jawline with botulinum toxin has been documented [24]. The aim is to denervate fibers of platysma along the jawline and
122
Fig. 10.27 Contraction or nasalis produces “bunny lines.” An injection is made at either side of the nose into the compressor naris component of the muscle. An additional injection into lower procerus softens the transverse nasal lines near the glabella
P.M. Prendergast
lower face where they insert into the dermis and pull the tissues inferiorly. The lifting achieved is usually subtle. In the author’s view, other techniques such as suture face lifting are more effective and more appropriate to improve jawline definition. A square-jaw appearance may be caused by masseteric hypertrophy, particularly in Asian patients. Botulinum toxin injections into the masseter at the angle of the jaw induces a partial paralysis leading to disuse atrophy. Muscle thickness reduces over time, creating a more oval shape to the face [25]. Three injections into the bulk of the muscle at the angle of the mandible is sufficient (Fig. 10.34). The author usually uses 100 U Dysport per side in equally divided doses, but more may be required depending on the size and strength of the muscle. Treatments are repeated at 3–4 month intervals until atrophy has occurred and facial shape has improved. Once muscle reduction has been achieved, subsequent treatments are less frequent [25]. Complications due to the spread of the toxin into perioral muscles are unusual [26].
10.11.8 Neck
Fig. 10.28 Treatment of perioral lines with botulinum toxin. Injections are placed symmetrically 5 mm above the vermilion border. The lower lip can also be treated. Always start with low doses (Dysport 2 U per site) to avoid excessive weakness or smile asymmetry
a
Fig. 10.29 Treatment of the “gummy” smile. (a) Before. Note the lower lip mouth asymmetry before treatment. (b) After 4 U Dysport in each levator labii superioris alaeque nasi (LLSAN)
Rejuvenation of the aging neck first requires a careful assessment to determine the most appropriate measures. Aging features include skin laxity, lipodystrophy in the submental and jowl areas, submandibular gland ptosis, ptosis of the digastric muscles and platysma, and platysmal hypertrophy and banding [27]. Surgical intervention with skin resection and platysmaplasty is appropriate with advanced signs. Botulinum toxin, injected directly b
muscle lateral to the nasal alae. A subtle but significant drop in the upper lip has been achieved
10 Botulinum Toxins
123
a
b Fig. 10.30 The “pebblestone” or “peach-pit” chin. At rest or during animation, dermal insertions of mentalis produce dimpling
Fig. 10.33 (a) The depressor anguli oris is treated by feeling for the muscle over the periosteum and marking the most lateral part of its origin. A slightly laterally placed injection reduces the opportunity for the toxin to affect the depressor labii muscles. (b) After 8 U Dysport in each depressor anguli oris. The mouth corners have elevated
Fig. 10.31 Chemodenervation of mentalis. Two injections are made, one into each head of the muscle
Fig. 10.32 The action of depressor anguli oris. Over activity of this muscle produces a sad or sullen look
Fig. 10.34 Injection points for treatment of masseteric hypertrophy. Three injections are made in the masseter over the angle of the mandible
124
into muscular bands, softens the vertical “turkey neck” appearance (Fig. 10.35). Platysmal band asymmetry can also be corrected using botulinum toxin A following rhytidectomy [28]. Although the bands may be visible at rest, asking the patient to forcefully grimace will make them prominent and facilitate marking and injections. Injections of 4 U Dysport at 1.5–2 cm intervals along the band softens the bands without risking spread into deeper muscles. Occasionally, intradermal injections of more diluted botulinum toxin can be made along horizontal “necklace” lines to soften the dermal insertions of platysma along these horizontal creases. Chemodenervation in the neck is also appropriate following lipoplasty when
a
Fig. 10.35 Improvement of platysmal bands with botulinum toxin. (a) Visible bands at rest. (b) Injection points every 1.5–2 cm along each visible band. (c) Injection technique. The
P.M. Prendergast
reduced submental volume postoperatively reveals underlying platysmal bands [29].
10.11.9 Décolleté Superficial, intradermal injections of botulinum toxin along the chest between the lower neck and cleavage provide some improvement to superficial lines where fibers of platysma insert into the dermis [30]. Small intradermal blebs are raised with 2 U aliquots of Dysport at 1 cm intervals (Fig. 10.36). For best results, chemodenervation of the décolleté is combined with
b
band is grasped and the needle is passed directly into the band. (d) Even with contraction, the bands appear softened 3 weeks after treatment
10 Botulinum Toxins
c
d
125
10.12 Hyperhidrosis The activity of eccrine and apoeccrine sweat glands is under autonomic control, stimulated by release of acetylcholine at postganglionic nerve terminals. Excessive sweating, or hyperhidrosis, may be focal or generalized and primary or secondary [32]. Topical agents such as aluminum salts and aldehyde agents are often ineffective and may cause irritation [33]. Intradermal injections of botulinum toxin represent a novel management option for focal primary hyperhidrosis [34]. Although the only toxin currently approved by the FDA for relief of severe axillary hyperhidrosis is Botox®, the other well-known botulinum toxins are equally effective and commonly used off-label for the treatment of hyperhidrosis [35]. To delineate the area of maximal sweating, the starch-iodine test can be performed. To perform the test, the skin is dried and an iodine solution is applied and left to dry. Then starch is sprinkled over the area. Areas of excessive sweating turn a blue/ black color as iodine reacts with starch. The affected area can be marked to guide placement of injections. In practice, the entire surface of the axilla, palms, or soles of the feet are treated and the test is not essential.
10.13 Axillary Hyperhidrosis
Fig. 10.35 (continued)
other skin rejuvenating procedures including intense pulsed light, laser resurfacing, chemical peels, and rejuvenation mesotherapy with hyaluronic acid and other stimulators [31].
Treating axillary hyperhidrosis with botulinum toxin A requires multiple low-dose intradermal injections throughout the axilla. Injections that are below the dermis in the subcutaneous plane spread too deeply and have little effect on the eccrine sweat glands that are located predominantly in the deep dermis. To inject superficially, the needle is angled at 30° to the skin and small blebs are raised at 1 cm intervals throughout the treatment area (Fig. 10.37). Results are noticeable about 2 weeks following the treatment and provide symptomatic relief from hyperhidrosis for several months. Using Dysport, a 500 U vial is reconstituted with 5 mL physiologic saline to enhance the spread of the solution in the dermis. About 250 U are sufficient to treat each axilla, with 50–70 injections per side
126
a
P.M. Prendergast
b
Fig. 10.36 Botulinum toxin in the décolleté. (a) Immediately after treatment; injections are intradermal. (b) After 1 month
delivering 0.03–0.05 mL each. The treatment is well tolerated and no anesthesia is required.
10.14 Palmar Hyperhidrosis
Fig. 10.37 Treating axillary hyperhidrosis with botulinum toxin. Using Dysport, the 500 U vial is reconstituted with 5 mL saline and 2–2.5 mL are injected in each axilla using equally spaced intradermal injections
The most significant challenge treating palmar hyperhidrosis with botulinum toxin is anesthesia. The palmar surfaces of the hands and fingers are extremely sensitive and patients may not tolerate the procedure unless proper regional anesthesia is performed. Various pain-relief methods are used, including topical anesthetic creams, ice, and topical cooling with forced air or ethyl chloride [36, 37]. However, the author routinely performs bilateral wrist blocks to achieve
10 Botulinum Toxins
a
127
b
Fig. 10.38 (a) Injection points for palmar hyperhidrosis. (b) The medial and lateral aspects and tips of the fingers should not be missed
o ptimum analgesia. With proper technique, intradermal injections are well tolerated. The technique for chemodenervation in the palms and fingers is similar to that for axillary hyperhidrosis. To inject the thick dermis of the hands, the needle is angled at about 60° and quickly passed into the dermis. If the tip is too superficial, or if injections are placed perpendicularly, the solution will leak from the puncture [38]. Deep injections should also be avoided to minimize potential denervation of the intrinsic muscles of the hand. Regular needle changes during the procedure facilitate puncture of the dermis. Injections are placed at 1 cm intervals over the palms and fingers, including the sides of the fingers and fingertips (Fig. 10.38). The patient should be warned that transient weakness of the hands might occur but usually resolves in 1–3 weeks. Severe weakness is rare [39]. Typically, a total of 500 U Dysport provides excellent reduction in palmar hyperhidrosis with results lasting 6–8 months.
10.15 Plantar Hyperhidrosis A similar technique to palmar injections is used to treat the relatively larger plantar surfaces of the feet. Pain on injection makes this a challenging treatment unless plantar nerve blocks are accurate and thorough.
Following nerve blocks, 250–400 U Dysport can be injected across the plantar surface of each foot and the toes. The patient should be accompanied for the procedure since transient instability is normal following anesthesia of the feet.
10.16 Complications Injection-related complications following botulinum toxin injections for facial rejuvenation include mild ecchymosis, swelling, and headache [40]. To avoid these problems, visible vessels should be avoided and the needle should be placed either in the belly of the muscle or more superficially, avoiding the periosteum. Brow ptosis occurs with excessive denervation of frontalis, especially in patients with pre-existing dermatochalasis. These patients should be treated conservatively, if at all. Even denervation of the glabellar muscles can lead to medial brow ptosis if there is significant spread to fibers of frontalis in the glabella. Conservative denervation of procerus and corrugators without treating the brow elevators is the best way to avoid potential ptosis in these patients. Eyelid ptosis is rare when botulinum toxin is carefully placed using standard doses. The patient should be advised to handle
128
the treated area with care for at least 3 days to minimize spread into surrounding muscles. The Mephisto sign or “Spock-eye” is caused by treating the medial frontalis and completely avoiding the lateral frontalis over the lateral brow in a patient with a moderately strong or strong frontalis muscle (Fig. 10.17). In these patients, the lateral frontalis should be treated with 1–2 injections, with reducing doses as the brow is approached. An additional injection in fibers of orbicularis oculi at the brow alleviates the downward pull on the brow here and helps reduce the likelihood of lateral brow ptosis, even when frontalis over the lateral brow has been treated. Chasing smile lines from crow’s feet onto the cheek should be avoided. This can result in paralysis of zygomaticus major or minor with drooping of the upper lip (Fig. 10.21). To address lower crow’s feet and smile lines, injections can continue around the orbit but not beyond an imaginary vertical line dropped from the lateral canthus (Fig. 10.23). The most inferior injections should remain high, close to the lateral canthus and should not be placed over the zygoma. Injections more medial to this for lower lid lines should only be placed in pretarsal orbicularis oculi close to the eyelash in the midline and not lower down over the preseptal part of the muscle. Denervation of preseptal orbicularis oculi can result in protrusion of sub-orbicularis oculi fat (SOOF) and worsen under-eye puffiness. Complications associated with chemodenervation around the mouth include lip weakness, difficulty speaking or eating, and smile asymmetry. In the neck, excessive doses of botulinum toxin have been associated with dysphagia and dysphonia due to spread of toxin into the deeper neck muscles [41].
10.17 Combination Approaches Although chemodenervation with botulinum toxin is the most commonly performed procedure in aesthetic medicine, it should not be considered the answer to all aspects of aging. Botulinum toxin is almost always the first-line choice for treating hyperdynamic lines, but it does not address deeper folds, facial volume loss, and actinic textural and pigmentary changes. For deep lines in the glabella or outside the vermilion border of the lip, a combination of intradermal hyaluronic acid with botulinum toxin achieves better results than each treatment
P.M. Prendergast
individually. Relaxing underlying muscles when fillers are used for augmentation may also increase the longevity of the filler by reducing movement [42]. For “etchedin” lines around the eyes or mouth, laser skin resurfacing combined with botulinum toxin yields excellent results. Botulinum toxin can be combined with almost every aesthetic medical procedure provided there are no contraindications. These procedures include suture lifting techniques, chemical peels, soft tissue augmentation, and photorejuvenation [43]. Botulinum toxins also compliment such cosmetic surgical procedures as brow lift, blepharoplasty, face lift, and platysmaplasty [44].
References 1. The American Society for Aesthetic Plastic Surgery (2009) Cosmetic surgery national databank statistics. ASAPS website, www.surgery.org 2. Erbguth FJ (2004) Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov Disord 19(Suppl 8):S2–S6 3. Van Ermengem EP (1897) Über einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus. Z Hyg Infektionskr 26:1–56 4. Snipe PT, Sommer H (1928) Studies on botulinus toxin. Acid precipitation of botulinus toxin. J Infect Dis 43(2): 152–160 5. Burgen AS, Dickens F, Zatman LJ (1949) The action of botulinum toxin on the neuro-muscular junction. J Physiol 109(1–2):10–24 6. Scott AB, Rosenbaum AL, Colins CC (1973) Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 12(12):924–927 7. Rohrer TE, Beer K (2005) Background to botulinum toxin. In: Carruthers A, Carruthers J (eds) Procedures in cosmetic dermatology, Botulinum toxin. Elsevier Saunders, Philadelphia, p 9 8. Clark RP, Berris CE (1989) Botulinum toxin: a treatment for facial asymmetry caused by facial nerve paralysis. Plast Reconstr Surg 84(2):353–355 9. Carruthers JD, Carruthers JA (1992) Treatment of glabellar frown lines with C. Botulinum-A exotoxin. J Dermatol Surg Oncol 18(1):17–21 10. Yang GC, Chiu RJ, Gillman GS (2008) Questioning the need to use Botox within 4 hours of reconstitution: a study of fresh vs 2-week-old Botox. Arch Facial Plast Surg 10(4):273–279 11. Klein AW, Carruthers A, Fagien S, Lowe NJ (2008) Comparisons among botulinum toxins: an evidence-based review. Plast Reconstr Surg 121(6):413e–422e 12. Karsai S, Raulin C (2010) Botox and Dysport: is there a dose conversion ratio in dermatology and aesthetic medicine? J Am Acad Dermatol 62(2):346–347 13. Jost WH, Blümel J, Grafe S (2007) Botulinum neurotoxin type A free of complexing proteins (Xeomin) in focal dystonia. Drugs 67(5):669–683
10 Botulinum Toxins 14. Baumann L, Elsaie ML, Grunebaum L (2009) Botulinum toxin. In: Baumann L (ed) Cosmetic dermatology. McGraw Hill, New York, p 171 15. Koussoulakos S (2009) Botulinum neurotoxin: the ugly duckling. Eur Neurol 61(6):331–342 16. Pickett A (2009) Dysport: pharmacological properties and factors that influence toxin action. Toxicon 54(5):683–689 17. Muraro L, Tosatto S, Motterlini L, Rossetto O, Montecucco C (2009) The N-terminal half of the receptor domain of botulinum neurotoxin A binds to microdomains of the plasma membrane. Biochem Biophys Res Commun 380(1):76–80 18. de Almeida AR Trindade, Marques E, de Almeida J, Cunha T, Boraso R (2007) Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 33(1 Spec No):S37–S43 19. Flynn TC (2007) Botox in men. Dermatol Ther 20(6): 407–413 20. Alam M, Dover JS, Arndt KA (2002) Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double-blind, randomized controlled trial. Arch Dermatol 138(4):510–514 21. Cheng CM (2007) Cosmetic use of botulinum toxin type A in the elderly. Clin Interv Aging 2(1):81–83 22. De Maio M, Rzany B (2007) Advanced indications and techniques. In: De Maio M, Rzany B (eds) Botulinum toxin in aesthetic medicine. Springer, Berlin, p 117 23. Wutthiphan S, Kowal L, O’Day J, Jones S, Price J (1997) Diplopia following subcutaneous injections of botulinum A toxin for facial spasms. J Pediatr Ophthalmol Strabismus 34(4):229–234 24. Levy PM (2007) The ‘Nefertiti lift’: a new technique for specific recontouring of the jawline. J Cosmet Laser Ther 9(4):249–252 25. Kim NH, Park RH, Park JB (2010) Botulinum toxin type A for the treatment of hypertrophy of the master muscle. Plast Reconstr Surg 125(6):1693–1705 26. Bas B, Ozan B, Muglah M, Celebi N (2010) Treatment of masseteric hypertrophy with botulinum toxin: a report of two cases. Med Oral Patol Oral Cir Bucal 15(4):e649–e652 27. Matarasso A, Matarasso SL (2003) Botulinum A exotoxin for the management of platysma bands. Plast Reconstr Surg 112(5 Suppl):138S–140S 28. Brandt FS, Boker A (2004) Botulinum toxin for the treatment of neck lines and neck bands. Dermatol Clin 22(2):159–166 29. Kane MA (1999) Nonsurgical treatment of platysmal bands with injection of botulinum toxin A. Plast Reconstr Surg 103(2):656–663
129 30. Becker-Wegerich PM, Rauch L, Ruzicka T (2002) Botulinum toxin A: successful décolleté rejuvenation. Dermatol Surg 28(2):168–171 31. Mazzuco R, Hexsel D (2009) Poly-L-lactic acid for neck and chest rejuvenation. Dermatol Surg 35(8):1228–1237 32. Shargall Y, Spratt E, Zeldin RA (2008) Hyperhidrosis: what is it and why does it occur? Thorac Surg Clin 18(2): 125–132 33. Kocyigit P, Bostanci S (2006) Botulinum toxin in the treatment of focal hyperhidrosis. Expert Rev Dermatol 1(2):217–225 34. Arad A, Blitzer A (2004) Botulinum toxin in the treatment of autonomic nervous system disorders. Oper Tech Otolaryngol 15(2):118–121 35. Dressler D (2010) Comparing Botox and Xeomin for axillary hyperhidrosis. J Neural Transm 117(3):317–319 36. Patel R, Halem M, Zaiac M (2009) The combined use of forced cold air and topical anesthetic cream for analgesia during the treatment of palmar hyperhidrosis with botulinum toxin injections. J Drugs Dermatol 8(10): 948–951 37. Richards RN (2009) Ethyl chloride spray for sensory relief for botulinum toxin injections of the hands and feet. J Cutan Med Surg 13(5):253–256 38. Glogau RG (2001) Treatment of palmar hyperhidrosis with botulinum toxin. Semin Cutan Med Surg 20(2):101–108 39. Glass GE, Hussain M, Fleming AN, Powell BW (2009) Atrophy of the intrinsic musculature of the hands associated with the use of botulinum toxin-A injections for hyperhidrosis: a case report and review of the literature. J Plast Reconstr Aesthet Surg 62(8):e274–e276 40. Wollina U, Konrad H (2005) Managing adverse events associated with botulinum toxin type A: a focus on cosmetic procedures. Am J Clin Dermatol 6(3):141–150 41. Carruthers JDA, Glogau RG, Blitzer A, Facial Aesthetics Consensus Group Faculty (2008) Advances in facial rejuvenation: botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies – consensus recommendations. Plast Reconstr Surg 121(5 Suppl):5S–30S 42. Coleman KR, Carruthers J (2006) Combination therapy with Botox and fillers: the new rejuvenation paradigm. Dermatol Ther 19(3):177–188 43. Flynn TC (2006) Update on botulinum toxin. Semin Cutan Med Surg 25(3):115–121 44. Balikian RV, Zimbler MS (2005) Primary and adjunctive uses of botulinum toxin type A in the periorbital region. Facial Plast Surg Clin North Am 13(4):583–590
Biostimulation and Biorestructuring of the Skin
11
Maurizio Ceccarelli
11.1 Epidermis The process of differentiation of epidermal skin cells is very complex and regulated by a series of information from the exterior, as well as through complex intercellular enzymatic systems which function as secondary messengers [1]. Among the external informers we must consider the alpha and beta adrenergic mediators that work by stimulating activity of the adenylcyclase and the cholinergic mediators, which work by stimulating the activity of the guanylate cyclase formation of c-GMP. Other factors ruling the keratinocyte differentiation are the Epidermal Growth Factor (EGF) and estrogens. Among the intrinsic regulating factors, the calones (34 KDa glycoprotein), tissue-specific but not very species-specific, blocks the cell cycle in G1 phase, thus preventing S phase [synthetic macromolecular] and then the M phase [mitosis itself]. Has the ability to re-enter the cells in G0 phase and also makes biological agents with power inducer of differentiation. The epidermal G1 calones appear to control the proliferation of adult cells, while the G2 calones set those primitives and are substances with similar hormonal activity and have significant importance. The epidermal calones are produced by keratins in an advanced phase of proliferation and have the function of prohibiting the cellular mitosis of the cells of the basal layer. This regulates skin thickness. The stimulus of the ECP increases the mitosis of the germinative layer; when the thickness reaches its optimal status, the concentration of the calones produced M. Ceccarelli Corso di Francia, 221, 00191 Roma, Italy e-mail:
[email protected]
by the keratinocytes also reaches the necessary level to block the mitosis of the basal layer. When the corneous exfoliation reduces the number of the corneocytes, the concentration of the calones is lowered and the stimulus of the EGF reactivates the mitosis. The correct function of this balance regulates the correct thickness of the skin. In concluding this report on the epidermis functions and bringing it into our aesthetic interventions, we must remember two points: the cholinergic mediators and the calones. This is because treatment with botulinum toxin anticholinergic reduces the effect of this mediator, altering the epidermal function and the peeling treatment exfoliating and reducing the corneocyte layer determines a reduction of the calones with an increase in the mitotic stimulus and epidermal hypertrophy. The quantity and frequency in the use of botulinum toxin and peeling, requires careful attention.
11.2 Dermis Below the epidermis there is the dermis that is formed primarily by collagen and elastic cells or fibers immersed in a colloidal matrix. The cells are represented essentially by fibroblasts. The colloidal matrix is formed by the fundamental substance (glycosaminoglycans (GAGs) and proteoglycans) and by fibrous proteins such as collagen and elastin. Collagen, elastin, and GAGs are produced by fibroblasts and chondrocytes. The physical status of the dermal matrix is important because, depending on its consistency, the metabolic exchanges are either facilitated or inhibited. The state of sol of the colloidal solutions which make up the matrix permits an easier
P.M. Prendergast and M.A. Shiffman (eds.), Aesthetic Medicine, DOI 10.1007/978-3-642-20113-4_11, © Springer-Verlag Berlin Heidelberg 2011
131
132
metabolic exchange, while the more solid state of the gel impedes this. The colloidal solutions are characterized by solute molecules of considerable dimension, and thus are unable to disperse in the intermolecular spaces of water, but are charged with the same electrical current. Due to gravity the first molecules settle on the bottom but impede others from doing so because the repulsion of the electric charge of the same sign keeps them suspended. If the electric charges of the colloidal molecules are saturated with charges of opposite sign, the repulsion force ceases and the various colloidal molecules become compact, transforming the colloidal solute (sol) into a colloidal gel (gel). In the dermis, the state of sol is maintained by the negative charge present on the surface of the macromolecules of GAG from which they are made. This negative electric charge derives from the dissociation of these macromolecules in the slightly alkaline environment which characterizes the dermis (pH 7.4). This pH value is maintained steady or unchanged by the buffer bicarbonate system. The normal cellular metabolism produces carbon dioxide. This, in a water solution, forms carbonic acid that when dissociating, frees hydrogen ions which acidify the solution. The hydrogen ions, positive, neutralize the negative electric charges of the GAG and determine gasification of the derma with a reduction of the metabolic exchanges. Also the inflammatory processes acidify the dermal matrix with consequent biological damage. Therefore, it is important that any aesthetic interventions does not induce acidification to the derma (inflammation) or a reduction in the buffer bicarbonate systems. The fibroblast is the dermis’ cell capable of producing all the components of GAG, collagens, and elastin. The productive capacity of the fibroblast differs in function; on the age of the cell, on the different stimulated receptors, and on the physicochemical ambiance surrounding it. In particular, we also have to make a distinction regarding the various types of collagen being produced. This is because in various aesthetic interventions we speak of neocollagenogenesis without mentioning the type of collagen being produced and if this neoproduction corresponds to a real biological rejuvenation of the skin. In young skin the relation collagen type III/type I is much higher in adults and that this relation tends to diminish with age. The fibroblast produces an immature collagen, tropocollagen that is assembled in different ways, utilizing portions of carboxy terminal (collagen type I) or
M. Ceccarelli
amino terminals (collagen type III). Collagen type III, reticular, is characteristic of young tissue and maintains the turgidity of the derma. Collagen type I, fibrotic, is characteristic of older and cicatricial tissue and hardens the dermis. Recent studies indicate the capacity of the fibroblast to be activated towards the production of one type or the other of collagen and in particular we can distinguish the fibroblast into two under populations, NF (natural fibroblast) and FF (fibrotic fibroblast) the latter being characterized by inflamed tissues. The NF mainly produces reticular collagen, while the FF mainly produces fibrotic collagen. Considering that the fibrotic collagen is a factor of aging skin, it is important that the neocollagenogenesis induced by our aesthetic treatment do not stimulate the formation, as even if the aesthetic look of the skin could improve, the biological functions are damaged. Neocollagenogenesis treatments of the reticular type is used to improve the skin of young patients, while fibrotic-type neocollagenogenesis for older patients, aware that there is aesthetic improvement even at a cost of damage to the physiology of the skin. A correct biological state of the dermis foresees: 1. Maintenance of the colloidal status of the matrix 2. Activation of the metabolism of the fibroblast 3. Stimulation of the neoformation of collagen and elastic fibers
11.3 Regeneration and Reparation It is important to examine closely the concept of neocollagenogenesis, analyzing the process of regeneration and reparation. Regeneration is a physiologic process at the base of a continuous reconstruction of certain tissues, such as those of the skin. In order to maintain functional tissues and apparatus our organism puts into effect a continuous regeneration process based on a dissolution of the pre-existing tissue and on its own reconstruction. In the skin, there are some particular enzymes called metalloproteinase capable of solubilizing through processes of hydrolysis the macromolecules that form the dermis [2]. The metalloproteinase distinguish themselves with progressive number indicators of the same molecule on which they effect their action: MMPI collagenase, MMP3 gelatinasi, etc. The metalloproteinase is present in the derma in an inactive form with its active site blocked by a residual of cysteine. The
11 Biostimulation and Biorestructuring of the Skin
hydrolysis of this amino acid frees the site containing zinc and permits the action of the enzyme. As in most parts of the biological systems, the dissolution of the matrix is governed by activators and inhibitors of the MMP. The correct balance between the two apparatus permits the maintenance of a healthy and functional derma matrix. Particular receptors on the cellular wall of the fibroblast are being activated by the growth factors or by the lysed components of the dermis and bring the sintering of new molecules. The receptors of the tyrosine–kinase that are activated by the growth factors (fibroblast growth factor), and the CD44 (cluster of differentiation), which are being activated by fragments of hyaluronic lysed acid, determine the hydrolysis of the polyphoinositide of membrane with the liberation of 1–3 of phosphoinositide. This reaches the endoplasmic lysed reticule where joining up with a specific reticule, induces the entry of calcium ions. The calcium ions activate the proteinkinase C with the stimulus of early induction of the Jun and Fos genes and the subsequent start of the protein synthesis. Thus, the neoformation of the components of the dermal matrix and in particular of GAGs of reticular collagen (type III) and of elastin. The reparation is a biological process useful to compensate the loss of part of a tissue as a result of damage. This loss is balanced with the neoformation of a connective tissue called cicatricial tissue. This tissue is richly represented by collagen of type 1. The cell governing the formation of the cicatricial tissue is always the fibroblast. Obviously in this case we have diverse stimuli to induce the construction of new tissue and not the original tissue. If previously there were the fragments freed by the hydrolysis of the normal components of the dermis to activate the regeneration of the skin, now there are the endocellular components freed by the biological damage and the inflammation mediators, consequent to the biological damage, to induce the activation of the reparation process. In particular, there is the activation of the CD39 on behalf of the fragments of the nucleic acid freed by the nucleus of the damaged cell and the activation of the CD40 on the part of the mediators of the inflammation (interleukin 4) to stimulate the formation of the fibrotic tissue rich in collagen of type 1. Is it sufficient to speak in a general way about fibroblast activation or do we have to be more precise about which receptors we activate? The stimulation of different receptors could bring biological improvement or aesthetic improvement. Biological improvement is
133
useful in all kinds of skins while aesthetic improvement is useful only in old skins. Therefore, if fibroblastic biostimulation is to be used in a young patient, we have to be sure that the stimulated receptors are only the CD44. While in fibroblastic stimulation of an older skin, also the stimulus of the CD39 and the CD40, even if inducing a biological damage, can be accepted because of the aesthetic improvement. In stimulating CD44: 1. The proteins derived from the damage of the extracellular matrix stimulate the synthesis of its components. 2. The CD44, cellular receptors of activation of the synthesis of hyaluronic acid, shows the biggest activity in the presence of complexes of 20–38 monomers. While: 1. The extracellular nucleotides stimulate the purinergic receptors of type 2. 2. The adenosine (Purina base) rules the inflammation and the reparation of the tissues. 3. The adenosine receptors play an active role in the pathogenic of the dermal fibrosis. 4. The extracellular nucleotides have been involved as inflammatory mediators in many pathological situations. 5. The stimulation of the purinergic receptors 2 of the CD39 is associated with a chronic inflammatory response. 6. Phlogogen stimulus select the under populations of fibroblasts with an important role in the formation of the fibrosis. 7. The interleukin IL-4 is tied up to the CD40 of the fibroblasts with a profibrotic effect and reduction of the antifibrotic effect of the IFN-range. The stimulus of the CD44 provides biological improvement that is seen also with an aesthetic improvement, while the stimulus of the CD39 and the CD40 determines only an aesthetic improvement consequent to a fibrosis of the dermis and therefore a biological damage.
11.4 Biostimulation The proposals, also medical, present in the field of the biostimulation tell us of the use of: 1. Vitamins 2. Hyaluronic acid
134
3 . Fractions of DNA 4. Organic silicon 5. Radiofrequency 6. Laser energy It is important before commencing any of these treatments, to consider the real biological effects of each (as doctors freeing ourselves from the simple economic business and choosing science and conscience). Nowadays the concept of biostimulation has become one of the most requested treatments of aesthetic medicine. Many names are utilized in its definition. 1. Biostimulation 2. Biorestructuring 3. Bioregenaration 4. Biorevitalization The author prefers the use of the term biostimulation to indicate an activation of the biological functions of the skin in order to optimize its physiology and achieve aesthetic improvement. The term biorestructuring is used to indicate an alteration of the normal cutaneous components with damage of the physiology of the skin even if there is an aesthetic improvement. Biostimulation for a young skin is to improve its physiology and the aesthetics, biorestructuring is for an older skin to obtain an aesthetic improvement. The correct biostimulation includes the skin functions being activated through a functional improvement of the epidermal and dermal cells that brings a normalization to the condition of the skin. This foresees a regular epidermal renewal and the optimization of the chemical–physical matrix. Regular epidermal renewal stems from a normalization of the EGF function and of the calones. The chemical–physical optimization of the matrix requires the neoformation of the structural components and the fluidity of its colloidal state. The neoformation of structural components of the matrix requires the physiological stimulation of the fibroblast in the regenerative rather than the reparative sense. The dermal regeneration becomes activated through the growth factor or the fragments of the normal components of the matrix. These work on the CD44 activating the protein synthesis in a regenerative sense and improving the neo formation of reticular collagen, Hyaluronic acid, and elastin. Normalization of the colloidal state of the matrix requires the maintenance of a physiological ph (7.4). This avoids the transformation of the matrix solution from the state of sol to that of gel to maintain free metabolic exchanges.
M. Ceccarelli
The technique of a more physiological biostimulation is today represented by treatment with Growth Factors derived from plasma rich in platelets. This permits the activation of the fibroblast through the use of homologous growth factors and inducing the normal reconstruction of the altered dermal components. The technique by Garcia [3] is histologically verified by its results and is, today, particularly widespread in Spain and is becoming well known in Europe and South America. Born from the clinical use of plasma rich in platelets and of the cellular growth factors connected to them a vast bibliography confirms the importance in ophthalmology, dentistry, neurology, orthopedics, and in branches of aesthetics. The only problem is the lack of legislation able to regulate this type of transplant. The EU is preparing a law on extracting, conservation, and use of any human cell, considering the diffusion of this new type of therapy. In the meantime the use of these off-label-activated platelets remains the responsibility of the physician. Growth factors are small protein fragments, belonging to the group of the cytokines, able to join the receptors of membranes to activate or inhibit the cellular functions. They can be produced by numerous cells and tissues: platelets, fibroblasts, osteoblasts, epidemics cells, liver, kidney, lachrymal glands, etc. The joining of the tyrosine–kinase receptors to the cellular membrane induces the hydrolysis of poliphosphoinositole of the membrane with the liberation of the 1–3 diphosphoinositole. This reaches the endoplasmic smooth reticule where, if joined to a specific receptor, induces the entry of calcium ions: the calcium ions activate the proteinkinase C with the stimulus of the genes at an early induction Jun and Fos and the subsequent start of the protein synthesis. Among the numerous growth factors freed from our cells, the PDGF was chosen for the ease of its finding, for its specific proliferation activity of the fibroblasts, and synthesis of the dermal matrix. The platelets also free other factors (TGF, EGP, VEGF, and IGF) extruded from the big granule alpha after activation. Biologically the activation of the platelets in these cells is by contact with the extravascular connective after a wound (lesion): chemically we obtain this effect with calcium chloride. The platelets, furthermore, also transport proteins useful in the reparation and regeneration of the tissues, whether derived from their precursor cell (megakariocytes) or captured through endocytosis from the plasma.
11 Biostimulation and Biorestructuring of the Skin
The use of the PRP (plasma rich in platelets) in clinics has always been directed towards the improvement of the reparation process. The merit of Garcia and of the studies at Barcelona University is in the verification of the use also in regenerative processes. Histological studies have shown that the introduction of the PRP induces, for a 9-month period, the neoformation of reticular collagen (type III) in the dermis justifying the affirmation of a biological rejuvenation of the skin of the patient. The treatment is carried out on the face, neck, décolleté, and hands in three sessions (the first, then after 3 months and after 6 months). The biological effect is related to the concentration of the platelets, therefore the plasma, before administration, must be enriched. The other certified technique that takes to the use of the PRP is the biostimulation affected with the SKIN-B product. This, a medical device of III level certified CE by the Italian Health Superior Institute, contains: 1. Fragments of hyaluronic acid of 20–38 monomers to activate the CD44 of the fibroblast 2. Amino acid precursor of the components of the matrix 3. Bicarbonate buffer to keep the condition of sol of the matrix Biostimulation with SKIN-B is affected during the intervals of the treatments with PRP. These two treatments represent the base for the biological rejuvenation of the patient’s skin.
11.5 Physical Biostimulation with LED Recently light, and in particular photo stimulation, has been approved by the American FDA for the treatment of wrinkles. The principle is based on the fact that the LED releases photons with a low power but able however to give a positive effect on the cells at a morphological and molecular level. The treatment is today placed at an international level amongst the nonablative technologies and in particular as photo rejuvenation with light emitted by diodes, without thermal effect. The difference between laser light and LED light is that the noncollimation leads to the divergence of rays with a consequent decrease of intensity at the point of irradiation. While the intensity of the laser is measured in watts, the LED is measured in microwatts. The absorption of the power of incident light is different according to the wavelength and the material met.
135
The wavelength between 600 and 900 nm is not absorbed by the biological molecules. In this range (600–900), the longer the wavelength the deeper penetration of the skin. But where is the site for action of the photobiostimulation? We know that in nature, whether in the vegetable or the animal world, there are molecules considered photosensitive, they change their functions on the basis of light stimulation. The light activates the photo systems of the vegetable cell by splitting the water and uses the hydro genes to activate the synthesis complex ATP and produce energy necessary for the biological synthesis. Also at an animal level we have some biological structures activated by the light. The most evident example is that given by the rhodopsin contained at a retinal level, the activation of which is at the basis of the mechanism of vision. Also the melanocytes of the skin are cells activated by the light for the production of melanin bodies. The light also develops an important function in the Light Repair of the cellular DNA. The enzyme photoliasis is a flavoprotein that, activated by the light, repairs the portions of the damaged DNA. However, the most interesting point in our discussion is represented by the tetrapyrrollic rings present in the mitochondrial cytochromes. At the mitochondrial level, the Chain of Transport of the Electrons allows the formation of the ATP molecules. The enzymes of the chain are represented by the cythrochroms. The scheme of the electronic transfer foresees the: 1. Transfer of the electrons from NADH to the cytochrome 2. Transfer of the electrons from the FADH to the cytochrome 3. Transfer of the electrons from the cytochrome Q to the cytochrome 4. Transfer of the electrons from the cytochrome c to the oxygen as per action of the cytochromoxidasis Essential in the chain of transport of the electrons is the protonic flux of the hydrogen ions. This flux consents the formation, by way of the ATP-synthetase, of the ATP molecules. The ATP-synthetasis mitochondrial has a particular stereochemical structure equipped with a clockwise and anticlockwise motion on the basis of the protonic flux. The ATP or adenosine– triphosphate is a particular molecule formed by an adenosine nucleus (adenine plus pentose) with three combined phosphoric radicals. The bond of the last phosphoric group is a one with a high energetic content,
136
the breaking of which gives off a high quantity of energy. We can now understand how the photobiostimulation with LED could be useful in the prevention of the aging process. Scientific studies confirm that the cytochromoxidase is the primary accepter of light between the red and the infrared and this light LED improves the electronic movement in the cytochromoxidase, heart of the formation of the free radicals of oxygen, capable of yielding up to four electrons to the molecule of oxygen. We have to point out the delicacy of this process because the mechanism of oxygen reduction foresees a necessary amount of time for the inversion of the spin of one of the two additional electrons. In fact, oxygen at two electrons with spin parallel in the last orbit and the addition of another two antiparallel spin electrons, must be preceded by an inversion of the spin. If this does not occur at precise times, there can be an escape of the free radicals free from oxygen; the base of cellular aging: 1. The first target is the mitochondrial DNA where only one deletion results in a loss of the function of the whole filament. 2. The damaging of the telomeres in the DNA, results in the nondisjunction of the chromos during the crossing over, with consequent cellular death. 3. The lipoperoxidation of the biological membranes results in a loss of function with cellular death. The loss of double ties of the phospholipids determines a rigidity of the membranes with loss of fluidity and an alteration in the functions of receptor expressions. 4. Liberation of the free radicals free from the oxygen of the cytochromoxidase, results in the activation of the caspasi with induction of the cellular apoptosis and death. The free radicals of the oxygen liberated by the mitochondria join the APAF 1 (protease activating factor 1) which joins the procaspasis 9 with successive aggregation and liberation of activated caspasi 9. This activates the cascade of the caspasi with final cellular apoptosis. Furthermore, the photobiostimulation with LED (red-infrared) results in the activation of the respiratory chain of the mitochondrial with activation of the synthesis of ATP and a functional cellular improvement. The synthesis of ATP is guided by the gradient proton. In fact, the electronic flux moving along the mitochondrial crests is accompanied by a protein flux in the intermembranal space. After the cessation of the electrons to the oxygen the protons pass into the
M. Ceccarelli
ATP synthetase, supplying the force for the formation of the ATP. So we have the passage of a disphosphoric radical in combined to a proton. The radical will join a new proton forming phosphoric acid which terminates its reaction and joins itself to the adenosine– diphosphate, forming ATP. The clockwise rotation consents the synthesis of ATP. The rotation anticlockwise results in the hydrolysis of the ATP. The liberated energy from the ATP is utilized by the cells for the protein synthesis, for the pumps of sodium and calcium and for the synthesis of DNA and RNA. The application times for the photo modulation, per session, range from 15 to 20 min. The number of the sessions can vary from 1 to 2 for a total of 8–10 treatments.
11.6 Heterologous Skin Regeneration Today, medicine, physiology, and aesthetic medicine, in the renewal of treatment for skin aging, are turning to an industry evolving: regenerative medicine [4]. The scientific approach which today must follow the doctor is to regenerate the biological status of skin tissue through autologous or heterologous activities. Skin regeneration, with the goal of inducing regeneration of the dermis and epidermis, which would bring the skin into a youthful state requires the use of autologous patient’s substances [3], such as: 1. Platelet growth factors 2. Plasma rich in platelets 3. Fibrin plasma 4. Support autologous biological tissue The heterologous skin regeneration always involves the activation of regenerative biological processes, however, made by Medical Device certified for this function. The regeneration heterologous replaces the generic term of biostimulation to indicate biological activity useful in functional improvement of skin. The generic term, biostimulation, indicates a generic biological activity, of course included in this term there will be positive and negative results. Undoubtedly the products proposed as biostimulants are accepted by the physician and the patient for a possible hit on the skin. But in reality, all products sold are biostimulants (activators of skin biology), but not all, lead to an improvement of the physiological skin, they often show a positive response on the aesthetic result, but with skin biological damage.
11 Biostimulation and Biorestructuring of the Skin
But what do we mean by physiological improvement of the skin? The physiological normalization of biological functions of the body and thus improve the skin indicates the physiological homeostatic optimization of biochemical reactions that must maintain our functional and trophic skin. To program proper biostimulation, or rather skin regeneration with a Medical Device, we must first understand the biological mechanisms relevant to the biology of the skin. From what we have stated, the dermo-epidermal regeneration obtained with the use of medical devices should lead to the skin: 1. An action of stimulation of receptor tyrosine kinase normally activated by growth factors necessary to enable the growth both of the germinative epidermal layer, and the fibroblast 2. Action mimetic that improves the epidermal cholinergic system 3. Useful buffer action to reduce the states of acidification induced by inflammation and helps to maintain the colloidal state of the matrix 4. Action to stimulate the new formation of matrix components (proteoglycans, elastic fibers and collagen type III) 5. Action to block the activation of metalloproteinase responsible for the dermis catabolization 6. Reduce the processes of skin aging caused by oxidative stress of free radicals of oxygen The pharmaceutical industry, for a long time, has provided a Medical Device Type III certificate for a biostimulation dermo-epidermal. This product contains: 1. Hyaluronic acid fragments of 20–38 monomers capable of activating the CD (Cluster of Differentiation). These receptors, once activated induce a metabolic activation and dermal–epidermal regeneration with multiplication. In particular lead to the synthesis, by the fibroblasts, of the matrix new components and collagen lattice [5]. 2. Amino acids precursors of matrix components, according to the endomodulation principles, trigger biochemical reactions anabolic allowing a growth of the dermis. 3. Amino acid cysteine, zip closing of the active site of metalloproteinases. The excess of this amino acid competes with the removal of the same to level of metalloproteinases, reducing the activation of these and the breakdown of the dermis. 4. Bicarbonate buffer system that inactivates the release of H + ions induced by inflammation of the skin, keeping constant the pH value of 7.4. This allows the
137
separation of anionic macromolecules that compose the matrix, keeping the electrostatic repulsion necessary for the maintenance of the matrix. The actions of this second III type device is medically undoubtedly good, omitted, however are two points that are: 1. The mimetic action of epidermal cholinergic system 2. The reduction processes of skin aging caused by oxidation of oxygen-free radicals This forced us to treat these two points with different drugs, not approved for this treatment (glycerate choline and reduced glutathione). Recently, the same pharmaceutical industry has proposed a new type III Medical Device containing the starting material described above with the addition, in one case, of choline, and in the other, antioxidants. The choline is the precursor of the acetyl-choline and, in turn, in its synthesis is stimulated by DMAE (dimethylaminoethanol), already known in cosmetics. Its addition in the Base Medical Device type III takes, according to the Endomodulation principles, an improvement of the acetyl-choline synthesis and an activation of the epidermal cholinergic system. In fact,, Kurzen et al. say, in Hormonal Metabolic Research, February 2007, that the non-neuronal cholinergic system of human skin is involved in basic functions of the skin through autocrine, paracrine, and endocrine mechanisms, like keratinocytes proliferation, differentiation, adhesion and migration, epidermal barrier formation, pigment-, sweat- and sebum production, blood circulation, angiogenesis, and a variety of immune reactions. The antioxidants (vitamin C and glutathione) act by inactivating oxygen-free radicals, escaped from the electron transport chain. Vitamin C reactivates with its reversible passage by ascorbic acid to dehydroascorbic acid, vitamin E oxidized in its function block of the superoxide radical. Glutathione converts hydrogen peroxide, formed as a result of SOD (superoxide dismutase) action on the superoxide radical, in water preventing thus the damage of Fenton Reaction.
11.7 Discussion This evolution of the means at our disposal for the biostimulation, allows us to review, for the better, our protocol on the heterologous regeneration, incorporating these two new medical devices. From this, we differentiate our
138
protocols on the basis of results of evaluation of our patient’s skin. In particular: 1. In the young patient who does not have excessive skin damage, we keep the classical treatment using the Base Medical Device. The times are those based on each mesotherapy treatment: one session a week for four times, a fortnightly meeting twice, and finally a maintenance session once a month. 2. In the patient with damage of biological aging (photo-aging or chronological-aging) we substitute the Medical Device Base with one with antioxidants, keeping the protocol. 3. In the patient with epidermal damages we replace the Medical Device Base with one with choline, always maintaining the same protocol. Finally, in patients at older ages where they often add up all the needs, the author’s current protocol provides a session with Medical Device Base week for four times. Then one session every fortnight with the Medical Device with choline and one session every fortnight with the Medical Device with antioxidants. Treatment should be maintained over time and supplemented with autologous regeneration.
11.8 Biorestructuring 11.8.1 Macromolecular Hyaluronic Acid Macromolecular hyaluronic acid is a polymer set up by the repetition of monomers formed by the union of hyaluronic acid with acetyl-glucosamine. This union is permitted by the binding of the hyaluronic acid and the uridine-triphosphate. We cannot speak of a biostimulant effect for the macromolecular Hyaluronic acid, because as stated in the scientific literature [6]: 1. The presence of hyaluronic acid does not have effect on the production of endogenous hyaluronic acid. 2. Hyaluronic acid (0.5–1 mmol) limit induce the reduction of the protein synthesis. 3. High concentration of hyaluronic acid limits the formation of extracellular matrix. 4. Hyaluronic acid (1 mg/mL) increases the expression of the metalloproteinase (MMP) and activates those which are latent in the extracellular matrix (MMPs). We speak only of an antioxidant and hydrating effect of the macromolecular hyaluronic acid. Recent reports described antioxidant properties of GAGs.
M. Ceccarelli
Since several have shown that hyaluronic acid (HYA) and chondroitin-4-sulphate (C4S) may act as antioxidant molecules. Hyaluronic acid and chondroitin-4sulphte possess antioxidant properties. Hyaluronan has been assigned various physiological functions in the intercellular matrix, e.g. in water and plasma protein homeostasis. Therefore, there is no stimulation of the fibroblasts and neocollagenogenesis but only a passive hydration and of antioxidant effect.
11.8.2 Fragments of Nucleic Acid Nucleic acid is an intercellular component contained in the nucleus, but present also in the cytoplasm, in the mitochondrions, and in the wrinkled endoplasmic reticule. So the contact of this material with the surface of the fibroblast foresees the cellular rupture due to biological damage. In the derma the fibroblast receives the information of biological damage from the endocellular materials produced by the damage or by the mediators of the inflammation to the damage itself. The joining of fragments of nucleic acid to the CD39, activates the reparative process with formation of a cicatricial tissue. Scientific works with the PDRN tell us of the increase of the fibroblastic activity of 30% with an increase of collagen, fibronectine, and dermal filling. This neocollagenogenesis is relevant to the formation of fibrotic collagen characteristic of a reparative cicatricial tissue. The literature asserts that [7–12]: 1. The extracellular nucleotides (PDRN) stimulate the purinergic receptors of type. 2. The adenosine (Purina basis) regulates the inflammation and the reparation of the tissues. 3. The adenosine receptors play an active role in the pathogen of the dermal fibrosis. 4. The extracellular nucleotides have been involved as inflammatory mediators in many pathological situations. 5. The stimulation of the purinergic receptors 2 of the CD39 is associated with a chronic inflammatory response. 6. Phlogogen stimulus selects some under populations of fibroblast with an important role in the formation of the fibrosis. 7. The interleukin IL-4is tied to the CD40 of the fibroblasts with profibrotic effect and reduction of the antifibrotic effect of the IFN-gamma.
11 Biostimulation and Biorestructuring of the Skin
We do not describe biological rejuvenation but only of the aesthetic, therefore we can only use this technique in older patients.
11.8.3 Radiofrequency in the Aging Skin The best known and publicized radiofrequency tool for the aging skin is thus presented: “It is a safe, clinically proven way to tighten and contour skin, with improvements in tone contour, and texture occurring naturally through the stimulation of your own collagen.” Also in this case we speak of neocollagenogenesis without indicating the type of collagen.
11.8.3.1 Concepts of Radiofrequency Radiofrequency permits the transformation of cold energy at high frequency relevant in heat, with an increase of the internal temperature by way of the Joule effect. All cells of the treated tissue absorb part of this energy, thanks to its grade of resistivity, and is transformed into heat. The law of physics at the base of the effects of radiofrequency, is given by the modification of the electric field of the treated zone with a change of the electrical charge and of the resistance, and to the movement of the ions and molecules which determine heat according to the formula: J = I × R × T, where J = Energy, I = Current (voltage), R = Impedance of the tissue, T = time. Generally the heat produced develops between 3 and 9 mm of depth, according to the tools used, and determines heat up to 55–65°C in homogeneous mode, without thermal diffusion in surrounding areas. The biological effect of the heat produced by the radiofrequency is a denaturation of the collagen fibers (from 5 to 30% of total fibers), with a consequent immediate contraction of the fibers themselves, with a progressive effect in the successive 4–6 months. The protein’s structure is characterized in four classes: primary, secondary, tertiary, and quaternary. The primary formed by a strong covalent bond, units various amino acids; the others formed by weak bonds permit the tridimensionality of the protein and their functions (structure, enzyme, antibody, etc.). The weak bonds break easy with just an increase of the molecular kinetics energy (heat). The covalent bond instead requires an enzymatic process of hydrolysis. The increase in heat beyond the physiological value of 37 °C denatures the protein, leading to a loss in biological functions. If the damage continues, this results in biological damage and
139
reparative response. The effects of the RF current are in relation to their frequency and force. Over 1.5 – 2 MHz there is elevated molecular friction which provokes intense heat, enough to induce tissue destruction. Frequencies inferior to 0.3 MHz produce undesirable stimulations in the nervous system. The literature confirms that: 1. Radiofrequency causes movement of charged particles within the tissue, and the resultant molecular motion generates heat. The heat in turn causes collagen shrinkage and new collagen deposition. 2. The physical agents (mechanical, thermal, electrical, radiant, etc.) determine an inflammatory process of varying degrees, on the biological material, resulting in self-damage. 3. Phlogogen stimulus select some under populations of fibroblasts with an important role in the formation of the fibrosis. 4. The interleukin IL-4 is joined to the CD40 of fibroblasts with a profibrotic effect and reduction in the antifibrotic effect of the IFN-range. So, even considering radiofrequency useful for the treatment of the aging skin, this technique must be used only for older skins because the biological effect is harmful and therefore the results are only aesthetic.
11.9 Laser Therapy for Ablative Cutaneous Rejuvenation An argument similar to that for radiofrequency is valid for laser treatment for aging skins. Use is made of a controlled vaporization of thin layers of skin. The light emitted by the laser is so intense that in a very short time (90 ms) it vaporizes and coagulates a thickness of skin between 40 and 60 mm (the thousandth part of a millimeter). Resurfacing with laser will produce very good results and the surface of the skin will regenerate, richer in fibrotic collagen and consequently more compact. A source of energy activates the molecules through a tube containing gas so to determine an atonics excitement followed by a successive release of energy which hits the skin bring about a coagulative or necrotic damage according to the intensity. The protein denaturalization or the coagulation is followed by a reparative process that is evidenced by a deposit of cicatricial tissue containing collagen of Type 1. The literature confirms that:
140
1. A 1440-nm inducing no ablative neocollagenesis in the remodeling of scars and rhytids. Histological evidence confirms the micro columnar nature of collagen heating using this microarray. 2. The physical agents (mechanical, thermal, electrical, radiant, etc.) determine the biological material an inflammatory process of varying degrees, with self-damage. 3. Phlogogen stimulus select some under populations of fibroblasts with an important role in the formation of the fibrosis. 4. The interleukin IL-4 is joined to the CD40 of the fibroblasts with a profibrotic effect and reduction of the antifibrotic effect of the IFN-gamma. This confirms the recognition that, although producing biological damage, laser resurfacing results in an aesthetic improvement of the skin, its use therefore is reserved for older patients.
11.10 Polylactic Acid Recently polylactic acid filler has been proposed not only as filler but also as biological stimulus for the rejuvenation of the skin. Polylactic acid is different from other fillers. Simply, its action is based not on the filling of the cutaneous defect, but on the increase in derma’s volume due to the proliferation of neocollagenesis, induced by the stimulus on the fibroblasts provoked by the Polylactic acid itself. This is a correct assessment because a permanent filler induces a fibrotic response from a foreign body. The literature states that: 1. Polylactic and microspheres (New-fill) induces a mild inflammatory response. Host defense mechanisms react differently to the various filler materials. 2. The chemical agents determine an inflammatory process of varying degrees on the biological material with damage of the same. 3. Phlogogen stimulus select some under populations of fibroblasts with an important role in the formation of the fibrosis. 4. The interleukin IL-4 ties itself to the CD40 of the fibroblasts with a profibrotic effect and reduction of the antifibrotic effect of the IFN-gamma. Therefore, the neocollagenogenesis is real but constituted by fibrotic collagen of type I and therefore does not induce a biological rejuvenation but only an aesthetic rejuvenation. The dimensions of the permanent fibrotic capsule which forms can be more or less
M. Ceccarelli
evident. The use of these products should be confined to the deep dermis, avoiding their use on areas of scarce thickness, for example the neck.
11.11 Silanoles A recent proposition has been made on an old product made of silanoles (onometiltrisilanolo orthohydroxybenzoate sodium–silanol salicylate pH:5.7). In this product the organic silicon is connected to the salicylic acid with hydrogen bonds, permitting the product to remain soluble, thus avoiding the polycondensation of the monomethyltrisilanolone. These bonds break once the substance is inserted in the derma. (Caution with those patients allergic to the salicylic acid!). The product is proposed for the treatment of wrinkles, scars, stretch marks, and cellulite, thus proposing the biological effect that silicon makes in the skin. Bridges of silicon among the GAGs and the glycoprotein form the skeleton of the intercellular matrix. In young people the skin is the tissue that, together with the arteries and the thymus, contains more organic silicon. These values decrease progressively with age. This affirmation is real but refers to the silicon introduced in the diet as the literature states: 1. Silicon is one of the important oligoelements for the regular metabolism of some of our tissues and in particular for the bony, cartilaginous and connective tissues. The silicon is being introduced normally in our organism through the diet and it is absorbed at intestinal level as orthosilicic acid. 2. Its principal role is developed in the synthesis of collagen of Type 1 and in the activity of the proline hydroxilasis. 3. Its deficiency is shown with an alteration of the formation of the bony tissue and with a reduced hepatic function of the Ornitina transaminase. 4. The exogenous supplementation of silicon in the diet allows, through the normalization of the concentration of orthosilicic acid, to regulate the formation of the extracellular matrix and the calcium metabolism. 5. The hydroxilate silicon or oxydated forms (silanoles) are utilized in the analytic medical technology (Technologies of selective separation) to stop hydrophilic molecules at high molecular weight, such as the Hyaluronic acid, and tying them up, separate them from other components.
11 Biostimulation and Biorestructuring of the Skin
6. The particles of organic silicon put into the organism induce an inflammatory reaction and a response of fibrotic character. So we cannot credit to an organic silicon put in the derma those actions made by the silicon put in the diet. The silanoles bind themselves to the hydrophilic molecules of the dermis. The silanoles induce an irritative inflammatory stimulation which stimulates a connective response with a neoformation of collagen type 1. The pH of 5.7 saturates the negative bindings of the colloidal solution of the matrix with the gelation and coagulation of it. The salicylic acid regulates the inflammatory process induced by the silanoles thus avoiding excessive damage. The use of the silanoles must be permitted only for the aesthetic rejuvenating of old skins.
11.12 Therapeutic Biostimulation A bridge of biological stimulation between the physiological stimulation and the aesthetic correction is represented from the so-said therapeutic stimulation. This foresees the skin treatment on the basis of the state of the same and has the aim of getting back from an altered state to a normal condition. There are six types of therapeutic biostimulation. The treatment called Sebum Less is needed to reduce the sebaceous secretion in excess in the seborrheic skins and uses the botulinum toxin introduced intradermally with small concentrations. The toxin reacts by blocking, in a reversible way, the liberation of acetylcholine at a neuromuscular level and it is useful in the reduction of the mimic face wrinkles. However, the use of this medicine can be enlarged also to other indications. A first use is that of regulating the epidermic growth stimulus, reducing the effect of the epidermal growth factor. Muscarinic receptors activate a metalloproteinase, which liberates surface-associated heparin-binding epidermal growth factor (HB-EGF) and causes transactivation of epidermal growth factor receptors (EGFRs). The use of the toxin after the peeling treatment that by exfoliating the epidermis move the scale EGF/caloni to an access of EGF, can find a usefulness. The toxin has an antioxidant effect. Acetylcholine is required for opening of mitochondrial (ATP) channels with the generation of reactive oxygen species (ROS). This action can be reduced by blocking the acetylcholine.
141
The toxin can be used in the seborrheic skins to reduce the production of sebocyte and to narrow the pores and there is a role for Acetylcholine (Ach) in sebum production and as a promoter of sebocyte differentiation. We can utilize the toxin in the couperosic skins to stimulate the vasoconstriction of the skin. Adrenergic neurons release noradrenalin and ATP to reduce cutaneous blood flow while cholinergic neurons release acetylcholine and a co-transmitter to dilate skin blood vessels. The mechanism of formation of the sebum foresees the stimulation of the sebaceous cells on behalf of the dihydrotestosterone, coming from the reduction of the circulating androgens on behalf of the 5-alpha reductase. The dihydrotestosterone reacts at DNA cellular level by stimulating the codification of the RNA necessary for the formation of the sebum. The botulinum toxin, by blocking the secretion of the acetylcholine, reduces the effect of this on the differentiation of the sebocyte and on the liberation of the sebum. It reduces, furthermore the increase of the ematic flux, always induced by the acetylcholine, and consequently to the flux of androgens. For the treatment 10 units of toxin diluted in 3 mL of physiologic solution is needed. Some intradermally injections in those areas with sebaceous hypersecretion. The Hydra Plus treatment utilizes some no crosslinked hyaluronic acid in order to increase the fixation of water at a dermal level. Hyaluronic acid contained in the core of the proteoglycans has the capacity of fixing a high number of molecules of water in the matrix. This is an important function in the keeping of the homeostasis of intradermal water. The intradermal introduction of noncross-linked hyaluronic acid increases the fixation of the water molecules, thus reducing the loss for transpiration and improving the hydration and the turgidity of the dermis. The treatment is repeated one or more times during the month, introducing the product into the dehydrated areas. The treatment called Aging Therapy utilizes the introduction of antioxidants to block the damage from the free radicals of the oxygen. The free radicals of the oxygen are normally produced, in the interior of the mitochondrias, through an enzymatic chain, called chain of transportation of the electrons, as products inbetween of formation of water molecules. The heart of this mechanism is th